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Abstract  
 
Viral infections have produced commercial drivers to develop products to treat and 
reduce viral outbreaks and infections. Antiviral disinfectants have found particular 
favour in limiting new infections. The nature of viruses has however necessitated a 
continued stream of products successfully moving through the research and 
development (R&D) stage into commercial usage. With high product failure rates in 
R&D, and difficulties for executive and R&D managers to communicate effectively 
in the R&D stage, there was a perceived need from within the sector to further 
elucidate antiviral disinfectant R&D. Prior research had shown that the R&D stage is 
technically sophisticated with a requirement for management to engage in the 
technical, scientific and business aspects. This can be challenging for management 
decision-making, as many aspects of R&D, have different levels of knowledge 
required as well as language used. The use of models has received much attention in 
simplifying the R&D stage, but with little attention paid to creating shared meaning 
between different managers. In this study, executive and R&D managers from 
antiviral disinfectant UK based R&D SMEs were examined, using semi-structured 
case study interviews within a phenomenological paradigm. Explicitation was used 
to draw out meaning from respondent interviews, which showed that executive and 
R&D managers were from business and scientific backgrounds respectively. This 
resulted in difficulties in communication about R&D between manager types, which 
added to the opacity of R&D. It was noted that executive managers had greater 
knowledge of wider organisational aims for R&D, but little knowledge about what 
was carried out in the R&D stage. Conversely, R&D managers had greater 
knowledge about the scientific testing carried out in R&D, but little understanding of 
the business drivers of R&D. Using interview information, an alpha and beta model 
were constructed that showed a linear path through R&D, based predominantly on 
technical stages. An expanded view of the model was utilised to aid in R&D and 
executive management sense made of the R&D. This model contributed to the 
knowledge base through shared and warranted knowledge between R&D and 
executive managers as well as expanded model views of each of the R&D process 
stages. Both of these factors are novel and have created new academic knowledge as 
well as this model currently being used by three respondent companies.   
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Glossary 
 
Business  
 
Case Study: A method often carried out under direct observation, 
without controlled variables, relying on multiple 
sources of evidence and requiring ‘triangulation’ (Yin, 
2009) and/or warranting (Wood and Kroger, 2000). 
Decision Making: A range of processes from conscious thought through 
to random picking, leading to a selection being made 
from numerous choices (Kahneman and Tversky, 
2000).  
Development The stage of R&D that is primarily concerned with 
exploiting knowledge for commercial gain (Di Masi et 
al, 2003).  
Emic An approach into how people sensitised to a particular 
environment think (Kottak, 2006). 
Etic An approach to shift the thinking of a sensitised 
individual to the role of the ‘researcher’ (Kottak, 
2006). 
Explicitation: The process of making respondent meaning clear from 
transcribed verbal discourse (Hycner, 1999).  
Bracketing: An attempt made by a researcher to limit their 
preconceptions of the phenomenon throughout the 
explicitation stage and become more open to it’s 
meaning (Hycner, 1999).  
Generalisability: The process (also known as ‘external validity’), where 
the extent to which research claims can be extended to 
wider populations are considered (Wood and Kroger, 
2000). 
High Technology: A categorisation of products constructed as ‘advanced’ 
that fill some level of societal need (Haverila, 2013).  
	   xii	  
Intersubjectivity: The agreement between individuals about a particular 
meaning (Scheff, 2006).  
Main Study: The in depth respondent interview stage, which is the 
secondary stage to the pilot study (Wood and Kroger, 
2000).  
Model: A symbolic representation of subjective or objective 
reality (Box, 1979).  
Phenomenology: A constructionism ontological stance, where a 
researcher attempts to see things from a respondent’s 
point of view (Bogdan and Taylor, 1975). 
Reduction: A phenomenological research finding in its own right, 
with its own attached meaning, and in this study 
achieved by the method of explicitation (Fouche, 
1993; Hycner, 1999).  
Research The initial stage of R&D that is primarily concerned 
with ‘discovering’ new knowledge that can be fed into 
development and commercialisation (Di Masi et al, 
2003).  
Pilot Study: The exploratory stage of respondent interviews, used 
as a basis to construct the main study (Wood and 
Kroger, 2000).  
Reliability: A collection of research processes to determine the 
‘quality’ of data and results (Wood and Kroger, 2000).  
Rigour: Often constructed as statistical validity, but in this 
study can be taken to mean replicability (Wood and 
Kroger, 2000).  
R&D: A collection of business activities composed of both 
‘research’ and ‘development’ stages, to construct new 
products for commercialisation (Di Masi et al, 2003). 
Sensitisation: The extent to which the researcher perceives they are 
influenced by prior experiences, while undertaking 
research (Kottak, 2006).  
Validation: A process in rationalist research where research 
findings mirror the ‘real’ world, but as this study is 
	   xiii	  
utilising discourse as data; the term warranting is 
preferred (Wood and Kroger, 2000).  
Verification: A process embedded within rationalist research where 
justification and grounds for claims made is provided 
(Wood and Kroger, 2000).  
Warranting: A process embedded within qualitative research where 
justification and grounds for claims made is provided 
(Wood and Kroger, 2000).  
 
Scientific 
Antiviral Disinfectant: A product (also known as an antiviral sanitiser) that 
‘targets’ pathogenic viruses to ‘kill’ them (OED, 
2012).   
Drug: A chemical treatment against a pathogenic disease-
causing agent (OED, 2012) which in this study refers 
to viruses.  
Efficacy: The percentage of viruses ‘killed’ by a drug or 
sanitiser (Xiao et al, 2007).  
In vitro: Testing that is carried out in an environment outside of 
a body such as a test tube (Alberts, 2008).  
In vivo: Testing that is carried out on a whole body or inside a 
body (Perkel, 2007).  
Stability: The shelf life of a product before it degrades and 
becomes unsuitable for sale (BS EN1276: 2009).  
Virus: A small biological cellular parasite capable of causing 
disease (Carter and Saunders, 2007).  
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Chapter 1. Introduction 
 
1.1. Motivation and Aim 
 
In an increasingly competitive and globalised marketplace, product innovation is an 
important part of the strategy for technology companies to sustain their market 
position and achieve growth (Teece, 1986; Freeman and Soete, 1997; Wang, Lin and 
Huang, 2010). Research and development (R&D) has been shown as pivotal for 
company strategies reliant upon the exploration and exploitation of knowledge, 
resulting in the production of novel products (Wang, Lin, and Huang, 2010). R&D is 
challenging for management, as it can be uncertain and risk-laden (Zhang, Mei and 
Zhong, 2013). Developing R&D process models has received attention in numerous 
sectors (Cooper, 1983; Adler et al, 1995; Browning, 2010; Bednyagin and 
Gnansounou, 2012; Popp et al, 2013) as they can provide greater management 
insight and understanding into R&D and be used to minimise risk and uncertainty. 
R&D models have also been perceived as a vehicle to reduce R&D resources used, 
which can potentially increase profitability. Even though R&D process models can 
be beneficial for management and the wider organisation, they can create challenges. 
These challenges are based on the difficulty of producing a ‘useful’ model that does 
not create confusion or misunderstanding during the R&D stage, and that adequately 
mirrors the phenomenon of R&D, and is generally ‘better’ than not having it (Dolk 
and Kottemann, 1993; Crowston, 2003; Browning et al, 2006). There are thus many 
conflicting drivers for developing and using a process model, but arguably, as the 
complexity of R&D increases (particularly technological complexity), so does the 
importance of using an R&D model to mirror a fit-for-purpose view of the R&D 
stage to allow shared meaning and understanding to be constructed and linked to 
R&D (Shane and Ulrich, 2004).  
 
Technological complexity throughout R&D can be particularly acute in the 
technology sectors including, biotechnology, pharmaceuticals and speciality 
chemicals. These sectors can have multiple unique considerations, which are crucial 
during and beyond the R&D process stage, and can include, product safety, toxicity, 
legislative compliance, efficacy (how well the product works), shelf life and risk, 
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amongst others (Dewar and Dutton, 1986; Henderson and Clark, 1990). Where the 
R&D environment and processes are not ‘adequately’ controlled, R&D may fail 
(Doctor et al, 2001; Raz et al, 2002; Lee et al, 2010) and is perhaps most clearly 
demonstrated by the pharmaceutical sector having an R&D to market success rate of 
less than 10 percent (CMR, 2006). This is however somewhat of a simplistic view 
for pharmaceutical R&D but is perhaps demonstrative of the difficulty of 
biologically based R&D. Process models can be used to facilitate how management 
make sense and decisions in and about R&D, particularly for increasing shared 
meaning between managers, reducing risk and uncertainty, as well as increasing 
company knowledge about R&D processes leading to an increased potential for 
successful product commercialisation (Smith and Merritt, 2002; Keizer et al, 2002; 
Bush et al, 2005; Pisano, 2006).  
 
The type of product of interest in this study, is antiviral disinfectants, which has had 
little academic attention paid to it or the relevant R&D processes. Simplistically, 
antiviral products are generally liquids that target viruses to stop them infecting new 
hosts or limiting the damage viruses can do to an already infected host (by ‘killing’ 
the virus or inactivating it). Developing commercial products to target viruses can be 
challenging for R&D companies, as viruses are small biological particles 
(approximately 0.00000002 metres in diameter) that can cause disease states in a 
wide variety of hosts. Their small size means that they cannot be seen by the ‘naked’ 
eye and are not easily detected by routine scientific analysis such as light 
microscopy. Although small, the health and mortality cost from viral infection is 
high, with examples of pathogenic human viruses including, human 
immunodeficiency virus (HIV), cytomegalovirus (CMV), herpes simplex virus 
(HSV) and influenza to name a few. Pathogenic viruses are not limited to infecting 
humans as they can also infect animals and crops, which can result in micro- and 
macroscale negative financial and economic impacts. As an example of the damage a 
human viral outbreak can cause, viral respiratory infections can cost the USA $25 
billion per annum (Fendrick et al, 2001). This is coupled with a loss to the USA 
economy of 148 million days of restricted activity, nearly 20 million days of missed 
work, 22 million days of missed school, and 45 million bedridden days (Adams, 
Hendershot and Marano, 1999). The wider claims of this data are backed up by 
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Zohrabian et al (2004: 1736) who linked viral pathogenicity to socio-economic 
impacts, ‘(1) medical costs (inpatient and outpatient); (2) non-medical costs, such as 
productivity losses caused by illness and premature death, costs of transportation for 
a patient to visit a healthcare provider, and childcare expenses; and (3) costs 
incurred by public health and other government agencies for epidemic control’. 
 
In many cases antiviral product R&D appear to have been driven by global disease 
outbreaks attributed to viral infections and market demand for novel products 
(Gilbert, Bestman-Smith and Boivin, 2002). There are three product types commonly 
used to stop the spread of viruses, including; (1) vaccines, which are administered to 
create immunity in a non-infected host; (2) in vivo antivirals, which inactivate 
(destroy) viruses present within the host; and (3) non-in vivo antiviral disinfectants, 
which inactivate viruses in the environment to stop their spread. All three products 
are different in the way they act, whether they can treat infected hosts, or are limited 
to stopping infection, as well as the side effects of treatments, costs and R&D 
processes. In this study, it is only non-in vivo antiviral disinfectants (herein referred 
to as antiviral disinfectants) that are of interest. In comparison to the two other 
product types of vaccines and in vivo based technologies, antiviral disinfectants have 
received little attention for understanding the R&D stage or the production of R&D 
process models.  
 
Although antiviral disinfectants are limited to being used outside of host bodies (i.e. 
external surfaces) Bray (2008) has suggested that their targeted use could be an 
invaluable tool in reducing the pathogenic spread of rapid viral outbreaks where 
there is limited time to develop vaccines and/or in vivo products. The development of 
antiviral disinfectants potentially offers much quicker routes to market as well as 
lower R&D costs, in comparison to the other antiviral product types (Dellanno, 
Vega, Boesenberg, 2009).  
 
This study is of importance to the author as he is the CEO of the sponsoring 
company that is actively involved in antiviral disinfectant R&D. Moreover, this 
research is perceived as having importance to management in other companies 
engaged in antiviral disinfectant R&D, for understanding and optimising their R&D 
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processes. While allied technologies within the antiviral sectors of vaccines and in 
vivo therapeutics have received much academic attention (Lakdawalla and Sood, 
2012), the ability to generalise this knowledge into the antiviral disinfectant sector 
for R&D was simply unknown. Coupled with much academic literature arguing the 
importance of models for R&D (Browning, 2010), a nuanced methodological 
approach was undertaken using phenomenology to ‘see’ the antiviral disinfectant 
process R&D stage through the eyes of managers engaged in this R&D. Thus 
enabling the production of antiviral disinfectant models that could be considered and 
contextualised in light of prior models in allied antiviral sectors but also as models in 
their own right. This approach was expected to develop a higher-level of business 
performance and bring new insights to this area. 
 
In this study, the examination of business and scientific processes relevant to the 
R&D stage was carried out by a multiple case study method, interviewing R&D 
managers in antiviral disinfectant small to medium enterprises (SMEs) and produced 
a model of antiviral disinfectant R&D processes. Model development took place by 
the production of an alpha model, which was subsequently modified through R&D 
manager verification/warranting, to produce a beta model. The ‘Research Question, 
Research Aim and Research Objectives’ driving this study are detailed in the 
following section.  
 
 
1.2. Research Question, Research Aim and Research Objectives  
 
To address the shortfall in research identified in the previous section, the research 
question guiding this study is: 
 
How do UK based SMEs carry out process R&D for antiviral disinfectants?  
 
From this a research aim was derived: 
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To examine current theory and practice in order to produce a model for process 
R&D used by UK SMEs producing antiviral disinfectants. From this a number of 
research objectives were constructed: 
 
 a) Through a literature review and current practice, to determine the current
  scientific and business processes for UK SMEs engaged in antiviral 
 disinfectant process R&D; 
 b) Informed by a) above to produce an initial alpha model for UK SMEs 
 engaged in antiviral disinfectant process R&D; 
 c) Informed by a) and b) above, to verify/warrant the initial alpha model and 
 so produce a beta R&D model. 
 
N.B. The words ‘verify’ and ‘warrant’ used in objective c) are more fully described 
in section 4.7.2 and 4.7.3 for how they relate to each other and are used in the social 
science method of ‘explicitation’.  
 
After developing the initial alpha model by examination of current theory and data 
derived from in depth interviews and analysed by explicitation, the researcher 
presented the alpha model to the case interviewees to receive further 
comment/feedback/verification/warranting. This process was to determine the extent 
to which the alpha model represented their view of antiviral disinfectant R&D 
processes within their company. It also allowed their responses to the alpha model to 
be used to further refine the alpha model into a beta model, encompassing their 
feedback.  
 
 
1.3. Research Methodology 
 
This study is based within the phenomenological interpretivist research paradigm 
(described in greater detail in section 4.2) and investigated how UK based SMEs 
carry out antiviral disinfectant process R&D, which resulted in the researcher of this 
study constructing an R&D process model. 
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Interviews with fourteen key managers (seven executive and seven R&D) was 
carried out as they were considered ‘experts’ who work in SMEs actively involved in 
antiviral disinfectant process R&D. The number of managers in this industry is 
relatively low, and was coupled with limited access to these individuals. Seven 
executive and seven R&D managers were chosen based upon the ability to access 
these individuals, their willingness to divulge information anonymously and that this 
number sits within the suggestion of Creswell (1998) and Mason (2010) for the 
number of interviewees required in phenomenological case study research. A further 
factor in reaching this decision was that there are a low number of SMEs actively 
involved in antiviral disinfectant R&D in the UK. Despite these limitations, the 
number examined in this study, represents 70 percent of the UK industry.  
 
The sample was limited to the UK geographically as the UK represents the vanguard 
of this type of research and is in line with the findings of Lager, Blanco and 
Frishammar (2013) who stated that this type of activity in this industry is strongly 
integrated in a few locations. A fuller justification of the number of manager 
interviewees is given in section 4.4.1. 
 
The next section examines the ‘Significance and Contribution of the Research’ 
carried out within this study.    
 
 
1.4. Significance and Contribution of the Research 
 
The research carried out in this study has provided an in-depth examination of 
antiviral disinfectant process R&D for SMEs in the UK. Prior to this study, academic 
examination had been paid towards vaccines and in vivo antivirals, but not antiviral 
disinfectants. As the commercial, legislative and scientific barriers for R&D are 
arguably lower for antiviral disinfectant technologies in comparison to other antiviral 
products, this study is of great potential interest and value to SMEs, who often do not 
have the resources to carry out vaccine and in vivo antiviral research. The timescale 
required for antiviral disinfectant R&D is also substantially shorter than for other 
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antiviral technologies, and with potentially fewer R&D managers and departments 
involved.  
 
Within the UK-based antiviral disinfectant R&D sector there are a low number of 
companies (ten), who employ a low-number of managers overseeing R&D, which 
supported the use of a phenomenologically based case study method to construct a 
warranted R&D model, reflective of management views. This approach facilitated a 
greater level of involvement from executive and R&D managers engaged in antiviral 
disinfectant R&D, which has resulted in the model produced in this study currently 
being trialled in three respondent companies. Importantly, and although extending 
beyond this study, the model will also be trialled by a further two companies, which 
will result in further research and a move to not only warrant the model but also 
validate it in light of prior R&D practices within these companies.  
 
This is a novel study as it has produced a model from a phenomenological case study 
method, which heavily considered management discourse regarding the complexity 
of R&D, and how a model could be used to aid in sense- and decision-making. 
Multiple warranting stages, and a further validation stage of this model will 
rigorously assess this model for its academic and practical management claims. 
Critically, this is the first model that has been constructed for the antiviral 
disinfectant sector, and it is expected that research findings will find international 
relevance to numerous other companies based outside of the UK.  
 
The main outcome from this study was the production of a DBA thesis. The thesis 
brought increased knowledge to the academic and business community in an area of 
research that has a high-value but has received limited research activity. Beyond the 
practical applications, research findings will be disseminated in appropriate 
management journals, focussing on the discursive elements of using a 
phenomenological approach for R&D model construction as well as the validation of 
the model, which will come from future work.  
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1.5 Thesis Outline 
 
Chapter 1. Introduction 
 
This chapter introduces the study, research question, aim and objectives as well as 
briefly detailing the methodology. The significance of the research carried out in this 
study is also examined in light of contributions to academia and practitioners.  
 
Chapter 2. Literature Review 
 
This chapter focuses on the theoretical background supporting this study. In 
particular there are two main areas that are examined including (1) antiviral R&D, 
and (2) modelling R&D. In part (1), the R&D environment is examined, including 
how antiviral R&D seeks to address market demands for antiviral products, but also 
the academic and business challenges of antiviral R&D. In part (2), modelling R&D 
is considered, including philosophical aspects of what a model is, including previous 
and current models used in R&D. Finally, antiviral R&D model production is 
examined in light of this being a phenomenological study utilising semi-structured 
in-depth interviews with R&D managers in UK based SMEs.  
 
Chapter 3. Literature Synthesis 
 
This chapter draws together the research gap in antiviral disinfectant management, 
with an examination of ‘executive’ and R&D management, to consider the 
production of an R&D process model for this area. The various strands of the 
literature are thus synthesised and the research question, aim and objectives are 
defined. 
 
Chapter 4. Research Methodology 
 
This chapter details the research methodology and phenomenological paradigm 
utilised throughout this study as well as a rationale for using phenomenology to 
develop meaning within social structures (the management of antiviral disinfectant 
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R&D) leading to the production of an R&D process model. This is alongside 
assessing the premise for the use of multiple case studies for interviewing. The 
theory behind content analysis, which in this study is explicitation, is explained and 
the reasoning behind this method detailed.  
 
Chapter 5. Pilot Study 
 
This chapter examines the rationale for carrying out an exploratory pilot study, as 
well as the findings produced in this stage. Finally, adjustments to the main study are 
considered and presented.  
 
Chapter 6. The Main Study and Construction of the Alpha/Beta Models 
 
This chapter introduces the results from the main study and covers the data collected 
and the analysis procedures utilised to achieve the aim of this study. How data was 
collected and explicitation used to produce an R&D process alpha and beta model is 
described. Further aspects of validity, reliability, warrantability, trustworthiness and 
generalisability were considered in light of data collection and analysis.  
 
Chapter 7. Conclusions and Recommendations 
 
This chapter examines the production of an R&D process model, and in particular, 
focuses on the production of an alpha model and the sequential beta model. Further 
to this, this chapter draws together the initial alpha and final beta model with 
theoretical work and considers the research findings in this light of what this study 
has brought to the research knowledge base. Finally, the limitations within this study 
are also recognised, with future work being suggested to address shortcomings with 
this work, and to allow greater impact for academic and practical aspects of this 
work.  
 
In the following chapter, the ‘Literature Review’, antiviral R&D is considered in 
both an academic and business context, particularly focussing on the production of a 
model.  
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Chapter 2. Literature Review 
 
2.1. Introduction 
 
In this chapter, the ‘Literature Review’ is presented in order to (a) provide the 
theoretical underpinning to the research and (b) to inform the research. In the first 
section of this chapter there is a particular focus on antiviral R&D, including the sub-
components of the physical, and business and management aspects of R&D. 
Attention is paid towards how management make sense of complex R&D 
environments, and subsequent decisions based on this information. Not surprisingly 
there have been a variety of vehicles found in previous management studies to make 
sense of R&D including the use of models and linguistic devices to produce shared 
meaning. This suggested an in-depth examination of the R&D environment, which 
could impact the sense- and decision-making of management, which is undertaken in 
this chapter. The most pivotal findings for complex R&D environments highlighted 
the difficulty in the construction of shared meaning between managers when the 
environment was highly complex, technical and with risk and uncertainty. The use of 
models, which is explored in the second part of this chapter, ‘Modelling R&D’, 
demonstrates how shared meaning between managers can be increased through 
model-based simplification, facilitating sense- and decision-making. Research into 
this area has indicated the benefit of simple models, to aid in sensemaking but has 
had a propensity not to warrant model construction between different manager types 
in and between companies in the same sector or carry out testing after warranting. 
This study sought to overcome this perceived limitation through the use of the 
phenomenological paradigm to ‘see’ R&D through the eyes of executive and R&D 
managers and construct a model based on findings. The macro-themes discussed in 
this section are drawn together to inform the research direction and questions 
required for this research to produce an R&D model, which are more thoroughly 
considered in ‘Chapter 3. Literature Synthesis’.  
 
As a starting point to set up this chapter and to contextualise the rest of the literature 
review, the process of examining the background literature begins with a 
consideration of ‘The Antiviral Market’ in the following section. 
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2.2. The Antiviral Market 
 
The antiviral disinfectant market is composed of companies carrying out R&D to 
produce antiviral products that can be sold in business-to-business (B2B) or 
business-to-consumer (B2C) markets, to sanitise surfaces contaminated with 
pathogenic viruses. While there is a wealth of literature on the business and scientific 
aspects of antiviral products produced by the pharmaceutical sector (Lakdawalla and 
Sood, 2012) the information for antiviral disinfectants is relatively sparse, and has 
received relatively little academic attention. The distinction between pharmaceutical 
antivirals and antiviral disinfectants will be explored more thoroughly in the 
following sections, but at this stage, it is sufficient to regard pharmaceutical antiviral 
products as being ‘drugs’ for consumption and antiviral disinfectants as cleaning 
products, not for consumption. While it is not the point of this section to necessarily 
distinguish between pharmaceutical antivirals (of which there are numerous classes) 
and antiviral disinfectants, the lack of research into antiviral disinfectants suggests 
that it is an area not well known in either a common or academic sense and needs 
some explanation. There is also the potential sensitisation of individuals to 
pharmaceutical antivirals to create prior concepts of knowledge of the ‘antiviral 
market’ or ‘antivirals’ as ‘one-size fits all’. This may skew the perception of the 
phenomenon of antiviral disinfectants as being more like pharmaceutical antivirals, 
which has been addressed by examining aspects of both types of antiviral to draw 
out a deeper understanding of product differences. Importantly, some understanding 
of other antiviral products has been considered to inform the phenomenon of interest 
i.e. how UK based SMEs carry out process R&D for antiviral disinfectants. Prior to 
the interview stage no assumption was made about how managers in antiviral 
disinfectant companies constructed aspects of the antiviral market and how they 
made sense or decisions for the environment they work in.   
 
Irrespective of how managers construct antiviral R&D, in the UK, both disinfectant 
and pharmaceutical antivirals are produced through R&D, with antiviral disinfectant 
companies in the UK predominantly being SMEs, and with pharmaceutical 
companies typically being larger and having a greater resource to carry out R&D 
(Reich, 1995; McKelvey, Aim and Riccaboni, 2003; Kotwani, 2010). While antiviral 
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disinfectant SMEs typically export globally, they do so through networks with their 
B2B-based customers usually selling their products in different locations. Data from 
the pilot studies carried out within this study (page 103-110) suggested that antiviral 
disinfectant customers (‘buyers’) who go on to sell these products, heavily influence 
(1) what products are sent into the R&D stage,  (2) what the aim of the product (or 
market need) is, and (3) what is an ‘acceptable’ cost per product unit etc. This is 
quite a different scenario to pharmaceutical antivirals, where products have a much 
higher cost, and are more likely to be monopolistic through patent protection 
(Acermoglu and Linn, 2004; Dubouis et al, 2011; Lakdawalla and Sood, 2012). 
Importantly, antiviral disinfectant companies sell their products produced from R&D 
to selling agents or larger companies, and do not sell directly into B2C markets. This 
aspect has been explored further in the main interview stage. 
 
After this overview of the antiviral market the following section introduces 
‘Research and Development’ to explore deeper the literature focussing on contextual 
and conceptual aspects important to this study.   
 
 
2.3. Research and Development  
 
R&D refers to a set of business activities that is composed of both ‘research’ and 
‘development’ stages. It is a totality of processes that allows new knowledge to be 
discovered, and once applied, can be used to create new, or improve existing 
products or services. Briefly and simplistically, R&D process can be regarded as 
successful if the product goes to market (Di Masi et al, 2003). R&D can often be 
company, product or sector specific, which can create difficulties for generalisability 
and warrantability of models produced to manage the R&D stage. This is no more 
apparent than in process industries like antiviral disinfectants, where, as Lager, 
Blanco and Frishammar (2013) stated, the R&D process is very asset intensive, can 
be sector specific and strongly integrated in one or a few physical locations. 
 
To aid in the understanding of R&D, this study examines how and why companies 
carry out R&D, alongside how they perceive it. Verma, Mishra and Sinha (2011: 
462) state that: ‘high tech firms compete in a dynamically changing market place 
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where, to survive and thrive, firms need to introduce a continuous stream of 
successful new products’. This suggests that R&D is part of a strategy for taking new 
products to market to secure company survival, which may be more difficult in high 
technology markets due to increased product and R&D complexity. While in many 
sectors, the conventional approach to improving R&D has been to focus company 
resources on reducing the time taken for R&D (Adler et al, 1995), which is arguably 
a myopic view. Interestingly, both Stalk and Webber (1993) and Gerwin and 
Barrowman (2002) have argued that focussing company resources purely on 
reducing the time taken for an R&D project, considers only aspects such as 
efficiency and ignores wider strategic considerations. At worst, this has the potential 
to result in products without customers. It also simplifies the phenomena of R&D, 
which can be complex, uncertain and risk-laden, which the author of this study 
suggests is more pronounced in biologically based products, such as antiviral 
disinfectants. Nobelius (2004) argued that understanding R&D is pivotal for 
companies undertaking it, as with a greater understanding of R&D processes comes 
an ability to manipulate the R&D stage, thus allowing a greater opportunity to reap 
financial benefit. A popular vehicle for understanding R&D is the use of models to 
mirror the R&D process stage, which can simplify complex technological aspects of 
R&D (Cooper, 1983; Adler et al, 1995; Bednyagin and Gnansounou, 2012; Popp et 
al, 2013). While it is accepted that R&D is complex, understanding the way that 
managers perceive, make sense of and construct this phenomenon can be pivotal. 
This study therefore sought to expand on prior work and more fully engage with 
these aspects via the phenomenological paradigm to construct R&D models, which 
could be ‘true to themselves’.   
 
The development of R&D models is influenced by multiple social factors that exist 
at the time of R&D model construction. Nobelius (2004) segmented many of these 
social factors into those of ‘context’ and ‘process’, which are used to show the five 
generations of R&D in Table 2.1, and that have occurred since the 1950s. Since the 
1950’s the two social factors of ‘context’ and ‘process’ have varied, based on 
numerous factors, but including the perceived ‘best’ practice at different points in 
time. Table 2.1 suggests that R&D models are continually changing through 
management driven evolution and adaption of ‘context’ and ‘process’.  
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Table 2.1. The Five Generations of R&D 
 
R&D 
Generation 
Context Process 
First  
Generation. 
 
Black hole demand 
(1950s to mid- 
1960s). 
R&D as ivory tower, technology-push oriented, seen as 
an overhead cost, with little/no interaction with 
company strategy. Focus on scientific discovery. 
Second 
Generation. 
Market shares 
battle (mid-1960s 
to early 1970s). 
R&D as business, market-pull oriented, and strategy-
driven from the business side, all under the umbrella of 
project management and the internal customer concept. 
Third  
Generation. 
Rationalisation 
efforts (mid-1970s 
to mid-1980s). 
R&D as portfolio, moving away from individual 
projects view, and with linkages to both business and 
corporate strategies. Risk-reward and similar methods 
guide the overall investments. 
Fourth 
Generation. 
Time-based 
struggle 
(early 1980s to 
mid-1990s). 
R&D as integrative activity, learning from and with 
customers, moving away from a product focus to a 
total concept focus, where activities are conducted in 
parallel by cross-functional teams. 
Fifth 
Generation. 
Systems integration 
(mid-1990s 
onward). 
R&D as network, focusing on collaboration within a 
wider system, involving competitors, suppliers, 
distributors, etc. The ability to control product 
development speed is imperative, separating R from D. 
 
Source: Nobelius (2004: 370). 
 
As might perhaps be expected, and as Nobelius (2004: 374) and Chaudri (2013: 228) 
have respectively argued, the fifth generation of R&D is now being superseded by 
the sixth generation, where: ‘management is predicted to return to the roots, i.e. 
back to the purpose of the first generation’s corporate research labs, one pursuing 
more radical innovations. One could see this as a re-focus towards the research part 
of research and development’. And further, ‘[t]he bases for the shift or new set of 
approaches are a broader multi-technology base for high-tech products and a more 
distributed technology-sourcing structure. There will be a palette of technology-
sourcing strategies available, e.g. corporate research labs, internal corporate 
venturing, technology company acquisitions, intellectual property acquisitions, 
corporate venture capital, joint ventures, independent research groups or networks, 
and internally driven R&D’. 
  
This prediction has for many sectors been realised, for example, in that the 
technology aspect of R&D is now within the hands of joint ventures, intellectual 
capital acquisitions and internal corporate venturing. The company for whom the 
author of this study works for is an example of internal corporate venturing and, 
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more significantly, this research mirrors Nobelius’s contention that the focus will be 
on the ‘research part of Research and Development’ whilst not ignoring by any 
means, the other important aspects of the process. Before the interview stage in this 
study it was not known which generation of R&D antiviral disinfectant companies 
would be based within, with this aspect being sought.  
 
Within the generations of R&D activities, are two main models of R&D, which are 
separated by the influence of commercial drivers and management decision-making 
(and are explored more fully throughout this study). The first model exists where the 
primary function of R&D is to develop new products and services and is commonly 
known as the ‘consumer’ or ‘marketing’ model (Kotler and Armstrong, 2010). In the 
‘marketing’ or ‘consumer’ model, the emphasis has been on (1) integrating the R&D 
technological function more with the marketing function (Leenders and Wierenga, 
2001) and (2) the ‘time to market’ response (Chaudri, 2013). Attempts have been 
used with this model to reduce the physical distance via ICT to help in integrate the 
‘technological’ process with the ‘marketing’ process. The second model exists where 
the primary function of R&D is to discover and create new knowledge about 
scientific and technological topics for the purpose of uncovering and enabling 
development of valuable new products, processes, and services and is known as the 
‘technological’ model (Kahn, 2004). The use of this model is more prevalent within 
technology R&D, such as process R&D, where antiviral disinfectants are situated.  
 
The two previously mentioned models are not the only models used to depict R&D 
however, as there have been numerous specific models developed for process R&D, 
which will also be discussed throughout this study. In developing an R&D process 
model for antiviral disinfectants, and understanding the reliability through 
generalisability and verification/warranting of any such model, is the requirement to 
examine the phenomena of antiviral disinfectant R&D. The author of this study 
believes that by considering the phenomena of antiviral disinfectant R&D through a 
phenomenological paradigm, the development of R&D models can more closely 
mirror the subjective reality of R&D managers interviewed in this study. With the 
antiviral disinfectant sector currently being under-researched, the direct application 
of either the ‘consumer’, ‘technological’ or other models is problematic, as none of 
	   16	  
these models appear to sufficiently cover the antiviral disinfectant processes under 
review, from either a business or technological perspective. 
 
Before a more in depth examination of these aspects is carried out, the following 
sections explore ‘Technology Companies and High Technology Products’ to engage 
directly with the way that companies produce new products (the focus of antiviral 
disinfectant R&D).  
 
 
2.3.1. Technology Companies and High Technology Products 
 
High-technology companies in B2B markets often have a more ‘intense’ product 
focus in comparison to other company types (Marcus and Segal, 1989; Dugal and 
Schroeder, 1995; Jobs, 1998; Rosen, Schroeder and Purinton, 1998). This can be 
problematic for product development and commercialisation, as R&D processes can 
be ‘long and tedious’ (Haverila, 2013: 4), with high technology companies putting a 
large emphasis on new products and their successful commercialisation. This can 
increase the pressure for successful product R&D and for management 
understanding of R&D. After products enter the commercialisation stage, failed or 
low product adoption can have damaging effects on these companies, necessitating 
‘fit-for-purpose’ marketing strategies (Kotler, 1994). Although this study is 
interested in the pre-commercialisation aspects of R&D, the interaction of marketing 
management is not mutually exclusive with the R&D process stages and both can 
influence each other.  
 
There are two types of market strategies that are broadly recognised for new 
technology products (Nemet, 2009), and include market pull (Schmookler, 1966) and 
technology push (Schumpeter, 1947). Briefly, technology push strategies are based 
on the idea that innovations are pushed through R&D, into sales and onto the market, 
without a proper consideration of whether it satisfies a user need (Martin, 1994). 
Market pull strategies are focused towards market and customer needs where there is 
‘opportunity recognition’ (Schmookler, 1966), and is based on the concept that 
companies find and exploit perceived market opportunities (Kirzner, 1979). 
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Wonglimpiyarat and Yuberk (2005) have argued that these two market strategies are 
the driving force in the process of innovation and commercialisation. Technology 
push has been argued as being greater during the initial stage of technology 
adoption; with market pull increasing as technology push decreases (Mowery and 
Rosenberg, 1979). High technology companies are often based with the area of 
technology push, which can create challenges during the marketing stage. 
 
Unfortunately there can be somewhat of an absolutist view of technology push 
commercialisation from technology-orientated managers, and as stated by Rogers 
(2003: 7), ‘[m]any technologists believe that advantageous innovations will sell 
themselves, that the obvious benefits of a new idea will be widely realized by 
potential adopters, and that the innovation will diffuse rapidly. Seldom is this the 
case. Most innovations in fact, diffuse at a disappointingly slow rate, at least in the 
eyes of the inventors and technologists who create the innovations and promote them 
to others’.  
 
This can influence the decision-making of management throughout the R&D stage, 
where fulfilling customers ‘needs’ is given a second place to the production and 
eventual promotion of technical innovation (Kotler, 1994; Craig and Douglas, 2000; 
Kustin, 2010), such as uniqueness, superiority, compatibility, performance, cost to 
user and a customer support-base (Cooper, 1980, 1981, 1983; Cooper and 
Kleinschmidt, 1987a, 1987b; Zirger and Maidique, 1990; Yap and Souder, 1994). 
Although the communication of technical innovation is potentially more complex for 
the selling company, B2B markets are often more niche in comparison to B2C 
markets, with lower numbers of potential buyers, reducing the resource potentially 
required for a higher frequency of selling (von Hippel, 1986). More than this though 
is the potential for different respondent managers to use or frame their R&D process 
stage based on their personal preferences. For example R&D managers may promote 
technology push, whereas executive managers may promote market pull based on 
their backgrounds. For larger companies engaged in R&D (albeit not antiviral 
disinfectant), biological R&D stages have been shown to be more separate from 
executive management, and thus more likely to be technology push orientated. As 
SMEs are smaller and with greater interactions between managers who often have 
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more than one organisational role and identity, it was unknown what influence this 
would have on the R&D stage.  
 
As the crux of R&D in antiviral disinfectant companies is based on R&D and 
commercialisation of new products, the following section examines the environment 
and activities carried out in ‘New Product Development’.  
 
 
2.3.2. New Product Development  
 
New product development (NPD) and innovation have been stated as being vital to 
the success of high technology companies (Yalcinkaya, Calantone and Griffity, 
2007), with both aspects being of greater importance in high-technology companies 
in comparison to other company types (Kobrin, Madhok and Osegowitsch, 2000). 
The importance of these aspects is coupled with high technology companies often 
having complex and opaque internal environments with multiple competing drivers 
for where resource should be allocated particularly throughout R&D (Jolly, 2012). 
This can create difficulties for management decision-making from the inception of a 
product to its commercialisation (Burgelman et al, 2008; Tidd and Bessant, 2009; 
Badawy, 2010). For companies carrying out NPD R&D, management can face many 
decisions, including, which products to send into the R&D stage, how much 
attention should be paid to market pull forces, and how and where to allocate 
resource throughout the R&D process stage (Shehabuddeen et al, 2006). All of these 
decision-making challenges are against a backdrop of internal and external 
competition for limited resource (Badawy, 2007), with various interest groups 
exerting pressure and pushing agendas within and external to the organisation (Jolly, 
2012). The paucity of data in the antiviral disinfectant sector meant it was not known 
to what extent these factors or others would be relevant and thus the interview stage 
was left open enough to capture ‘unexpected’ information. What was known 
however was that R&D and executive managers would have to make sense and 
decisions made on a host of such factors, potentially based on their background 
knowledge and information available to them.  
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Cooper (1999: 118) argued that ‘today’s complex projects require a multitude of 
technical and people skills to be an effective, well-rounded team leader or player’ 
for developing new high technology products. Unfortunately though, ‘one recurring 
problem is the lack of experience and/or education of people expected to undertake 
new projects’, which was cited for new product development in both B2B and B2C 
based markets (Cooper, 1999: 119). The lack of education and knowledge within 
high technology companies can result in various problems for NPD and R&D, 
particularly for communication between managers. This study therefore addressed 
this aspect in the interview stage.  
 
More generically, and drawing on resource-based theory (RBT), background 
resources have been argued as being vital for NPD, with one of the most important 
aspects of this being the experience of the individuals and teams in carrying out 
management of NPD (Cooper, 1999; Adams-Bigelow, 2006). Nevis, DiBella and 
Gould (1995) suggested that higher levels of experience could result in more 
successful R&D; product launches, and creates a competitive advantage through 
marketing. Ordanini, Rubera and Sala (2008) have argued that management often 
overlooks these aspects, thus reducing the potential return to companies engaged in 
R&D activities.  
 
Prior research has examined the link of educational and professional backgrounds of 
key personnel in high technology companies engaged in NPD R&D through to 
marketing (Cooper and Kleinschmidt, 1990; Zirger and Maidique, 1990; Yap and 
Souder, 1994). This research found that ‘high’ skill levels including engineering, 
manufacturing, sales and marketing, and project management were significantly 
positively correlated with NPD performance in opaque and uncertain environments. 
For lower levels of uncertainty (Haverila, 2011), a much weaker correlation was 
found between skills and new NPD. This potentially suggests that higher levels of 
individual knowledge enable a greater view for looking at organisational life and fits 
with the suggestions of Weick (1995). This study expanded on prior research to 
examine manager backgrounds (education and professional) and expanded this 
consideration by also looking at the discourse used by different managers to make 
sense of R&D.  
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Central to the products being developed by antiviral disinfectant based SMEs are the 
biological entities being targeted by the products and the nature of the R&D being 
carried out. The following section therefore examines ‘Viruses and Antiviral R&D’.  
 
 
2.3.3. Viruses and Antiviral R&D 
 
Antiviral disinfectants (also known as antiviral sanitisers) ‘target’ pathogenic viruses 
and can be described as ‘a drug or treatment active or effective against viruses’ 
(OED, 2012). Viruses exist in a wide variety of environments, including living hosts, 
such as humans, animals, crops etc. or non-living environments such as tabletops, 
door handles, clothes etc. A virus is a disease-causing pathogen, with the word virus 
being derived from the Latin and referring to a poisonous or noxious substance. 
Importantly however, the Latin meaning of virus is no longer suitable today, as 
describing viruses as ‘poisonous’ or ‘noxious substances’ is suggestive of many 
disease-causing agents. In a common sense meaning, viruses can perhaps be 
regarded as ‘poisonous’ or ‘noxious substances’ but these definitions are not helpful 
for companies carrying out antiviral R&D. Looking beyond the older definitions it is 
interesting to examine the medical meaning of a virus, which can be taken from 
Harper (2012) who described it is a small entity that causes an infectious disease. 
Again, for companies carrying out antiviral R&D, this is still not a particularly 
helpful description, especially where there is a requirement for R&D using selected 
product ‘ingredients’ to target and inactivate viruses. Carter and Saunders (2007: 11) 
provided a scientific definition, and they stated that: ‘a virus is a very small, non-
cellular parasite of cells’. Although a scientific definition provides a foundation for 
understanding the biological pathogens that antiviral disinfectant R&D companies 
target, it was not assumed by the author of this study that all managers in such 
companies use scientific definitions of viruses and may perhaps use quite different 
socio-linguistic constructions. A different way of defining or engaging with the 
concept of a virus is through visual representation, as shown in Figure 2.1. 
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Figure 2.1. Human Papilloma Virus  
 
xxxxxxxxxxxxxxxxxx  
 
Source: http://news.softpedia.com/news/How-to-Reduce-Pap-Testing-Frequency-in-HIV-
Positive-Women-282594.shtml#sgal_0). Last accessed 01/11/2014. Other viruses may vary.  
 
Physically, viruses are small pathogenic cellular parasites that through their infection 
and interaction with host cells (often in a larger host organism) create diseased states 
for the host. Due to their small size of between 2.5 million and 50 million times 
smaller than a metre (Koonin, Senkevich and Dolja, 2006) and coupled with their 
biochemical traits, viruses are able to penetrate larger cellular entities such as 
bacteria, yeast and mammalian cells (with the latter composing organisms such as 
humans). Edwards and Rohwer (2005) have expressed a belief that viruses are the 
most abundant biological entities on the planet. This ‘fact’ often receives little 
attention as it not possible to see viruses with the ‘naked’ eye. Unlike many other 
biological infectious agents (such as bacteria and fungi), viruses require living cells 
to survive and replicate, but when they do replicate, they do so at incredible rates, 
and for example, a person infected with HIV can potentially produce 1011 viruses a 
day (Carter and Saunders, 2007).  
 
In the replication and transmission of viral particles from one host to another (i.e. 
human to human), numerous routes may aid in viral transmission, such as sexual 
contact, sneezing, coughing, touch etc. (Bielanski et al, 2013; Gorgos, 2013; Wen et 
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al, 2013). The method of transmission can be briefly described as (1) the virus exists 
inside the host, (2) the virus leaves the host (existing on an external surface), and (3) 
if transmission and infection is successful, the virus will enter a new host.  
 
The physiology of viruses and their replication requirements predicates the types of 
product treatments used to reduce pathogenic infection due to the viral requirement 
to exist inside a host cell (which is not to say that they cannot temporarily exist 
outside of a cell). As described previously, there are three treatment methods, which 
act in quite different ways to stop the transmission of a virus and are as follows. (1) 
The use of a vaccine, which stops an uninfected host becoming infected, (2) the use 
of an in vivo antiviral, which treats an already infected host, and (3) a non-in vivo 
antiviral disinfectant which ‘kills’ viruses that have left one host, before they enter a 
new host. A diagrammatic decision-making diagram for the three antiviral treatments 
is shown in Figure 2.2. 
 
Figure 2.2. Diagrammatic representation of antiviral treatments 
 
 
 
 
 
 
This flowchart shows when it is pertinent to use the different types of viral treatments, 
including vaccination, in vivo antiviral and non-in vivo antiviral. 
 
In this study, it is the use of (non-in vivo) antiviral disinfectants that is of primary 
interest and it is important that the difference between the three products is noted, as 
it greatly influences the R&D strategy. Simplistically, both vaccinations and in vivo 
treatments are to be administered directly into a host, whereas antiviral disinfectants 
(which are always non-in vivo) are used outside of a host, such as on the hands, 
tabletops and door handle etc. The difference for where a product works (in or 
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outside of a body) creates different R&D processes. An example of this is that there 
is generally no requirement for animal or human testing via clinical trials for 
antiviral disinfectant testing of toxicity, whereas this is always a requirement for 
vaccines and in vivo antivirals (Griffith, 2008). This greatly reduces the requirements 
for antiviral disinfectant R&D resources and time to complete a project. Antiviral 
disinfectants are often much less specific in their mechanisms of ‘killing’ viruses, as 
they can be used outside of a host, so generic antimicrobial constituents such as 
bleach (Fraise, 1999) can be used instead of complex molecules. This means that in 
rapid outbreaks of viral infection, existing antiviral disinfectants can be trialled 
against new pathogens or an existing formulation modified, thus potentially allowing 
a quick route to market. However, as viral outbreaks can often mean that infecting 
viral particles can infect a wide variety of surfaces outside of a body, this 
necessitates different product testing challenges, to make sure that the product 
doesn’t negatively impact of numerous surfaces that an antiviral disinfectant product 
may contact, when used.  
 
Viral outbreaks and particularly pandemics are becoming major drivers for antiviral 
disinfectant R&D (Hom and Chous, 2007). Examining literature from over the past 
100 years shows that viral pandemics have resulted in large losses of human life, as 
shown by Lim and Mahmood (2010):  
 
a) Spanish flu A(H1N1) occurred in 1918-1919 and resulted in 20-40 million 
deaths;  
b) Asian flu A(H2N2) occurred between 1957-1958, with over 2 million deaths;  
c) Hong Kong Flu A(H3N3) occurred between 1968-1969, with between 1-4 
million infections and over 30,000 deaths in England and Wales alone.  
 
More recently however, and linked with increased ease of human global travel, there 
have been numerous viral outbreaks, with pandemics including:  
 
a) Severe acute respiratory syndrome (SARS) which infected over 8,000 people 
and killed 74 people in 2003 (Lingappa et al, 2004);  
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b) Avian influenza H5N1, which infected a minimum of 108 people and killed 
54 people in 2005 (CDC, 2005; WHO, 2005);  
c) Swineflu H1N1, which infected over 18,000 people and killed 1799 people in 
2009 (Sinha, 2009).  
 
All of these outbreaks have resulted in increased consumer demands for ‘new’ 
products that can easily be incorporated into existing products such as hand washes 
(Cargill et al, 2011), used to clean easily contaminated areas such as medical devices 
(Teich, Cheung and Friendman, 1992) and transport systems such as airliners (Hom 
and Chous, 207). Looking briefly at the example of airliners, it has not been possible 
to eradicate person-to-person spread, but it has been possible to heavily reduce viral 
transmission, by the use of antiviral disinfectants in conjunction with other 
strategies, and is a cheap and relatively easy to use method.   
 
Finally, in biologically orientated product development in general, there have been 
many products developed for an end use other than what they were initially designed 
for (Jurovcik and Holy, 1976). In part, this is often due to the uncertainty 
surrounding biologically orientated product development, where unexpected side 
effects can prohibit commercialisation or may make the product more attractive for a 
different application. This is coupled with the general difficulties of predicting the 
return-on-investment (ROI) and longevity of biologically orientated products, 
including antiviral disinfectants. This was certainly the case for HIV in vivo 
antivirals, where it took many years for development companies to understand their 
life-cycle value (Asante-Appiah and Skalka, 1999). Factors such as these can 
complicate management decision-making for the R&D stage. Thus the interview 
stage sought to draw out management understanding of viruses and antiviral 
disinfectants and contextualise this knowledge with the sense made of these aspects 
and how decisions are made for R&D.  
 
Importantly R&D does not exist in isolation from external forces within and outside 
of the organisation undertaking R&D, and while it has been pivotal to understand 
viruses and antiviral R&D, an examination must also be undertaken to understand 
‘The R&D Environment’.  
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2.3.4. The R&D Environment 
 
The R&D environment can be defined as a totality of all factors that surround and 
interact with R&D. It can include factors such as, employees, management, the 
micro- and macro economy and customers etc. Within this description is a potential 
segmentation of internal and external R&D environments, which both interact and 
influence R&D. The internal environment is process based and in this study is 
focussed on which processes occur, as well as how and why they occur. As these 
processes are management driven, R&D management decision-making is important 
for how companies attempt to internally regulate the R&D environment, while still 
focussing on external factors.  
 
R&D environments are not static, and can change multiple times during the R&D 
stage, which in turn can alter goals and requirements during this stage. As Verma, 
Mishra and Sinha (2010: 463) stated: ‘R&D projects in high tech firms are also 
characterized by changing goals and requirements during a project’s lifetime, which 
can span several years’. These environments can be regarded as dynamic, uncertain 
and risk-laden, which create challenges for managing these projects (Brown, 1995). 
These elements inherent within the R&D environment lead to management drivers to 
understand the R&D stage, which in many cases can be through modelling the R&D 
stage, to aid in management decision-making to create shared meaning for complex 
phenomena.  
 
Beyond the aspects discussed so far is the question of how do companies approach 
R&D projects? As argued by March (1991) and Mudambi and Swift (2011), there 
are two main paths available for companies, including exploration and exploitation, 
both of which can be used to create or appropriate company value through R&D. It 
has been argued that exploitation occurs where companies leverage their existing 
knowledge base (Rosenkopf and Nerkar, 2001; Benner and Tushman, 2003), while 
exploration involves the search for new utilisable knowledge in areas that are 
relatively distant from the company’s core knowledge base (Baum et al, 2000; 
Rosenkopf and Nerkar, 2001; Benner and Tushman, 2003; He and Wong, 2004). 
Exploration can involve aspects such as experimentation, varying processes  (Baum 
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et al, 2000) or changing the technological trajectory  (Benner and Tushman, 2003; 
He and Wong, 2004). Exploitation however, can involve re-using existing 
knowledge (Rosenkopf and Nerkar, 2001; Benner and Tushman, 2003) or changing 
company competencies (He and Wong, 2004). Gupta et al (2006) have suggested 
that successful exploration and exploitation skills can require fundamentally 
different skills.  
 
Exploration and exploitation are not mutually exclusive however and can be carried 
out, individually, simultaneously, or with fluctuation between the two paths. Where 
there is movement between exploration and exploitation, the R&D environment has 
been described as under conditions of ‘punctuated equilibrium’ (Mudambi and Swift, 
2011) due to the change between management drivers between these paths. The 
process of moving from exploitation to exploration has been argued as a form of 
extreme organisational change (McGrath, 2001; Burgelman, 2002; Katila and Ahuja, 
2002; Lee et al, 2003; Benner and Tushman, 2003; Holmqvist, 2004; Gupta et al, 
2006). This can be challenging for managers (particularly between non-R&D and 
R&D managers) due to a lack of symmetry of information and knowledge between 
these two types of manager (Stein, 2003).  
 
R&D projects can suffer due to their opacity in the eyes of executive R&D 
managers. Opacity can occur as a consequence of difficulties in predicting R&D 
outputs, particularly what the output will be, and when it will occur (Anderson and 
Tushman, 1990). This can be coupled with the types of information disclosed to 
executive management from R&D management not always being clear and vice 
versa. Where information from R&D management is not clear, it can be difficult for 
executive management to accept or refute R&D claims (Stein, 2003), complicating 
decision-making.  
 
With such challenging information environments, it has been argued that the ‘best’ 
companies are capable of operating between such conflicting goals as described so 
far (March, 1991, 1996, 2006; Dougherty, 1992; Eisenhardt and Martin, 2000; 
Ancona et al, 2001; Benner and Tushman, 2003; Feinberg and Gupta, 2004; 
Levinthal and March, 1993). The argument has been made that the ‘best’ performing 
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companies engage in exploration and exploitation activities simultaneously 
(Tushman and O’Reilly, 1996), although, this has been disputed by other theorists 
(March, 1991; March, 1996; March, 2006; He and Wong, 2004).  
 
R&D can act as a vehicle for companies to leverage their existing knowledge base, 
and for antiviral disinfectant SMEs, this can be in the form of new products being 
brought into existing or new markets entered. As Mudambi and Swift (2011: 429) 
stated: ‘Proactive management of the firm's R&D function requires not only 
exploiting current knowledge-based competencies, but also exploring new 
opportunities once those competencies lose their competitive edge.’ Exploring new 
competencies can be through infrequent discontinuities that enable new knowledge 
to be leveraged. Management of discontinuous events by companies is not a simple 
task, as the timing of such events can be difficult to predict (Kuhn, 1962). Even 
though discontinuities can create benefits for R&D companies (as well as 
difficulties), there can be long periods of stability, where companies can exploit their 
existing competencies (Mudambi and Swift, 2011).  
 
For companies undertaking R&D (exploration/exploitation based), company size can 
impact on the level of resource, knowledge (management and scientific), as well as 
the level of commitment that can be given to an R&D project. Smaller companies are 
more likely to be entrepreneurial consisting of single business units (Reinganum, 
1983), and as Lubatkin et al (2006: 647) argued, they are more likely to lack 
‘facilitating resources’ and ‘slack resources’, which enable larger companies to have 
a greater flexibility in R&D. Perhaps not surprisingly, R&D capability has been 
shown to increase with company size (Kogut, 1991; Hernan et al, 2003) and can 
increase the likelihood that a company can carry out the exploration and exploitation 
of new technology at the same time (Zahra and George, 2002).  Mansfield (1981) 
demonstrated this point, by showing that while R&D expenditure dedicated to 
refining existing products increased with company size, R&D portfolios, including 
new products were also likely to increase.  
 
With resource being a challenge for smaller companies carrying out R&D, it has 
been shown that smaller companies specialise as a method of dealing with this lack 
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(Beckman, 2006). Specialisation can occur on many fronts, including whether a 
company engages in exploitation or exploration, with Benner and Tushman (2003) 
arguing that smaller companies typically focus on one of these aspects. Due to the 
limited resource that SMEs face for carrying out R&D, it is acknowledged that 
inefficiency, lack of resource and management ability to understand the R&D 
process can ‘hurt’ the company, and particularly R&D outcomes.  
 
Beyond the challenges facing R&D companies, it is interesting to look at what 
‘facilitates’ a company to be successful. Fines (1998) have stated a belief that 
‘successful’ companies exist in ‘clockspeed’ industries; where rates of product 
development, process, capital equipment and design have relatively rapid 
management decision-making, which allows them to keep pace with the speed of 
opportunities confronting them (Davis et al, 2009). Companies existing in lower 
‘clockspeed’ industries can often place a greater emphasis on operational efficiency 
and less on strategic flexibility (Pisano, 1994; Rivkin and Siggelkow, 2003). For 
SMEs, these problems can be compounded by a general lack of resource to exploit 
opportunity (Beckman, 2006). Simplistically, as Mudambi and Swift (2011: 430) 
stated: ‘firms must have the domain expertise and knowledge management processes 
that enable them to move in the right direction, at the right time.’  
 
Verma and Sinha (2002: 451) argued that high-technology companies rarely produce 
one product at a time, and instead: ‘introduce a continuous stream of successful new 
products to survive in today’s intensely competitive and dynamically changing 
market place’. This is not to argue that all R&D companies carry out simultaneous 
R&D on multiple-products but that it can be a popular method and bring 
requirements for managing multiple R&D projects, as well as using shared resources 
between multiple companies working together (Adler et al, 1995; Gupta and 
Wilemon, 1996). The use of networks in R&D is long recognised (Huston and 
Sakkab, 2006) and in this study, this aspect was investigated during the interview 
stages. R&D carried out via network structures can result in pooled 
interdependencies between companies (Thompson, 1967). Verna and Sinha (2002) 
segmented R&D interdependencies into three distinct categories including, (1) 
resource interdependencies, (2) technology interdependencies, and (3) market 
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interdependencies. As Verna and Sinha (2002: 451) stated: ‘market interdependcies 
stem from (i) a new product’s diffusion into an already existing market and (ii) 
utilizing a current product’s market knowledge (e.g. how to manager a dealer 
network) for a new product for an entirely different market’. Companies working 
together on R&D have created greater output with less resource (Gupta and 
Wilemon, 1996; Cooper et al, 1997), but the notion of best practice for an individual 
company or one engaging in a network is still not well understood (Gupta and 
Wilemon, 1996; Krishnan and Ulrich, 2001).  
 
To continue exploring the relevant literature underpinning this study, the following 
section moves on to consider ‘The Antiviral R&D Environment’.   
 
 
2.3.5. The Antiviral R&D Environment 
 
The antiviral disinfectant sector can be considered highly specialised, with valuable 
physical and knowledge-based resources. Penrose (1959) believed that these 
conditions create an incentive for companies operating within such sectors to expand 
via R&D, to more profitably exploit their capabilities (Teece, 1982; Teece, 1986; 
Wernerfelt, 1984; Montgomery, 1994). Within this incentive is a drive for R&D 
management, capable of creating a clear pathway through the physical and business 
processes of R&D, while reducing waste and optimising resource, with attempts to 
achieve this often being through the creation of a model (Kerssen-van Drongelen and 
Bilderbeek, 1999). To develop a model for management that adequately reflects the 
reality of R&D is a requirement to understand the phenomena of R&D, particularly 
the environment that R&D operates within. This section is therefore focused on 
understanding the environment surrounding the phenomena of R&D.  
 
From limited academic literature and the author’s prior sensitisation to the sector, 
antiviral disinfectant R&D can in many ways be regarded as sector and product 
specific, but with some similarity to other product and process based R&D. 
Fundamental to the R&D stage is the antiviral product being developed, with much 
product R&D potentially being complex, with many uncertain and risk-laden 
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decisions to be made by management. These decisions can include, when and how to 
carry out a process, and in which order, as well as how much resource to commit to 
any process stage. R&D is not necessarily linear and if one process stage ‘fails’, a 
product may be recycled through previous stages until it achieves internal criteria set 
by management for ‘success’. Coupled with this are changing management 
preferences throughout R&D and a paucity of information about the product. An 
example of this was early stage HIV drug R&D, where management perceived drugs 
as having limited usage with any patient i.e. they would ‘cure’ the disease. At the 
latter stages of R&D, it was found that the product was required to be used 
throughout a patient’s lifetime as opposed to a simple cure, which greatly increased 
product sales (Wainberg, 2009). Situations like this make it difficult for management 
to estimate the resource that should be committed during R&D as the product could 
arguably have a greater or lesser value than anticipated. These issues can also 
complicate the business case for R&D, which for antiviral disinfectants is inherently 
complex, with understanding required of the following process stages for product: 
(1) formulation, (2) toxicity, (3) stability, (4) legislation and (5) economics. Within 
each of these stages are aspects including cost, risk, uncertainty and ROI etc.  
 
Arguably the first stage associated with R&D is design. Bolken and Hruby (2008: 2) 
stated that ‘the first challenge that drug developers face is the paucity of available 
information.’ The paucity of information can be with regard to business and 
scientific knowledge held within a company, as well as the ability of a company to 
access information outside of itself i.e. through specialists and access to journals etc. 
Beyond knowledge, is whether a company has access to physical facilities to carry 
out adequate antiviral disinfectant R&D? While, all companies have the choice of 
whether to carry out their own R&D, or subcontract it, antiviral work can bring its 
own unique challenges for R&D companies. This is based on companies either 
having their own facilities or requiring access to facilities for testing products against 
highly pathogenic viruses, which are heavily regulated and not easy to set up or 
maintain. In cases where companies do not have access to these facilities, it limits 
R&D, and can mean that companies use substitute viruses or less pathogenic viruses, 
which can limit the marketing claims of subsequent product releases. Not 
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surprisingly, Baker and Peacock (2008) have stated their belief that for antiviral 
product development, access to literature and facilities is paramount for R&D. 
 
The formulation of an antiviral disinfectant product is pivotal to the pre-
commercialisation stage of R&D, as well as the post R&D stage, including the 
marketing claims that can be made. As mentioned previously, antiviral disinfectants 
target viruses outside of a host, when and where an infected host has spread the virus 
through sneezing, coughing or the release of other biological fluids (blood, semen 
etc.). Once on an external surface (and depending on environmental surface 
conditions and the type of virus) the virus can remain active for up to a month 
(Terpstra et al, 2007). As antiviral disinfectants are predominantly liquid-based, they 
are suitable for incorporation into a wide variety of disperal systems, including 
sprays, wipes, fogging machines etc. (Spencer, Cohen and McAllister, 2007). A 
further advantage is that they can also be added into existing products, for example 
directly into an antibacterial formulation, to give it further functionality (Mecitoğlu 
et al, 2006). This can allow numerous market entry points into already existing 
product ranges such as hand washes (Cargill et al, 2011), medical device cleaners 
(Teich, Cheung and Friedman, 1992) and airliner cleaners (Hom and Chous, 2007).  
 
One of the advantages of antiviral disinfectants is that there is no requirement for 
animal or human testing, as the products function entirely outside of the body, unlike 
vaccines and in vivo antivirals, which do operate inside a host body, and complicate 
the R&D stage. Briefly, antiviral disinfectant products operating outside of a host 
means, greatly simplifies the scientific testing for product toxicity throughout the 
R&D stage. A potential disadvantage of antiviral disinfectants is that each product 
target market, may have its own toxicity requirements (even if not human or animal), 
and may therefore add additional stages to R&D. Beyond toxicity, is the challenge of 
identifying surfaces that products may come into contact with, as each surface could 
potentially interact differently with each product, requiring further R&D testing. 
Bleach based antiviral disinfectants are an example of this, as they can be suitable 
for cleaning tabletops, but not carpets or medical instruments, as in the latter case, 
they may burn patients. Generically, using ‘simpler’ product constituents like bleach 
can reduce the time to market as well as lowering R&D costs (Federsel, 2000; Lin 
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and Saggi, 2002; Federsel, 2010) but do have disadvantages. There is of course the 
requirement for the antiviral disinfectant to have a limited detrimental effect on the 
surface, to which it is applied. A further challenge is that the environment where the 
product will be used could inactivate the product, as in the case of heavy organic 
‘dirt’ contamination on kitchen floors (Favero and Bond, 1991; Rutala and Weber, 
1997). Arguably, all of the interactions that the product may have with environments 
when used as a product need to be considered during the formulation stage, even if 
not physically tested. These and other factors can reduce ‘R&D Risk and 
Uncertainty’, which is explored more fully in the following section.  
 
 
2.3.6. R&D Risk and Uncertainty 
 
The issues of risk and uncertainty have received much attention in R&D and 
management literature (Bacon et al, 1994; Smith, 1988; Kim and Wilemon, 1999; 
Doll and Zhang, 2001) and with perceptions varying for how they should be 
addressed and perceived. Nobelius (2004: 369) has argued that: ‘many companies 
perceive research and development (R&D) as somewhat fuzzy, involving high 
uncertainty, with unclear rate of return, and troublesome to manage.’ However, as 
Verma, Mishra and Sinha (2010: 463) stated, these aspects can be considered in the 
wider context of R&D, particularly from the viewpoints of exploration and 
exploitation: ‘Generally speaking, R&D projects can be classified into two broad 
categories: (i) projects that operate within the realm of current technical capabilities 
or require a stretch of current technologies, and (ii) projects that require a radical 
innovation to deliver functions. The first category requires exploitation of old 
certainties and involves mutual learning between members of an organization and 
an organizational code. The code is buried in many features of organizational forms 
and customs, e.g., in organizational policies of reducing risk. The second category 
requires exploration of new possibilities leading to learning and competitive 
advantage’.  
 
R&D projects based on the exploration of new possibilities are arguably less certain 
than exploitation based projects, as they require more time and are organisationally 
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more complex in comparison to exploiting an existing knowledge base. Although 
exploitation is often preferable for short-term gains, it has the potential to hinder 
company growth in the longer-term (Tushman and O’Reilly, 1996). It has therefore 
been argued as important for companies looking to achieve long-term growth, to 
engage in some risk-laded R&D projects via exploration of knowledge, but once the 
knowledge is attained, to exploit it (March, 1991). It is not an easy task for managers 
to select between different R&D projects, which can vary in their potential for short 
and long term profits (Benner and Tushman, 2003). This can be coupled with general 
difficulties faced by managers making decisions about R&D, as poor decision-
making and regulation of the R&D stage can result in R&D being halted or 
terminated (Gurgur and Morley, 2008). In such circumstances increased 
development times and costs can be incurred, as well as an increase in the likelihood 
of R&D failure (Wang, Lin and Huang, 2010). This can be particularly problematic 
where multiple R&D projects occur simultaneously, which can create further 
challenges for management sense- and decision-making (Kavadias and Chao, 2006).  
 
As might be imagined, different R&D projects have varying levels of uncertainty 
and risk associated with them (Doctor et al, 2001; Raz et al, 2002; Lee et al, 2010). 
Biologically based R&D is regarded as being inherently difficult, uncertain, and risk-
laden, with high levels of R&D product failure not being uncommon (CMR, 2006). 
Within the biological R&D sectors and as Bush et al (2005) argued, much risk 
management has focussed on identifying and understanding the physical issues of 
product R&D such as toxicity. Once identified, subsequent development often 
focuses on risk mitigation strategies) to increase R&D success and business 
opportunity (Blau et al, 2000; 2004; Rajapakse et al, 2005), which has resulted in an 
overall lack of research examining risk management for R&D processes beyond 
toxicity (Wang, Lin and Huang, 2010). Although important, linking risk almost 
entirely to potential product toxicity is limiting and ignores many other risk aspects 
associated with R&D.  
 
To understand the importance of risk to an R&D project, it is important to be able to 
understand what risk is. Simplistically, risk can be considered an event that has an 
unknown but often negatively perceived outcome (Browning et al, 2002; Raz et al, 
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2002; Smith and Merritt, 2002; Keizer et al, 2002, 2005; Perminova et al, 2008; 
Wang, Lin and Huang, 2010). Not surprisingly, risk is defined differently in different 
academic disciplines. In economics, risk refers to situations where a decision maker 
can assign probabilities to different outcomes (Knight, 1921). In decision theory, risk 
is the construct that a decision is made under the condition of known probability 
over the state of nature (Luce and Raiffa, 1957). In project management, there is a 
lack of a consistent definition for risk (Ward and Chapman, 2003; Perminova et al, 
2008) but was defined by the Project Management Institute (PMI, 2004) as being ‘an 
uncertain event or condition that, if it occurs has a positive (opportunity) or negative 
(threat) impact on project objectives’. There is however a predominant focus from 
academics and practitioners to viewing risks in a negative light (Williams, 1995; 
Boehm and DeMarco, 1997; Smith and Merritt, 2002; Ward and Chapman, 2003). 
As Wang, Lin and Huang (2010: 602) stated: ‘from this perspective, project risk 
management seems to be about identifying and managing threats to the project’. It 
has been argued that management of risk and uncertainty throughout the R&D 
processes is important to improve the success rate of products making it through 
R&D (Smith and Merritt, 2002; Keizer et al, 2002; Bush et al, 2005; Pisano, 2006).  
 
As Wang, Lin and Huang (2010: 601) stated: ‘risk management is a structured 
approach for the identification, assessment, and prioritization of risks followed by 
planning of resources to minimize, monitor, and control the probability and impact 
of undesirable events’. While from a common sense perspective, it could be argued 
that minimising ‘undesirable events’ is desirable; it doesn’t take into account the 
impact of serendipitous discovery, which may arise out of ‘undesirable events’. Risk 
management has been utilised in a wide variety of sectors and processes, but in R&D 
management, the focus is towards increasing the potential success of the R&D 
project (Wang, Lin and Huang, 2010).  
 
Related to R&D risk, is uncertainty, which in R&D management literature is defined 
as an inability to predict the R&D environment, R&D environmental change, and the 
consequences of decision-making (Milliken, 1987; Doctor et al, 2001; Sicotte and 
Bourgault, 2008). It has also been argued as the absence of relevant information 
(Galbraith, 1977) and can be considered a measure of an organisation’s lack of 
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awareness of the value of defining constructs in the planning process (Doll and 
Zhang, 2001). Importantly, risk has been defined as the exposure to uncertainty 
(Smith, 1999; Browning et al, 2002; Raz et al, 2002; Smith and Merritt, 2002; 
Keizer et al, 2002, 2005). Interestingly, considering that risk and uncertainty are both 
often linked to negative R&D outputs, it is not surprising that managing R&D 
uncertainty (Doctor et al, 2001; Loch et al, 2006) and risk (Williams, 1995; Smith, 
1999; Keizer et al, 2002; Raz et al, 2002; Cooper, 2003; Smith and Merritt, 2002) 
has received much academic attention. Academic studies have thus focussed on 
managing risk management to improve project success rates (Raz et al, 2002; 
Salomo et al, 2007; O’Conner et al, 2008), with modelling R&D also being favoured 
(Kerssen-van Drongelen and Bilderbeek, 1999). Thus modelling R&D can be seen as 
not only a management practice to reduce the loss of R&D resource, but to 
effectively ensure a desirable R&D outcome. Considering that these are potentially 
desirable aspects of R&D, the social and cognitive aspects of the organisation can 
also be considered for how individuals, groups and the organisation makes sense of 
technical and management orientated. This is particularly the case for how 
representation through the use of language and images can enable sense to be made 
of complex and uncertain environments. Importantly and although sensemaking has 
been applied to numerous areas of organisational life, thus study sought to add 
knowledge to the production of an R&D process model to understand and potentially 
mitigate risk in the R&D stage. Mitigation of risk and other organisational R&D 
aspects comes under the umbrella of ‘Management of R&D’ and is considered in the 
following section.  
 
 
2.3.7. Management of R&D 
 
Nobelius (2004: 369) stated that: ‘the perspective on R&D processes has been 
different throughout the years, since the structure and prerequisites of the economy 
have changed and so has the presumption of best practice’. R&D and management 
practices can thus be considered as existing in a perpetually changing landscape, 
where perceptions of requirements and best practice continually change over time, 
which at some level can be linked to ‘der Geist seiner Zeit’. This can be translated to 
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mean ‘the spirit of his time’, and in this context means that ‘no man can surpass his 
own time, for the spirit of his time is also his own spirit’ (Magee, 2011: 262). This 
has created a shift of management R&D from a view of isolation, to existing in 
complex and connected internal and external influences. 
 
Overseeing and managing R&D, are various managers, who have different roles and 
perceptions with regard to this activity. At the most senior level are executive 
managers who oversee wider company objectives, of which R&D feeds into, but 
these managers are arguably less ‘hands on’ in day-to-day decision-making. There 
are also R&D managers, whose sole function is to manage the R&D stage, and who 
have less interaction with wider company management and agendas. Due to 
sensitisation to management literature and experience of working in the antiviral 
sector, the author of this study, perceived that executive managers and R&D 
managers, are pivotal in the management of the R&D stage, although potentially 
interact with R&D differently. Through the construction of a management model of 
R&D, both management views can be considered and represented, thus both types of 
manager were interviewed.  
 
Badawy (1989) has argued that while many companies might successfully develop 
new technology, management of the R&D and commercialisations stage is pivotal 
for the commercial success of products. While a wider management view is 
important for the commercialisation of products, this study has a predominant focus 
on the pre-commercialisation aspects of R&D, but methodologically has allowed 
respondents to discuss post R&D elements if they perceived it as necessary. In this 
way, the researcher attempted to draw out the most important points of R&D and 
factors influencing R&D that would enable the translation of R&D products into 
commercial products, while understanding management aspects (Lansiti, 1977). It is 
important to note that the researcher was embedded within the antiviral disinfectant 
sector before and throughout this study, which challenged the notion of objectivity 
on behalf of the researcher. While the notion of complete objectivity of any 
researcher is a moot point and is rejected in this study, this researcher’s objectivity 
was dealt with through the explicitation process, particularly phenomenological 
bracketing (as detailed in page 90).  
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Prior to the physical aspects of R&D being undertaken, is the first consideration 
made for R&D, which is to determine what level of front-end planning is carried out. 
This is where management first considers an idea for R&D, all the way through to a 
decision being made for whether a potential product should enter the R&D stage 
(Kim and Wilemon, 1999). It is at this point in time that management must decide 
what desired output of product R&D is, as well as the level of resource to commit 
(Moenaret et al, 1995). Various planning activities can be carried out to facilitate 
management understanding and decision-making for the R&D project, and can 
include, R&D strategy formulation, opportunity identification and assessment, 
technological feasibility studies, R&D project planning, and internal interviews 
(Cooper, 1997; Khurana and Rosenthal, 1988). Song et al (2007: 232) confirming the 
work of Nobelius (2004:369), stated that: ‘Because of embedded uncertainties, 
ambiguities, or “fuzziness’ with respect to market, technology, R&D process, 
funding, etc,. this stage is characterized as knowledge seeking, learning, 
communication and study, experimenting and creating’. Thus the sense made of this 
stage is pivotal to facilitate R&D decision-making.  
 
Although, R&D has numerous challenges for companies undertaking it, successful 
R&D has the potential to create ‘greater market share, premium prices and 
dominant designs, leading to a much sharper competitive edge’ (Nobelius, 2004: 
369) through management. The management of R&D processes and the R&D stage 
raises several management challenges for companies, including (1) strategic, (2) 
operational, and (3) methodological (Nobelius, 2004). Throughout these three 
aspects, are both physical and mental elements, in that physical processes are carried 
out, but are also socially and cognitively interpreted, communicated and with a 
requirement to manage these elements. The processes of how managers make sense 
of their world in company life and R&D is important, for understanding how 
management is carried out, and decisions made. In the next two sections, ‘Making 
Sense of R&D’ and ‘Management Decision-Making’ these aspects are considered. 
This study was predominantly focussed towards the operational but also 
encompassed an exploration of the strategic and methodological elements.  
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2.3.8. Making Sense of R&D 
 
Managers exist in a complex environment where competing organisational and 
individual drivers, compete for resource. Within this environment is a need for 
managers to be able to make sense of their world, communicate effectively about it, 
make decisions and facilitate shared meaning and understanding to aid in their role 
as manager. These aspects often lead to physical action and the communication of 
complex ideas, such as in R&D.  
 
Making sense of complex phenomena is not necessarily an easy task for individuals, 
particularly where it is opaque, ambiguous, uncertain, or risk-laden, as is often the 
case within biological R&D. This can be further complicated, where individuals 
within a company communicate using different discourse styles based on their self-
identities as scientists and managers etc. via different terminology, and non-verbal 
intonations to communicate about the same phenomena. This can make the 
production of shared meaning more difficult, resulting in challenges for making 
sense and ultimately decisions about R&D.  
 
There is a set of cognitive (Starbuck and Milliken, 1998) and social (Weick, Sutcliffe 
and Obstfeld, 2005) processes known as sensemaking that can enable individuals to 
make and communicate sense about complex aspects of their world. Briefly, 
language and image based cues (amongst others) can be used in sensemaking to 
produce a simpler version of reality, or a version that is more preferred by the 
individual experiencing it (Brown, 2000; Maitlis, 2005; Weick, 1995; Sutcliffe, 
2013). Sensemaking can be defined as creating ‘rational accounts of the world that 
enable action’ (Maitlis, 2005: 21), and is ‘a continuous effort to understand 
connections (which can be among people, places, and events) in order to anticipate 
their trajectories and act effectively’ (Klein et al, 2006: 71). Prior sensemaking 
research in a business environment focused on a variety of aspects including 
strategic change and decision-making (Gioia and Thomas, 1996; Sonenshein, 2010; 
Rerup and Feldman, 2011), innovation and creativity (Drazin, Glynn and 
Kanzanjian, 1999) and organisational learning (Weick, 1988, 1990, 1993; Gephart, 
1993; Blatt et al, 2006; Catino and Patriotta, 2013).  
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In R&D environments, which can be complex and uncertain, there is often a 
requirement for technical and business concepts to be communicated between 
individuals, groups and to the wider organisation, to produce action. In other words, 
once an individual has information, there is a need for the information to be 
distributed throughout the organisation to promote sense and facilitate decision-
making (Day, 2002). The term for disseminating sense is known as sensegiving 
(Weick, 1969, 1979, 1995) and is concerned with how communication is used to 
give sense to a recipient, upon which they will construct, meaning and reality, 
leading to action. Gioia and Chittippeddi (1991: 442) argued that sensegiving is 
concerned with ‘the process of attempting to influence the sensemaking and meaning 
construction of others toward a preferred definition of organizational reality’. The 
question can be raised though, how does this occur in R&D environments where 
there is a split between ‘science speak’ and business speak?’ This study expanded 
the literature, which had previously given little attention to this aspect.  
 
The method of communicating information and sense is critical for the success of 
management and what sense recipients make of a communication (Weick, 1995; 
Clark, Abela and Ambler, 2006; Pauwels et al, 2009). Language is often regarded as 
a vehicle to convey sense to promote individual and shared meaning (Weick, 1995; 
Taylor and Robichaud, 2004; Nicholson and Anderson, 2005; Sonenshein, 2006). 
Taylor and Van Every (2000: 40) supported this view by stating that: ‘sensemaking 
involves turning circumstances into a situation that is comprehended explicitly in 
words and that serves as a springboard for action’. There can be an even greater 
requirement for this in R&D environments, where there may not be shared 
understanding of terminology, processes and organisational drivers etc. between 
R&D management and executive management. Perhaps not surprisingly, the vehicles 
of narrative (Abolafia, 2010; Maitlis and Christianson, (2014: 31), metaphor 
(Cornelissen, 2005; Nicholson and Anderson 2005; Cornelissen et al, 2012), and 
models (Hill, 1995) have all found favour in constructing shared meaning between 
individuals and social groups within organisations, which ultimately result in 
management decision-making and action. Cornelissen (2010, 2012) has suggested 
that linguistic tools such as metaphors can simplify complex situations and aid in 
providing order and justification for certain actions in unfamiliar situations. While 
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this is not a sensemaking study, it does utilise concepts from the area of 
sensemaking, in that individuals often look to simplify communications regarding 
complex phenomena to increase the sense given, which can result in desired action. 
The author of this study believed that there may be synergy between some of the 
concepts from sensemaking and R&D models, whereby the model simplifies the 
communicated aspects of the R&D processes to facilitate decision-making by 
different organisational members, but particularly management. This could impact 
on the construction of R&D by different managers’ discourse styles about R&D and 
many other factors feeding into R&D. The following section therefore examines 
‘Management Decision Making’.  
 
 
2.3.9. Management Decision Making 
 
R&D is constructed by management, insofar as what product to design, enter into the 
R&D stage, processes to carry out, and how these processes are moderated etc. It is 
however accepted that there are wider influences such as the market pull view of 
product development that may influence the R&D stage. Management decision-
making is therefore crucial for the R&D stage. The management of R&D is carried 
out by individuals with a variety of skills sets and knowledge about the different 
aspects of R&D. Due to prior sensitisation of the author to the antiviral disinfectant 
R&D sector, it has been argued that there is a predominant splitting of management 
into executive and R&D, which may be attributable to factors including individual 
knowledge and experience. Importantly, Mudambi and Swift (2009) have shown that 
management utilise different knowledge sets to communicate about business and 
science/technology can subscribe to different belief systems, which influences the 
way they interact with R&D. For example, there can be differences in what R&D 
managers perceive as social and business incentives for successful R&D. 
Management from non-technical/scientific backgrounds are more likely to view 
‘excellence’ in terms of market performance (Dasgupta and David, 1994; Gittelman 
and Kogut, 2003). This can be at odds with management from technical/scientific 
backgrounds, where the creation of knowledge is perceived as having an inherent 
value in itself irrespective of market performance (Duncan and James, 1974), and 
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where ‘excellence’ is measured in terms of primacy (Mudambi and Swift, 2011). 
Examples of this can include making ‘significant’ scientific discoveries, which can 
result in rewards such as research grants, professorships and increased esteem but 
which may have little value for R&D (Merton, 1957; Dasgupta and David, 1994; 
Sorenson and Fleming, 2004). These divergent views over what constitutes scientific 
‘excellence’ in a business environment can compound management decision-making 
and efforts to evaluate R&D projects, which at worst can produce products with 
scientific merit but little to no commercial value. With this and other difficulties, it 
can be seen that clarity is needed in R&D management decision-making and a 
vehicle for shared meaning of these values. This can involve aspects such as how 
and when to carry out a process as well as how and when to allocate resource. Where 
there is uncertainty in management decision-making, for when and how to allocate 
resource, there is the potential for inefficiency, meaning that promising products may 
not receive adequate resource and failing products may continue to act as a drain on 
resources.  
 
Although this study is primarily concerned with understanding R&D processes for 
antiviral disinfectant R&D, drawing out and understanding management decision-
making for processes is also beneficial to understanding the how and why of R&D. 
In this study, respondents detailed how they made decisions, which could have 
varied from deliberation all the way through to ‘just random picking...or just using 
the likeability heuristic’ (O’Shaughnessy, 2005). Importantly, Kotler (2000: 88) 
suggested that managers make decisions via the following processes, ‘both 
marketing and environmental stimuli enter the buyer’s consciousness. In turn, the 
buyer’s characteristics and decision process lead to certain purchase decisions. The 
marketer’s task is to understand what happens in the buyer’s consciousness between 
the arrival of outside stimuli and the buyer’s purchase decisions’. The marketing 
management view is useful but limited by its simplicity and while it is not possible 
to understand the buyer’s consciousness, his/her mental processes can arguably be 
examined via the examination of discourse (Ellis and Hokinson, 2010), such as the 
method of explicitation (Hycner, 1999) as used in this study.  
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Numerous perspectives have been used to examine decision-making (Kahneman and 
Tversky, 2000), whether it is rational and if it is an individual or group-activity. It 
occurs when a selection is made from alternatives, with every decision ultimately 
producing a final choice (Reason, 1990). Decision-making can be regarded as a 
problem solving activity via reasoning or emotional processes, which can be 
rational/irrational and reaches completion when a satisfactory solution is attained or 
an unsatisfactory selection is made, but the individual is not prepared to make more 
selections. Kenji and Shadlen (2012) argued it as an involuntary process, where 
individuals seek to maximise benefits and minimise costs via analysis of available 
data (Schacter, Gilbert and Wegner, 2011). This is referred to as ‘Rational Choice 
Theory’ (RCT), which assumes that individuals maximise benefits and minimise 
costs (Schacter, Gilbert and Wegner, 2011). According to Hollis (1987, 1996) 
standard economic theory constructs individuals as rational maximisers of ‘utility’ 
who select the most efficient means of achieving goals, based on self-interest. 
Although RCT has been extensively used in a variety of academic disciplines (Ryan, 
2003) there are limitations of this theory, as detailed more extensively by Baron 
(1998). Perhaps the crux of the challenge of RCT is the assumption that self-interest 
is pursued at the exclusion of all other factors (Sen, 1987). As Kahneman, Knetsch 
and Thaler (1990) pointed out, classical microeconomics assigns no role for other 
factors such as generosity, social conscience, goodwill and fairness, but research 
suggests that people act out of these interests and against self-interest at times.  
 
Irrational behaviour on the part of a manager may also be linked to factors such as 
availability bias or availability heuristic (Schacter, Gilbert and Wegner, 2011). This 
is a shortcut for judgment making about the probability of an event occurring, based 
on how easily information can be recalled. In such cases, the individual perceives 
recalled information as important, with a positive relationship having been 
demonstrated between recalled information and the consequences of something 
occurring based on recalled information (Tversky and Kahneman, 1973). For 
example, this could result in an R&D management decision being influenced by the 
manager having watched a film that depicts the technology in a particular way, 
which is a non-intentional communication. For managers with a lower knowledge of 
science/technology, there is a greater potential for ‘information overload’ which, 
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occurs, where there is a high volume of cost/benefit information resulting in 
processing problems which impact on decision-making (Kutty and Himanshu, 2007). 
The problem can at this point become how to make a decision, when all criteria are 
being considered simultaneously, and how to prioritise processes and resources.  
 
The issues explored in this section suggest that R&D management decision-making 
is not only complex but potentially takes place within risk-laden and uncertain 
environments, and is not as simple as Kotler (2000) has suggested. Using R&D 
models to represent complex environments has been shown to aid management-
decision making, and R&D outcomes (Bean and Guerard, 1989; Tian, Ma and Liu, 
2002; Wang et al, 2013). Although a model may not represent ‘all’ of reality, it is 
not always necessary for high-levels of information to be presented for decision-
making. For instance, Weick (1995) has suggested that often, managers seek 
information that is ‘good enough’ for them to operate in complex and opaque 
environments (Hastie and Pennington, 1995). Andreassen and Kraus (1989) believe 
that for some managers, the process of finding ‘enough order’ and clarity must be 
rapid, with managers needing little to clarify their decision-making when incoming 
data met with their expectations. The need to make sense and dig deeper only 
became important when expectations were violated. For decision-makers, the 
question can be asked though, to what extent can models be driven by plausibility or 
accuracy. Lundberg (2000) argued that ‘accuracy’ could be less important than 
prompting action and bringing order to the world. As Bruner (1973: 30) stated that, 
‘[t]he cost of close looks is generally too high under the conditions of speed, risk, 
and limited capacity imposed upon organisms by their environment or their 
constitutions. The ability to use minimal cues quickly in categorizing the events of 
the environment is what gives the organism its lead-time in adjusting to events. 
Pause and close inspection inevitably cut down on the precious interval for 
adjustment’.  
 
This concludes the examination of the ‘Antiviral Market’, where aspects including 
the nature of viruses, how they are inactivated by antiviral disinfectants, as well as 
the business aspects of managing and making sense of antiviral disinfectant product 
development, risk and uncertainty and decision-making have been considered. 
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Importantly, the complexity and opacity of this area was highlighted for managers in 
both R&D and executive posts were drawn out, suggesting the need for a simpler 
view of R&D. Thus, the following section explores ‘Modelling R&D’, as a symbolic 
representation of the reality of antiviral disinfectant R&D, to aid in management 
understanding, and decision-making.  
 
 
2.4. Modelling R&D 
 
The development of models is widely used throughout business and science, and has 
found both theoretical and practical use in various academic fields and industrial 
sectors. Not surprisingly, modelling has focussed on numerous areas of R&D, 
including business outputs such as producing patents (Popp et al, 2013) as well as 
the physical processes carried out and understanding how processes impact upon the 
business (Bednyagin and Gnansounou, 2012). One of the challenges for modelling 
R&D is what it means to ‘model R&D’ and what is expected from such a model. As 
much as there is a requirement to understand the term model and accept that it can 
mean many things to many people, but also be able to have managers construct 
shared meaning about models so they are of wider organisational benefit. Coupled 
with this is a need to define what is what R&D means to management, and whether it 
is predominantly ‘R’, ‘D’ or ‘R&D’ being modelled. These issues will be examined 
in the following sections.  
 
According to Geertz (1973: 5) anthropology is ‘not an experimental science in 
search of law, but an interpretive one in search of meaning’. The researcher of this 
study believes this statement is relevant (although from a different academic area), as 
through the production of an R&D model, we have an interpretation in search of 
meaning and not a law. More than this though, an R&D model is an interpretation of 
R&D that is to aid in sense- and decision-making and is not necessarily ‘correct’.  
 
The exploration of modelling R&D starts in the following section, by briefly 
exploring ‘Modelling ‘Reality’ i.e. ‘What is a Model?’ 
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2.4.1. Modelling ‘Reality’ – What is a Model? 
 
A model can be defined as an explicit representation of some portion of reality as 
perceived by an individual (Wegner and Goldin, 1999). It can be regarded as ‘active’ 
if it influences the reality it reflects, which in the scheme of this study, would be the 
ability of a model built on antiviral disinfectant R&D processes, to influence 
management engaged in this field. As both Hirschheim and Klein (1989) and 
Schuette (1999) have argued, the development of models can be based upon their 
ontological and epistemological stance. Briefly, ontological realism assumes that 
reality exists independently from an individual, whereas ontological idealism (or 
nominalism) refutes this claim (Schuette, 1999). Epistemology allows objectivism 
(the stance that objective knowledge is possible) and subjectivism (the stance that 
objective knowledge is not possible) to be distinguished (Schuette, 1999). Viewing 
reality as a being socially constructed (Burr, 2003) allows these perspectives to be 
connected in a way that is beneficial to model development. Due to the importance 
of social constructionism to this study and sensemaking, interview questions were 
framed through a phenomenological paradigm whereby respondents’ construction of 
the organisational and R&D realities were accepted on the basis of their discourse. 
This deviates from objectivism whereby respondents’ claims could be verified 
against external factors outside of themselves (this being a simple view however). It 
is important to recognise that although respondent discourse was taken as a proxy to 
respondent inner worlds, constructed realities of organisational life and R&D, the 
process of warranting (Wood and Kroger, 2003), was used to differentiate good and 
bad discourse. 
 
Examining the work of Berger and Luckmann (1996), objectivity and subjectivity 
were integrated in an on going dialectical process of articulation, objectivation and 
socialisation. In this way, subjective reality affects objective reality through 
articulation, and is affected by objective reality through socialisation, although it is 
worth pointing out that ‘this conception of philosophy is, however a recent historical 
development’ (Rabinow, 1986: 235). Thus Jørgensen (2004) has claimed that 
interactive models can become an objective reality. There is however the 
requirement for models to reflect an individual’s subjective reality, for instance, and 
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as an example, to facilitate discourse through storytelling (Brown and Duguid, 1991; 
Orr, 1996) and negotiation of meaning (Wenger, 1998) throughout the business. One 
of the challenges of developing a business model is to embed it within the 
phenomenon being examined. The challenge of embedding the business model 
within the phenomenon is in understanding the phenomenon being examined at a 
deep enough level to be able to mirror it in the model. Arguably a danger for 
companies is not adequately modelling the phenomena of interest, which can result 
in a model ‘without origin or reality’ (Baudrillard, 1994: 1). In the next section the 
aspect of ‘Modelling ‘Reality’ – What is a Business Model?’ is explored.  
 
 
2.4.2. Modelling ‘Reality’ – What is a Business Model? 
 
Models are developed and used by businesses for a variety of reasons, including, 
increasing management understanding of R&D, standardising procedures, quality 
control, aiding in commercialisation, unlocking latent value in a technology and 
facilitating theory development within a business environment (Chesbrough and 
Rosenbloom, 2002; Morris et al, 2005). There is however, a lack of consensus of 
what constitutes a business model, or how to define it. This can be coupled with the 
questions, which as Baden-Fuller and Morgan (2010: 156) asked ‘are business 
models useful?’ ‘who uses them, for what, and how?’ A simple answer is that 
‘business models have the characteristics and fulfil the roles of ideal types: they are 
based on both observation and theorizing’ (Baden-Fuller and Morgan, 2010: 162).  
 
Morris et al (2005) have suggested that there are three categories of business model, 
including (1) economic, (2) operational, and (3) strategic, with each having a unique 
set of parameters and variables. The economic model is based upon the logic of 
profit generation, and focuses on revenue sources, pricing, costs, margins and 
volumes. As Stewart and Zhao (2000: 287) stated, the economic model is ‘a 
statement of how a firm will make money and sustain its profit stream over time.’ 
The operational model is based on an architectural configuration, which focuses on 
internal processes and design of infrastructure, which enables the business to make 
money (Morris et al, 2005). Mayo and Brown (1999: 20) referred to this as: ‘the 
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design of key interdependent systems that create and sustain a competitive business.’ 
The strategic model focuses on aspects such as the businesses’ marketing position, 
growth opportunities and interactions across organisational boundaries (Morris et al, 
2005). A fundamental for this type of model is competitive advantage and 
sustainability. Slywotzky (1996: 15) refers to this as: ‘the totality of how a company 
selects its customers, defines and differentiates its offerings, defines the tasks it will 
perform itself and those it will outsource, configures its resources, goes to market, 
creates utility for customers and captures profits.’ 
 
Trott (2012) suggested that there are eight models for new product development 
R&D, which are, (1) departmental-stage models, (2) activity-stage models and 
concurrent engineering, (3) cross-functional models (teams), (4) decision-stage 
models, (5) conversion-process models, (6) response models, (7) network models, 
and (8) outsourced. The two main types of models used are the activity-stage model 
and the decision-stage model, which have similarities with each other, based on their 
‘over-the-wall’ approach to R&D. Looking at allied technologies to antiviral 
disinfectants, such as the pharmaceutical industry, biotechnology and specialty 
chemicals, there are numerous models used in product R&D. The stage-gate process 
(herein referred to as the ‘consumer’ model) is commonly used, as is the 
departmental-stage model (herein referred to as the ‘technological’ model). These 
commonly utilised models are further described in the following sections, with the 
next section focussing on ‘Process Models in R&D’.  
 
 
2.4.3. Process Models in R&D  
 
One of the first process models of industrial product development was proposed by 
Cooper (1983), which was a seven-stage model to serve as a normative guide to 
management, to reduce critical steps being overlooked. Cooper’s model focussed on 
products being developed sequentially and not simultaneously, and was perceived as 
a flaw by Adler et al (1995), where interdependent R&D was taking place. While 
studies such as Cooper (1983) and Adler et al (1995) are vital for developing core 
theory, the practical aspects of defining and understanding a specific phenomenon in 
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company R&D environments is also important. From initial studies such as these, a 
variety of R&D process models have been proposed, with different philosophical 
and business constructions attached to them. It is important however to define 
process R&D models.  
 
Within process R&D models, Hammer (2001: 5) stated that a process is ‘an 
organized group of related activities that work together to create a result of value’. 
A process or processes may span the entire R&D stage. In an attempt to produce a 
fuller understanding of R&D processes, academics and practitioners have used 
different models to represent R&D (Browning and Ramasesh, 2007). Simplistically, 
‘a model is an abstract representation of reality that is built, verified, analyzed, and 
manipulated to support a particular purpose, even if that purpose is merely to 
increase understanding of a situation’ (Browning, 2010: 317). As Box (1979: 201) 
however stated, ‘all models are wrong, but some are useful’. Not surprisingly, no 
model truly represents objective or subjective reality, as each model selectively 
communicates information. It can be argued that this is the same for process R&D 
models and although they do not communicate all information they can simplify 
shared meaning and a simple view of R&D. Importantly, the philosophical basis for 
constructing models and shared meaning must also be considered. In prior studies 
reductionist stances have been predominantly embedded within a positivist paradigm 
has been used for model production. While informative and insightful, a more 
‘holistic’ approach was taken in this study, which is via phenomenology to allow the 
phenomenon of R&D to be ‘true to itself’. There is arguably no right or wrong way 
for which philosophical stance to take, but more that for exploratory research with 
the aim of getting close to the phenomenon, phenomenology is more fitting than 
prior approaches based in positivism.  
 
Shane and Ulrich (2004) have argued that as the complexity of R&D increases, so 
does the need for a model. The complexity of the R&D model, and ability of 
management to interpret the model is paramount for the success of the model 
(Browning, 2010). This often necessitates the need for a simplified model, or even 
‘mental models’ (Senge, 1990) to describe and control projects (Flanagan et al, 
2006). Little (1970) argued that managers tend to prefer models that are (1) simple 
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and easy to understand, (2) complete and including pertinent phenomena, (3) robust 
and limited to pertinent answers, (4) adaptive and easy to adjust for new information 
inputs, (5) easy to control, whereby the user knows what input roughly equals what 
output, and (6) easy for the manager to interact with. Not surprisingly, some of these 
criteria conflict with each other, such as robustness and simplicity, which creates 
further challenges for constructing models. Arguably though, whichever route is 
taken for modelling R&D, the model has to be capable of being interpreted by 
different managers and stakeholders who will carry out physical actions based on the 
model. Thus the language and symbolic representation is pivotal for model 
production. While symbolic aspects have received much attention for how to 
represent models, less attention has been paid for the language used to communicate 
sense. This study has therefore expanded the literature in this area to directly 
consider language used by different managers to convey sense and shared meaning. 
Coupled with a more encompassing approach created the potential for something to 
more adequately capture the ‘essence’ of R&D and would enhance the reflexivity of 
the model.  
 
The factors discussed so far arguably necessitate the need of a model to be useful to 
the manager for whatever purpose in process R&D the model was developed for. As 
Browning (2010: 317) stated: ‘a process model should include the attributes of a 
process which are deemed appropriate to describe it. However, this determination of 
appropriateness is always made (explicitly or not) in relation to a particular 
purpose’. Fitness and appropriateness are arguably subjective constructions however, 
with Engwall et al (2005) describing project managers as perceiving ‘canonical’ 
process models as having a variety of different purposes. This can create challenges 
for process models, as a process model developed for one purpose may not 
necessarily be appropriate for another (Browning et al, 2006; Crowston, 2003; Dolk 
and Kottemann, 1993). A simple example of this is a general process model would 
likely be insufficient in detail for each process part. Whereas it might seem easy to 
rectify this lack of data in the general model, it might make it too complex for a 
general model, meaning that the elements of complexity may have to be dealt with 
elsewhere (for example through an expanded view). This suggests that managers 
may well use process models differently, which was argued by Browning (2010), 
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who argued that not only do different managers have different reasons for using 
process models, but that they can be used as a preliminary method to further their 
understanding of process situations. Perkins (1986) contended that understanding 
requires three things, including; (1) a purpose for analysis, (2) a model of the process 
to be understood, and (3) arguments about why the model is fit for purpose. Further 
to this, Steiger (1998) argued that evaluative arguments include, model accuracy, 
simplicity, conceptual validity and model component sufficiency. ‘In particular, the 
necessity and sufficiency of a model’s components help determine the alignment 
between a managerial purpose and a model used to support it’ (Browning, 2010: 
317).  
 
It is important for management to understand the desired results of developing an 
R&D model, and whether the type of model can adequately deliver the desired aims. 
Put more simply, whereas a model can demonstrate the processes in R&D, it can 
show much more beneath the surface of the processes, allowing more considered 
decision making, if required. In utilising process models in R&D is the requirement 
to understand that there is a temporal order and sequence in which discrete and 
continuous events occur throughout R&D processes occur. Prior research had 
predominantly considered process R&D as relatively static, and in line with realist 
thinking something that is ‘is’. Utilising a lens of attempting to more closely mirror 
R&D led this study to step away from singular constructions of R&D even within 
the same organisation, other than through shared meaning, based on social 
construction and discursive framing.   
 
As Meredith and Mantel (2003) argued, initiating an R&D project does not 
guarantee that the R&D stage will be completed or that a new product will be 
commercialised. ‘As R&D organizations have limited resources, a project in an 
R&D organization has to continuously justify its existence in the presence of other 
projects’ (Verma, Mishra and Sinha, 2011: 464). Reasons given for a project not 
being completed include: changing market conditions, unanticipated technological 
challenges, competitor actions and a change in competitive strategy of the R&D or 
funding company (Balachandra et al, 1996: Guan et al, 2002). For the R&D stage to 
continue, it is important for the activities and output from R&D to be viewed 
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favourably by the wider business, particularly management (Verma, Mishra and 
Sinha, 2011). This need has become more pronounced among high technology 
companies due to an increasingly competitive global market place (Huston and 
Sakkab, 2006). This arguably necessitates the need for models with a wide context 
for different stakeholders, or different models for different business segmentations.  
 
The model literature is ‘vast’, but much research has focused on theoretical models 
at the expense of understanding how these models impact on practice (Shane and 
Ulrich, 2004). This has also been the case for understanding different management 
stakeholder views on model development, implementation and use. Taking a more 
practical approach, as carried out in this study enabled a more thorough examination 
of model development from multiple stakeholders within and between companies 
engaged in a specific sector (antiviral disinfectant R&D), as well as feedback for the 
final construction and use of such a model.  
 
Moving more to look at what R&D models have been constructed and given 
theoretical and practical examination in the past, the following section digs into ‘A 
Critique of R&D Models’ to create a foundation of prior academic knowledge to 
facilitate the production of process models in this study.  
 
 
2.4.4. A Critique of R&D Models 
 
R&D models have ‘evolved’ over the last fifty years from the ‘Black Hole’ first 
generation model to the ‘Network/co-operation/acquisition/lab based’ sixth 
generation model (‘fuzzy’) (Nobelius 2004; Lager, Blanco and Frishammar, 2013). 
This evolution has taken mainly two pathways, the ‘market/consumer’ model, 
focusing on market needs i.e. ‘the outside in’ approach (Cooper and Edgett, 2013) 
and the ‘technological’ model, focusing on optimising resources and processes, i.e. 
‘the inside out’ (Canongia, 2007). On studying the evolution of models, and 
according to Nobelius (2004), it would appear that although the technological model 
has advanced into the sixth generation, the consumer model seems still to be a 
mixture of the second and fourth generation, with its emphasis on cost, quality and 
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particularly, time to market (Chaudri, 2013) However, a deeper study of the 
consumer model, in theory and practice, (Liedtka, 2011; BRIDGE Collaboration 
(2013) indicates that in the desire to collapse the process time, the first stage at least, 
requires that all actors in the R&D process are identified and utilised. This has some 
resonance with the sixth generation with its emphasis on networking and 
collaboration. In the research under review, where entrepreneurism, asset intensity 
and ‘lab based’ development are key processes (Lager, Blanco and Frishammar, 
2013), it was not clear at the beginning of the research how these factors would 
relate to an antiviral disinfectant R&D model and as such necessitated an exploratory 
approach for an under researched sector. In capturing the phenomenon of any R&D 
process, arguably no ‘one size’ will fit all but again raises the issue of what it is to 
model a process, and how closely that any model should fit the process. Given these 
diverse and numerous attempts at designing models and frameworks in the 
‘technological’ and ‘consumer/market’ domains, and in their attempted integration, 
no wonder Pisano (2012) concluded that no one R&D model that is universally 
superior has emerged over the last few decades and ‘it’s not surprising that attempts 
to revolutionise the process has met with jaded skepticism’. Given this comment, the 
researcher of this study, feels justified in modelling process R&D for the antiviral 
disinfectant industry, hitherto informed by, but not embraced, in past research. This 
approach may have produced a model similarly mirroring a prior model but this 
could not have been known prior to the research element of this study being 
undertaken.   
 
When deciding how to interact with R&D models, companies have a choice of using 
existing and potentially ‘popular’ models such as the ‘consumer’/‘marketing’ model 
(Cooper and Edgett, 2013; Kotler and Armstrong, 2010) with numerous variants e.g. 
the ‘time to market’ model (Kahn, 2004) or the ‘technological’ model (Canongia, 
2007). Briefly, the ‘consumer’ model concentrates on the R&D processes driven by 
marketing research, which can be regarded as an ‘outside-in’ approach, and prior to 
the research stage, it was expected that executive managers may utilise this model 
for constructing R&D. The ‘technological’ model is driven by scientists and 
technicians, which can be regarded as an ‘inside-out’ approach, and with it being 
perceived likely that R&D managers may well construct similarly. An example of 
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the ‘consumer’ model is the Stage Gate Model, redrawn and shown in Figures 2.3 
and 2.4. 
 
Figure 2.3. Stage Gate Model 
 
Source: http://www.prod-dev.com/stage-gate.php. Last accessed 01/06/2013 
 
Figure 2.4. Gates for the Stage Gate Model 
xxxxxxxxxxxxxxxxxxx  
Deliverables: Inputs into the gate from the preceding stage, and defined in advance.  
Criteria: What the project is judged against in order to make the go/kill decisions.  
Outputs: Results of the gate review, where gates must have a decision and a path forward.  
Source: http://www.prod-dev.com/stage-gate.php. Last accessed 01/06/2013. 
 
Influential marketing authors like Kotler et al (2013) have used this model as the 
basis of their writings to describe the R&D process. Models like the Stage Gate 
Model are believed to enhance product innovation and technology strategies, 
improve business innovation cultures and allow investment in the right projects 
(Cooper and Mills, 2005; Jaruzelski, Dehoff and Bordia, 2005; Cooper and Edgett, 
2013). They have also been used by organisations to inform their product 
development through to commercialisation (Koen, 2003; Adams and Hubilkar 2010; 
Grőlund, Rőnneberg, and Frishammar 2010; Cooper, 2011). Arguably however, 
although simple to use, at best such models produce a ‘thick’ representation of the 
phenomenon. Although the researcher could envisage similarities between the Stage 
Gate Model and his emic experience of R&D in the antiviral disinfectant sector, it 
was not known at what level if any such a model might be used in different 
companies.  
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Attempts have been made through the use of models such as the Design Thinking 
Model (Martin et al, 2012) to simplify the R&D process further. Although the 
Design Thinking Model can be considered an attempt to ‘collapse’ the Stage Gate 
Process to accelerate the R&D stage, this is an over simplification of this model, as 
there are different elements in the Design Thinking Model.  Figure 2.5, shows an 
example of the Design Thinking Model, which is composed of five stages, including, 
(1) empathy (getting to ‘know’ the actors), (2) defining (what the problem and 
parameters include), (3) Ideate (find an ideal solution), (4) prototype (produce a 
working model) and (5) test (the model or solution). Perhaps not surprisingly, the 
Design Thinking Model has a greater focus on ‘design’, including greater potential 
aspects of creativity to achieve the goals of R&D. This can be seen from the stage 
(1) where there is an attempt to get to know the actors, enabling a greater access to 
internal actor knowledge. Secondly, defining the problem and ideating can be 
construed as drawing out the problem and theoretically solving it (even though this 
may not occur in objective reality), before prototyping begins. Undoubtedly 
organisational culture may well influence the use of the Design Thinking Model, 
where for example R&D managers may perceive terms such as ‘empathy’ 
negatively, as something not fitting for the natural sciences. These aspects could only 
be drawn out during the interview stage, and as discussed previously, this study 
sought to embed itself within a greater examination of language used which was 
addressed by questions asked in the interview stage.  
 
Figure 2.5. Design Thinking Model  
 
xxxxxxxxxxxxx  
Source: Martin (2012:12).  
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As well as the ‘consumer’ model is the other type of ‘popular’ model, known as the 
‘technological’ model. This model is focussed towards the technological aspects of 
R&D and often segments R&D into different ‘thick’ stages such as formulation and 
toxicity etc. An example of this redrawn model is shown in Figure 2.6. 
 
Figure 2.6. Technological R&D Framework Model Overview  
 
 
Source: http://www.roche.com/research_and_development/r_d_overview.htm. Last accessed 
02/06/2013.  
 
This example model used by the pharmaceutical company Roche, is composed of 
three main R&D stages, including, (1) R&D, (2) clinical development, and (3) 
commercialisation. This model can be considered a ‘thick’ description as it shows 
generic process stages and simplistically segments for example, an entire stage into 
‘target selection’. It also does not show what happens if there is a failure at a specific 
stage of R&D, or if a stage has to be repeated. Representing R&D in the way shown 
by the Roche model can be helpful for capturing how one company carries out R&D, 
but it is simply not known at what level such a model can be extrapolated through 
the biological sector.  
 
Although both the ‘consumer’ and technological’ models are ‘popular’ they arguably 
‘suffer’ from how much ‘reality’ should be expressed within the model. A model can 
be simple and act generically and has a potential to widely used across sectors ‘as is’ 
or it can be sector or company specific, with a lower chance of generalisability. The 
model shown in Figure 2.6 is undoubtedly sector specific and an example of a 
‘technological’ model but fails to show what happens when an R&D stage fails. The 
model developed by Cassimon et al (2011: 1203) explicitly shows stage failures 
albeit for a pharmaceutical drug model, and is shown in Figure 2.7.  
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Figure 2.7. Technological R&D Model with Increased View 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Cassimon et al (2011: 2103).  
 
By showing stage failures, Figure 2.6 is arguably expanded into an increased view 
from that in Figure 2.7. Interestingly this increased view showcases success and 
failure for each R&D stage, with a potential of discontinuation. Arguably however, 
this expanded view also has limitations in representing the subjective and objective 
‘realities’ of research, which are fundamentally that symbolic representation of 
mental and physical phenomena is always potentially challenging. For instance, 
looking at Figure 2.7, R&D is depicted as a linear event with the only potential 
outcomes being either a ‘success’ or a ‘failure’, which is an either/or event and could 
be argued as having some similarity with the Stage Gate Model. However, it is 
interesting to consider that this linear approach to such a model is itself perhaps 
misleading, as it is suggestive that if the product fails one stage, R&D will be 
discontinued, whereas it might perhaps be cycled back through an earlier stage to 
achieve a success on a previously failed stage. This is speculative on behalf of the 
researcher of this study, but does suggest the problems for how management 
interacted with constructed models, how they are interpreted, and how rigidly they 
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should be followed. To address this issue, the interview stage drew on this aspect to 
further understand the phenomenon as it relates to antiviral disinfectant R&D.  
 
Of interest to this study was, does the antiviral disinfectant R&D sector, follow, 
customise or have its own completely unique processes and ergo model(s)? Further, 
does ‘one size’ fit all? This is a gap in the current literature, which this study has 
explored. Briefly, the advantage of using either the ‘consumer’ or ‘technological’ 
model is that they already exist, and have been examined by both practitioners and 
academics. They do however have the disadvantage of being non-sector and non-
product specific. The alternative is for companies to devise and implement a 
phenomena (sector and/or product) specific model, which might capture more of the 
phenomenon of interest but is more complex for management to interact with. In the 
next section ‘Management Interaction with R&D Models’ is examined to more fully 
consider what prior literature has highlighted about this area.  
 
 
2.4.5. Management Interaction with R&D Models 
 
R&D is a complex series of management and process events consisting of 
continuous and discontinuous elements. Within R&D is the aim for identifying, 
researching and developing a product that can be taken to market. PMI (2008) stated, 
that a project could be defined as ‘a temporary endeavor undertaken to create a 
unique product, service or result’, but importantly over the past decades the number 
of high-cost, large and complex R&D projects and programs has grown significantly, 
creating further challenges for management (Winter et al, 2006). Throughout 
numerous sectors (beyond just those using R&D), ‘projects are notorious for cost 
and schedule overruns, and insufficient management of them wastes the equivalent 
of billions of dollars around the world each year’ (Browing, 2010: 316). As a way of 
managing resource, process models are routinely relied on to understand and regulate 
the R&D stage. The challenge for process models, particularly in R&D is the nature 
of product development, as R&D processes can vary from product to product, 
meaning that a management model for one product is not necessarily transposable 
(although it depends what level of reality is required to be represented). Even though 
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there is a potential deviation within each stage of the process stage, it is still possible 
to standardise the broad information aspect of the processes, i.e. formulation and 
toxicology etc. Although there are numerous ways of representing a process model, 
particularly for management, it is usual for only one model representation to be used 
for any one process set (Browning and Ramasesh, 2007). Examples of views include 
flowcharts (IBM, 1969), network diagram (Moder et al, 1983), Design Structure 
Matrix (DSM) (Browning, 2001), Graphical Evaluation and Review Technique 
(GERT) diagram (Pritsker and Happ, 1966), textual narrative (SPC, 1996), IDEF0 
diagram (NIST, 1993), IDEF3 diagram (Mayer et al, 1987), State diagram (Harel, 
1987), Create-Read-Update-Delete Table (Kilov, 1990), value stream map 
(McManus, 2005), Supplier-Input-Process-Output-Customer (SIPOC) diagram 
(Browning et al, 2006), IPO diagram (Radice et al, 1985), extended Event-Driven 
Process Chain (eEPC) diagram (scheer, 1999), Responsibility Assignment Matrix 
(RAM) (PMI, 2008) and classic spreadsheets (Browning, 2010). Not all of these 
process models are suitable for R&D, particularly for the phenomenon of antiviral 
disinfectant process R&D. Before carrying out the interview stage it was simply not 
known which if any of these approaches were already being used, would find favour 
and the rationales behind these decisions. In principal, while any of the previously 
models could be used in antiviral disinfectant R&D (even if badly) the researcher 
utilising a phenomenological approach and staying close to the phenomenon of 
interest, allowed the experts within the sector of interest to define their realities of 
modelling R&D. Coupled with phenomenological bracketing the researcher 
attempted to reduce any induced bias on his part into the model building stage.  
 
With numerous process R&D models available, managers in any sector must decide 
which model(s) to use, if any at all, as each model potentially communicates 
different information to management and the wider organisation. Examples of this 
are the use of flow charts to determine the length of a project and GANTT charts to 
assign tasks etc. The challenge for using models is how they reflect reality of R&D 
within an organisation, as arguably no model ‘truly’ reflects constructions of 
objective or subjective reality. On this basis, even though potentially advantageous 
to management, the model may distort the reality of R&D and associated processes. 
This may be through the emphasis or omission of certain process aspects of R&D.  
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Constructing a model is no small task, and as Bendoly and Speier (2008: 169) 
questioned: ‘what information to include/disregard when making specific decisions’. 
Management decision-making can therefore be linked to what the model contains, 
what reality it communicates to the manager, and how the manager uptakes the 
information from the model and makes sense of R&D. More simply put, what a 
manager decides is based on what they perceive and understand (Bendoly and 
Swink, 2007). At best, models exist that at some level mirror objective or subjective 
reality and facilitate successful R&D, leading to commercialisation, whereas at worst 
the models are not congruent with the purpose and tasks faced in R&D (Browing, 
2010). From a management perspective, production of information, even in a 
symbolic model has a requirement for management to interact with the model, which 
necessitates organisational resource. Overly large and complex models can create 
information overload for both individuals and groups. Farhoomand and Drury (2002) 
argue that the presence of a ‘poor’ model can allow management to believe that 
information has been received and acted upon in a way that is desirable to 
management, when it has not been. Through a phenomenological approach and 
against a backdrop of numerous previous models used for R&D, this aspect was 
directly addressed in the interview stage and incorporated into the construction of an 
antiviral disinfectant model.   
 
The potential outcome of information overload and the consequences of it must be 
taken into account for the construction of a process R&D model. To avoid this 
outcome, the aspect of information overload and how it occurs must also be better 
understood. Schick et al (1990) state that information overload occurs when a task’s 
information processing demands, exceed the individual’s capacity to process 
information in a given period of time. Studies have shown the negative consequences 
of decision-making for management faced with information overload, and include, 
(1) a reduction in the quality of decisions (Stocks and Harrell, 1995; Pennington and 
Tuttle, 2007); staff overlooking what they themselves may perceive as critical 
(Herbig and Kramer, 1994); obscuring relevant and known information (Wilson, 
1995). For projects where the size and complexity of R&D increases, and models 
mirror this by having their size and complexity increased, management can become 
less able to critically engage with the model, which can further produce poor 
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decision making (Bendoly and Speier, 2008). This aspect was considered pivotal for 
the construction of an antiviral disinfectant model as biological R&D is often 
complex, opaque and with technical terminology, all of which can cause confusion, 
resulting in poor sense- and decision-making.  
 
A potential way around the production of an information rich single model, which 
can cause information overload, is the production of a model with subgroups and 
subsets also known as an expanded view (Browning, 2010). This can allow 
information to be displayed in a format that more easily facilitates information 
uptake and management decision-making, but is dependent upon relevant subgroups 
and subsets being identified for use within the model. As Browning (2010: 318) 
stated: ‘this motivates the concept of a “view”. Whereas a model is an abstraction 
from reality, a view is a second layer of abstraction, an arrangement of symbols, a 
table, or another depiction chosen to display a selected subset of a model’s 
attributes and assumptions’. With two management respondent types being 
examined in this study (executive and R&D) this aspect was explored as a vehicle to 
enhance communication and sensemaking between managers in the same 
organisation.  
 
A process model should be a symbolic representation of the processes carried out. 
While using model views can allow an increased representation of reality, there can 
often be a requirement for practical limits on the information displayed to inhibit 
management information overload. The advantages of a view according to Browning 
(2010) are that it enables users to focus on more detailed aspects of the phenomenon, 
and potentially show different attributes to different model users.  
 
According to Parnas (1972), incorporating views into models can draw out 
information that can otherwise remain hidden and increase the ease with which 
decision makers interact with models. When deciding what information to include in 
a view, Browning and Ramsesh (2007) indicated that it should only include 
information that was perceived as useful for making a certain type of decision 
(which of course benefits and suffers from decision-making about what to include in 
a view). Beyond what information to include in a view, the way that the data is 
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presented in the view is also important, as ideally it will facilitate understanding, 
reduce complexity or ‘complicatedness’ (Tang and Salminen, 2001). It should also 
focus on the needs of specifc users and their needs from the model views. Arguments 
have been made than ‘better’ views can be a significant driver of innovation in 
system design (Alexander, 1964, Simon, 1981; Zachman, 1987; Schätz et al, 2002; 
Keller et al, 2006); product development decisions (Krishnan and Ulrich, 2001); and 
decision support systems (Basu et al, 1997). The concept of views can be linked with 
‘natural intelligence theory’, in which Minsky (2006) postulates that the human mind 
contains multiple models of any given system that an individual encounters. Such 
individually and mentally held multiple models can include physical, social, 
emotional, mnemonic, strategic, visual and tactile etc. According to Minsky (2006), 
rapid switching may occur between models depending on other internal and external 
stimuli, with multiple views of a complex model being found attractive in 
representing R&D (Keller et al., 2005; Browning, 2009). In this study the use of 
expanded views was used to represent both executive and R&D manager subjective 
experiences of R&D which if not addressed has the potential to create confusion and 
problems for management sense- and decision-making. The ways that individuals 
can reach shared meaning through intersubjectivity is thus explored in the following 
section of ‘Intersubjectivity and Development of R&D Models’.  
 
 
2.4.6. Intersubjectivity and Development of R&D Models 
 
One of the challenges of producing an R&D model based upon phenomenological 
research is that of intersubjectivity, which is based upon whether different 
individuals can achieve agreement on a given set of meanings or definition of a 
situation (bluntly, whether if in another’s ‘shoes’ we might see the world in the same 
way). Briefly, Scheff (2006: 196) defined intersubjectivity as ‘the sharing of 
subjective states by two or more individuals’. It can also be regarded as a ‘common 
sense’ view of situations. In producing an R&D model, intersubjectivity must be 
considered as multiple managers have been interviewed in this study to produce an 
R&D model. Heritage (1984) addressed this issue by raising the question, how can 
two or more individuals truly share an experience in the same way? Schutz (1967: 
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99) agued that the full subjective experience of another is ‘essentially inaccessible to 
every other individual’, but that individuals assume that they share the same 
experiences and act is they are identical for all practical purposes. Heritage (1984) 
argued that individuals ‘know’ that the way they encounter objective reality is 
different from other individuals. This is based on two principles, with the first being 
that each individual approaches objective reality from a different place, and thus 
perceives objective reality differently from other individuals. The different position 
of individuals results in each individual interacting with objective reality in a 
different way, which alters the individual’s perception of objective reality. Secondly, 
each individual approaches objective reality with a different view to the way that 
they would wish to engage with objective reality, meaning that they are ‘interested’ 
in objective reality in different ways. Considering these two principles an argument 
could be made that intersubjective knowledge is not possible, which in this study 
would hinder the production of an R&D model based on intersubjectivity. However, 
in practice, intersubjectivity can occur, as individuals perform two basic 
idealisations, which Schutz (1962: 11) refers to as ‘the general thesis of reciprocal 
perspectives’. Simply, these two idealisations are as Schutz (1962: 11-12) argued, 
based on if I change place with you, I see the world the way you do (the idealisation 
of the interchangeability of standpoints). Secondly until evidence is presented to the 
contrary, we take it for granted that most differences in perspective are irrelevant and 
we all see the world the same way (the idealisation of the congruency of the system 
of relevance).  
 
Schutz’s proposal is critical for the production of an R&D model based upon semi-
structured in-depth interviews, as each manager being interviewed approaches their 
reality from a different standpoint and is ‘interested’ in reality in different ways. 
Using the proposal by Schutz and the assumptions previously detailed allows a 
‘common world’, which arguably transcends individuals’ private experiences. 
Looking at an example by Schutz (1962: 316), it is only through these idealisations, 
that: ‘we both see the “same” flying bird in spite of the difference of our spatial 
position, sex, age, and the fact that you want to shoot it and I just want to enjoy it’. It 
is only by sustaining and sharing these idealisations that knowledge can be 
established and maintained. As Heritage (1984) argued, a common world is 
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maintained by the contradictory assumptions of individuals accepting they share a 
common world, and that at the same time there are perspectival differences between 
individuals. By continually adjusting their perspectives, individuals can resolve 
discrepancies in their perspectives, facilitating a shared view. Importantly, as 
suggested by Schutz (1964), as there is often little quest for absolute certainty in the 
way that the world is viewed, meaning that a less rigid, softer and more shared view 
can be maintained, and even if this aspect is questioned, it is often not necessary for 
anything other than a simple view to be found, which finds synergy with 
sensemaking (Weick, 1995).  
 
For the construction of a model based on executive and R&D manager interview-
based perceptions of R&D, the aspects discussed in this section are pivotal. In the 
first place, with interintelligibility and shared meaning being possible, the 
construction of an R&D model can mirror R&D. In the second place, conceptual and 
methodological elements must facilitate this endeavour through fit-for-purpose 
interview questions. Utilising a phenomenological approach arguably enabled the 
researcher to get closer to the phenomenon of interest from respondent perspectives 
and ‘see’ the world through their eyes. Although many of the interview questions 
were based in a style to ask ‘what’, ‘how’ and ‘do you’ the discourse utilised by the 
researcher was more open as is fitting for semi-structured interviews. Thus, follow 
up questions could be asked to ascertain more information, with a continued 
awareness on the behalf of the researcher that he was there to guide the interview 
through questions but at the same time, allow the phenomenon of interest to be 
discussed with minimal bias from prior preconceptions. An example of this is 
question 20 from the interview stage, which asked ‘How do you address different 
communication styles between management?’ This question enabled a wide range of 
answers, which could be followed up by further questions and also acknowledged 
that individuals with different self-identifications can use different language styles 
(Boyatzis, 1998). Utilising warranting between managers would thus facilitate 
shared meaning through interintelligibility.  
 
Summing up this aspect, it is possible to produce an R&D process model from 
management interviews. The validity and warrantability of such a model will be 
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discussed later in this study, along with the potential of generalising such a model. 
As the data collected from respondents was from semi-structured in depth interviews 
and was language-based within a phenomenological paradigm using explicitation, 
‘Language, ‘Reality’ and Modelling’ is explored in the following section to further 
understand the foundations of these aspects.   
 
 
2.4.7. Language, ‘Reality’ and Modelling 
 
Language as a vehicle of communicating about and describing the social world of 
R&D management is an important aspect of this study, due to the use of respondent 
interviews with subsequent explicitation. Research findings constructed from the 
explicitation process and used to model R&D has necessitated a philosophical 
understanding of how language can be used to develop a model, which is 
symbolically representative of the social world of R&D management.   
 
The importance of communication in management is routinely spoken of, with 
estimates of the amount of management activity being taken up by communication 
being between 58 – 89 percent (Boden, 1994 [quoted in Bryman and Bell, 2011: 
520). Communication from one individual to another can take multiple forms, such 
as talking, writing and body language that allow the organisation to carry out 
business activities such as coordinating and allocating resources etc. Importantly and 
in this study, it is only verbal utterances, based on talking that are of interest and that 
have been examined. According to Shotter and Cunliffe (2003), in performing 
discourse-laden activities, managers become ‘practical authors’ who shape their 
organisational environments. As Boden (1994: 8) stated: ‘talk makes the 
organizational world go round’, and is ‘the lifeblood of all organizations.’ The act of 
communication has also been argued as allowing ‘institutional facts’ to come into 
existence (Searle, 2010). While the importance of language within organisations is 
commonly accepted, there can be a divergence between management theory and 
practice when it comes to the way language constructs organisational reality. While 
social scientists may hold the belief that language constitutes reality, management 
practice can often be embedded within a realist position, in that language functions 
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to provide labels that can be ‘stuck’, ‘rubber stamped over’ and ‘attached’ to objects 
without affecting them. An example of this within the sector being researched could 
be “It is R&D, because that’s what it IS”. An attachment of a label in this case could 
disguise that R&D isn’t being carried out, or that it is ‘R’ and not ‘D’ or vice versa. 
Simplistically, and from a social science view, the phenomenon is altered or 
changed, which may result in naive realist positions holding considerable ideological 
power. This study has approached this aspect by allowing respondents to define their 
own organisational realities of R&D, while the researcher bracketed his 
preconceptions. This fits within a phenomenological paradigm, where respondent 
language was examined to ‘see’ their organisational realities.  
 
Many themes have been discussed in this chapter, which can be broadly split into the 
areas of ‘The Antiviral Market’, ‘Research and Development’ and ‘Modelling 
R&D’. A summary of the ‘Literature Review’ is pulled together in the next and final 
section of this chapter to draw together major research findings from the literature to 
produce a platform for  ‘Chapter 3. Literature Synthesis’ is introduced. 
 
 
2.5. Summary 
 
Antiviral disinfectant R&D exists in a highly complex and technologically focussed 
sector, where companies can take advantage of many market and technologically 
driven opportunities. Technological/scientific complexity and opacity within the 
R&D stage necessitates companies to engage in sense- and decision-making to 
further understand R&D challenges. The benefits of management developing an in 
depth understanding can be increased commercialisation and ROI, while a failure to 
address these issues can result in reduced R&D outputs and at worst failed 
commercialisation. Making sense and effective fit-for-purpose decisions by 
management is critical during the R&D stage, which has received great academic 
attention in the allied technologies of antiviral therapeutics and vaccines, but only 
limited attention for antiviral disinfectants. Antiviral therapeutics and vaccines are 
dissimilar to antiviral disinfectant R&D, due to both antiviral and vaccine-based 
products being used inside human and animal bodies, and antiviral disinfectants 
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being made chemically and used on surfaces such as table tops and kitchen floors 
etc. This impacts greatly on the nature of R&D, as there is a gulf between the 
technologies for the legislative requirements, which R&D aims to answer before 
commercialisation. Antiviral disinfectant is also more likely to magnitudes lower in 
financial investment and in time taken to commercialise a product in comparison to 
antiviral therapeutics and vaccines. This paucity in knowledge of the antiviral 
disinfectant R&D stage has led to this study being undertaken, which is exploratory 
in nature to develop a foundation of knowledge from managers (executive and R&D) 
from within the UK antiviral disinfectant sector.   
 
Within any technologically orientated R&D company is a requirement for key 
stakeholders and managers to understand relevant aspects of R&D, particularly 
managers involved in R&D decision-making. While it is not expected for all 
managers to understand R&D equally, knowledge should be able to be shared 
meaningfully enabling effective and fit-for-purpose decision-making within a 
company’s aims for R&D. One of the ways suggested for dealing with R&D 
complexity is through the development of R&D models, which symbolically 
represent the R&D stage and facilitate shared meaning, communication and 
decision-making. While modelling R&D is not without challenge, as many different 
models can be produced, they can be an informative way for management to make 
decisions, particularly in areas where they might not fully understand the scientific 
or management requirements of the stage. Previous models have not addressed 
antiviral disinfectants, but models such as the Stage Gate and Technological Model 
were perceived as potentially relevant in their overall structure to a model for 
antiviral disinfectants. The differences in the sectors coupled with an attempt to draw 
closer to the phenomenon of antiviral disinfectants via phenomenology necessitated 
this study to more fully understand what R&D processes are involved with this 
sector, and how different managers (R&D and executive) perceived R&D.  This 
approach (although embedded within the literature) sought to be able to take 
‘nothing for granted’ and thus construct a management model based on the 
perceptions of management, and more importantly warranted by management. 
Drawing on these aspects, the following chapter ‘Literature Synthesis’ has engaged 
with some of these aspects more fully to create a foundation for interview questions. 
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Chapter 3. Literature Synthesis 
 
3.1. Introduction 
 
The preceding chapter reviewed the literature regarding the significance of the 
scientific and management aspects of antiviral disinfectant R&D. This was alongside 
understanding how modelling processes in complex technological environments can 
aid in management communication, sense- and decision-making. In this chapter, 
these aspects have been synthesised to assist in refining the research question, aim 
and objectives, which is considered in the following section the ‘Research Gap in 
Antiviral Disinfectant R&D Management’.  
 
 
3.2. Research Gap in Antiviral Disinfectant R&D Management 
 
Extensive research into R&D management has been carried out in numerous sectors 
over the past decades (Nobelius, 2004), with the management focus towards 
antivirals being through the allied technologies of in vivo antivirals and vaccines 
(Jurovcik and Holy, 1976; Fraise, 1999; Griffith, 2008; Cargill et al, 2011). Limited 
attention has been paid however to antiviral disinfectants and corresponding R&D, 
with research gaps being considered in this section, a rationale for research 
undertaken, as well as research implications from this study detailed.  
 
The driving force for companies to carry out R&D is to produce new market ready 
products, which can be used to establish, maintain and/or expand their market share 
(Nobelius, 2004). This is in line with Verma, Mishra and Sinha, (2010) who argued 
that companies seek to achieve and maintain an advantage over their competitors 
through R&D. Technology companies often have a more intense focus on R&D to 
produce new products, in comparison to non-technology companies (Marcus and 
Segal, 1989; Dugal and Schroeder, 1995; Jobs, 1998; Schroeder and Purinton, 1998), 
as they seek to generate a financial return based on their knowledge and physical 
capabilities. These aspects can increase the pressure to produce successful products 
out of the R&D stage that are market ready (Haverila, 2013). Simplistically, R&D 
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can be considered successful if the product leaving the R&D stage ends up being 
sold in the market (Di Masi et al, 2003). There are many areas to be understood with 
the main aspects being, how is R&D carried out? And how is communication used to 
facilitate sense- and decision-making between managers? More than this though, 
where is prior research drawn on and where is the literature expanded? These 
elements are discussed in this section.  
 
In practice, there has been a propensity for management to focus on reducing the 
time taken for the R&D cycle (Adler et al, 1995), which as argued by both Stalk and 
Webber (1993) and Gerwin and Barrowman (2002) focuses company resources on 
one R&D aspect, and negates many other important strategic considerations. For in 
vivo antivirals and vaccine orientated R&D, reducing the time taken to complete the 
R&D stage is not surprising due to the number of years taken to get through multiple 
clinical phases (Cassimon et al, 2011). However, regulatory requirements for 
antiviral disinfectants are much lower than in in vivo antivirals and vaccines, 
meaning that the R&D cycle is substantially shorter and lower in cost. Thus while 
potentially attractive for managers in antiviral disinfectant companies, reducing the 
R&D cycle is not as important as in allied technologies. Within antiviral disinfectant 
R&D are many other competing factors that need to be examined for successful 
management of R&D, where fit-for-purpose products are eventually sold. Thus it is 
important to draw out the process stages of R&D to highlight the areas that different 
managers engage with, and that might result in reduced sensemaking and difficulties 
in decision-making.    
 
Before undertaking this study, it was not known to what extent R&D might vary 
from company to company within the antiviral disinfectant sector. While a micro-
level examination of the science being carried out was not required (for example x 
grams of salt is added to y grams of acid), the business aspects of the physical 
processes were required, which can be considered as an overarching macro view. 
This element was explored in the interview stage to not only understand what goes 
on in the R&D stage but the management concepts of R&D i.e. what are your R&D 
stages? Understanding the business processes would enabled a greater understanding 
of the interpretations of R&D, and perceived necessity of each stage. Central to the 
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R&D stage is the product being developed, which is known to influence the R&D 
stage, and as Lager, Blanco and Frishammar (2013) stated, can be asset intensive, 
sector specific and strongly integrated in one or a few physical locations. This 
fundamental question of the nature of the product was explored in the interview 
stage to inform this study about demarcation points of antiviral disinfectants being 
made and relation to other technological products. In other words, what is the 
difference between the antiviral disinfectants and other products? It was not assumed 
that simple answers would be forthcoming to such questions, which necessitated a 
semi-structured interview approach within a phenomenological paradigm. Thus, a 
subjectivist stance was taken to ‘see’ the world through respondents’ eyes to more 
fully engage with the phenomenon of antiviral disinfectant R&D.  
 
R&D projects can suffer due to the scientific opacity in the eyes of executive R&D 
managers, who may not have the in depth scientific knowledge that R&D managers 
have at their disposal. Opacity can occur as a consequence of difficulties in 
predicting R&D outputs, particularly for what the output will be, and when it will 
occur (Anderson and Tushman, 1990). This can be coupled with the types of 
information communicated between executive and R&D management being unclear, 
with poor sense communicated. Where information from R&D management is not 
clear, it can be difficult for executive management to accept or refute R&D claims 
(Stein, 2003), complicating decision-making. Likewise poor sense given to R&D 
managers from executive managers can lead to confusion about company 
requirements from the R&D stage. Another way of looking at this is that both 
manager types are likely to have culturally relevant interpretive repertoires at their 
disposal to enable them to construct and share meaning. However, prior to the 
interview stage, it was apparent that both respondent types (R&D manager and 
executive manager) might use different repertoires and terminology, for the same 
processes, which in turn could result in confusion. This was therefore considered in 
the interview stage via the language used by both managers, which expanded the 
literature for language repertoires used at the R&D isthmus between executive and 
R&D managers.  
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The issue of sense- and decision-making and language used can be particularly 
pronounced for managers in technology companies, as they often exist in complex, 
opaque and uncertain environments. As Nobelius (2004) argued, a company’s ability 
to understand its own R&D stage is pivotal, as with a greater understanding of R&D 
comes an ability to manipulate the R&D stage, thus allowing a greater opportunity to 
reap financial benefit. Being able to communicate effectively and create shared 
meaning between managers is therefore a way to achieve greater R&D rewards  
(Weick, 1995; Clark, Abela and Ambler, 2006; Pauwels et al, 2009). Although, 
R&D has numerous challenges for companies undertaking it, successful R&D has 
the potential to create ‘greater market share, premium prices and dominant designs, 
leading to a much sharper competitive edge’ (Nobelius, 2004: 369).  
 
A popular vehicle for understanding R&D is the use of models to mirror the R&D 
process stage, which can simplify complex technological aspects of R&D (Cooper, 
1983; Adler et al, 1995; Bednyagin and Gnansounou, 2012; Popp et al, 2013). The 
development of R&D models is influenced by multiple social factors that exist at the 
time of R&D model construction, with these factors being more or less relevant at 
different points in time. Research has been carried out to examine the construction of 
R&D models (Kahn, 2004; Canongia, 2007; Kotler and Armstrong, 2010; Cooper 
and Edgett, 2013), which has highlighted three areas that are often addressed by 
R&D models and include, (1) strategic, (2) operational, and (3) methodological 
(Nobelius, 2004). There has been a propensity for modelling to focus on the physical 
processes carried out by the business and understanding how processes impact upon 
the business (Bednyagin and Gnansounou, 2012), but with less attention being paid 
to how models can be used to communicate shared meaning between different 
management groups based on the constructed model, which this study is considering. 
This was directly explored by enabling managers to warrant constructed models to 
increase the shared meaning derived from the model.   
 
Constructing a model is no small task though and Bendoly and Speier (2008: 169) 
raised the question of what information should be included? And how should it be 
represented? The interview stage enabled these aspects to be explored and rationales 
provided by both respondent types, based on their use of language and backgrounds 
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(education and work). Examining both R&D manager and executive manager 
perspectives, sought congruence with the ‘reality’ of the purpose, tasks and decisions 
made about R&D (Browning, 2010). Practically, the production of a model requires 
management time to construct the model, as well as to operationalise and 
validate/warrant it, necessitating some management benefit for committing this 
resource. More than this though, companies involved in this sector and study trialled 
this model after it was constructed. Within all of these aspects was the issue of 
whether to produce an overly large and complex model (with multiple expanded 
views for executive and R&D managers), which could result in information overload 
and render the model practically unusable. At the other end of the spectrum would be 
the production of a model so simple that it would arguably miss the phenomenon of 
interest, and might allow management to believe that information has been received 
and acted upon in a way that is desirable to management, when it has not been 
(Farhoomand and Drury, 2002). For projects where the size and complexity of R&D 
increases, and models mirror this by having their size and complexity increased, 
management can become less able to critically engage with the model, which can 
produce poor decision-making (Bendoly and Speier, 2008). This study thus took the 
approach of raising this aspect with the respondents, particularly during the model 
warranting stage, to enable them to make changes to the model that would aid them 
in using it. Through interviewing both executive and R&D managers it was 
perceived as being able to address specific manager needs.  
 
Beyond what information to include in a model, is the decision that needs to be made 
about how to visually represent the model, as ideally the model will facilitate 
understanding, reduce complexity or ‘complicatedness’ and increase shared meaning 
(Tang and Salminen, 2001). If using an R&D model, managers have a choice of 
using existing and potentially ‘popular’ models such as the ‘consumer’/‘marketing’ 
model (Cooper and Edgett, 2013; Kotler and Armstrong, 2010) with numerous 
variants e.g. the ‘time to market’ model (Kahn, 2004) or the ‘technological’ model 
(Canongia, 2007). It was not known until the interview stage, whether manager 
perceptions of R&D would be embedded within a technology push or market pull 
view, which might have altered the production of an R&D model. This study was 
however encompassing enough to take this challenge into account and although 
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questions were not put to respondents using the terms ‘technology push’ or 
‘marketing pull’ they were considered.  
 
Examining academic literature, antiviral modelling at the R&D stage has 
predominantly been within a scientific paradigm, focussing on the scientific 
mechanisms of antiviral activity (Ding and Wu, 1999; Takayanagi, 2013; Basta et al, 
2014). The modelling of scientific interactions is important for management and 
particularly R&D managers but is only part of the R&D phenomenon, as the 
management aspects of the process stages must also be integrated. The construction 
of a model to integrate executive and R&D manager perspective was examined as a 
vehicle for creating shared meaning between different managers who have different 
views of the reality of R&D and who potentially use different language repertoires to 
communicate about R&D. This study sought to rectify these shortfalls of knowledge 
by the production of a management ‘ready’ process model.   
 
The gap in existing knowledge for antiviral disinfectant process R&D management 
has been clearly established in this study. R&D management is a complex area, 
existing within a potentially opaque, uncertain and risk-laden environment. This has 
resulted in this study being exploratory and within the phenomenological paradigm, 
to dig deep into the phenomenon of antiviral disinfectant process R&D and 
management. The qualitative approach used, provided an insight into how different 
managers in R&D companies (executive and R&D) perceived R&D, communicated 
and made decisions about it. The process of explicitation aided in examining the 
communicated subjective inner worlds of executive and R&D management and 
facilitated the production of an R&D process model.  
 
The information drawn out in this section, enabled the construction of a research 
question, research aim and research objectives, which are detailed in the following 
sections.  
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3.3. Research Question 
  
Examination of the literature has led to the following research question:  
 
How do UK based SMEs carry out process R&D for antiviral disinfectants? From 
this we are able to derive a research aim: 
 
 
3.4. Research Aim 
 
To examine current theory and practice in order to produce a model for process R&D 
used by UK SMEs producing antiviral disinfectants. From this we can produce a 
number of research objective(s): 
 
 
3.5. Research Objectives 
 
In this study, there are three research objectives, with each objective building on 
previous objectives:  
 a) Through a literature review and current practice, to determine the current
  scientific and business processes for UK SMEs engaged in antiviral 
 disinfectant process R&D; 
 b) Informed by a) above to produce an initial alpha model for UK SMEs 
 engaged in antiviral disinfectant process R&D; 
 c) Informed by a) and b) above, to verify/warrant the initial alpha model and 
 so produce a beta R&D model. 
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Chapter 4. Research Methodology 
 
4.1. Introduction 
 
The preceding chapters have detailed the antiviral disinfectant process R&D in UK 
SMEs, and have shown a defined gap in academic and practitioner understanding of 
this area. The gap identified has shown a paucity of information regarding how 
different managers communicate about the complexity of the R&D process stage not 
only in antiviral disinfectant R&D, but also for technology products in general. The 
challenge for managers engaged in technology and biologically based R&D is how 
to communicate in an effective way that gives the intended sense to the recipient that 
enables ‘fit-for-purpose’ decision-making. While it has been acknowledged that 
R&D models can facilitate R&D sense- and decision-making, little research has been 
carried out into models that construct shared meaning between different managers 
with backgrounds in science and business, where language used may be culturally 
different. Thus as an exploratory study, a phenomenological paradigm to ‘see’ the 
world through respondent eyes was chosen that could create new knowledge, and 
link the use of ‘business’ and ‘science’ speak into one R&D process model that 
could be used by both manager types. By utilising this approach, and enabling the 
managers involved in this study (70 percent of the industry), ‘ownership’ of the 
constructed model could be taken by the managers involved as they move towards 
becoming practical authors of their respective R&D environments. This chapter 
therefore outlines the methodology utilised in this study to fill this gap, as well as 
addressing the research question, aims and objectives.  
 
The practical elements of this study were carried out in two stages, with the first 
being a pilot study using exploratory interviews with three executive and three R&D 
managers. With there being ten UK based antiviral R&D SMEs, and with each SME 
having one R&D and one executive manager, the pilot studies captured 30 percent of 
each type of manager, to understand and refine questions for the main study. The 
second stage used semi-structured in-depth interviews and was with single executive 
and R&D managers from seven SMEs. Explicitation was used to examine 
transcribed interviews and produce an alpha model of antiviral disinfectant process 
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R&D. Verification/warranting was ‘achieved’ through further interviews with R&D 
managers to seek feedback on the alpha model, and where appropriate, modify the 
model, to produce a beta model, which subjectively reflected manager views of the 
R&D stage. To gain access to respondents, the letter shown in Appendix A was sent 
to prospective companies, detailing the nature of this study.  
 
The next section explores ‘The Phenomenological Paradigm’, to construct an 
understanding of phenomenology within this study.  
 
  
4.2. The Phenomenological Paradigm 
 
There are two main research paradigms or philosophies that can be used to examine 
objective and subjective phenomena, and include positivism and phenomenology 
(Bryman and Bell, 2011). The choice of research paradigm is based on whether it is 
believed that social research can be carried out using the principles, procedures and 
the ethos found in the natural sciences (Bryman and Bell, 2011). Positivism (an 
‘objectivism’ ontological stance) is a research paradigm that functions more within 
the natural sciences framework, where objectivity is preferred over subjectivity. In 
phenomenology (a ‘constructionism’ ontological stance) ‘the phenomenologist 
attempts to see things from that person’s point of view’ (Bogdan and Taylor, 1975: 
13-14), which is more subjective than objective. Phenomenology can be considered a 
more holistic approach that can address aspects of ‘how’ and ‘why’, as well as 
potentially providing understanding in inherently complex phenomena. The use of a 
phenomenological paradigm was considered particularly relevant due to the issues of 
language discussed in section 2.4.7. Through the adoption of a phenomenological 
paradigm, it was expected that a high-level description and understanding of the 
phenomenon would be achieved (Kvale, 1996). The vehicle for drawing out an 
understanding of the phenomenon of antiviral disinfectant R&D was through semi-
structured in depth interviews with managers from within the antiviral sector. 
Respondent views were used as the foundation to build alpha and beta models of the 
phenomenon. This research approach was therefore classed as ‘interpretative’ within 
the phenomenological paradigm.  
	   76	  
There are two approaches to carrying out research, which are synonymous with 
positivist and phenomenological research philosophies, and include deductive and 
inductive research (Bryman and Bell, 2011: 11). The inductive approach focuses on 
studying the system or phenomenon of interest to the study and subsequently tries to 
produce a model (in this case) or results based on research findings, which is where 
this study is based. This is in contrast to the deductive approach, where existing 
theory is examined first and research findings are tested against accepted theory. The 
inductive approach was favoured, as this study is exploratory, and although R&D 
models have been constructed in other technology areas, it was not known how well 
the model produced from this study would replicate prior models.  
 
In producing a model, ontological and epistemological stances have been considered, 
in light of how reality is viewed, as an argument could be made that the production 
of a model is creating or representing ‘one reality’ and is thus more embedded within 
positivist than phenomenological research. A positivist typically adopts the ontology 
of one reality, in comparison to a phenomenologist who adopts an ontological stance 
of multiple views of reality (Bryman and Bell, 2011: 11). In this study, the 
researcher has examined the subjective views of respondents, and subjectively 
interpreted these views of executive and R&D managers engaged in antiviral 
disinfectant R&D. This has presented multiple views of the reality of R&D based on 
the respondents interviewed. The model produced in this study, is not being claimed 
as a ‘definitive’ view of antiviral disinfectant R&D, but shows expanded views, 
which is arguably suited to the phenomenological study of multiple views of reality.  
 
The epistemology of how research was captured was also considered. Typically, 
within positivist-based studies, an objective approach is used to limit the influence 
and interaction of the researcher on the subjects being studied. In this way, the 
positivist can often make the claim that their research has a greater closeness to 
objective reality. Phenomenologists however, reject the notion of their research 
being objective, embracing subjectivity and embedding themselves within their 
research methods (Bryman and Bell, 2011). Within this study, this meant that the 
researcher actively engaged with respondents throughout the interview process, as 
the researcher believed this had the potential to allow a more thorough exploration of 
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the phenomenon of interest, which was the ‘why’ of decision-making for R&D 
processes. The researcher being embedded within the antiviral disinfectant 
community thus took a combined emic and etic approach, utilising inner knowledge 
from working in the sector, but also contextualising this knowledge 
methodologically through the explicitation process. Case studies were used for the 
research strategy in this study, which is detailed more fully in the following section.  
 
 
4.3. Research Strategy: Case Studies 
 
Within social science research, there are several research strategies that enable 
phenomenon relevant information to be drawn out. These methods can be drawn on 
from both positivist and phenomenological research philosophies and include case 
studies, experiments, surveys and histories etc. Each research strategy has its own 
philosophy, routes to collect information, and examine data, as well as perceived 
advantages and disadvantages. With multiple methods available, it is important to 
consider why any method is preferable. According to Yin (2009), there are three 
conditions, which can be used to determine when to use a research strategy in social 
science. These conditions include (1) the form of the research question, (2) the 
amount of control the researcher has over behaviour events and (3) the level of focus 
on contemporary events. Table 4.1 shows the relationship between these three 
conditions and the different research strategy commonly used in business research. 
 
Table 4.1. The Relationship Between Research Methods, and when to Use them 
 
Strategy (1) Form of research 
question 
(2) Requires control 
of behaviour events 
(3) Focuses on 
contemporary events 
Experiment How, why? Yes Yes 
Survey Who, what, where, 
how many, how 
much? 
No Yes 
Archival 
analysis 
Who, what, where, 
how many, how 
much? 
No Yes/no 
History How, why? No  No 
Case study How, why? No  Yes 
 
Source: Yin (2009: 8).  
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To determine which strategy to use, Table 4.1 was examined with the three 
conditions and the areas of interest to this study. Taking condition (1) first, the ‘form 
of research question’, Yin (2009) stated that the case study method should be used 
primarily when there are ‘how’, ‘why’ or ‘what questions’, which fits with the 
research question of this research, which is: ‘how do UK based SMEs carry out 
process R&D for antiviral disinfectants?’ This aspect is particularly pertinent when 
the research question is exploratory, which it is in this study. As the researcher felt 
that he would have limited control over behavioural events (the second condition), 
the case study method was perceived as suitable. The overall design of this study, 
therefore, was based on an empirical approach using an embedded (multiple units of 
analysis) multiple case study design. Thiti (2010) suggested that this approach 
allows for contingencies (potentially from multiple cases) to be taken into account 
and for a range of factors to emerge as potentially relevant to the investigation, all of 
which may not be apparent from previous knowledge or research. Finally, as this 
study focussed on contemporary events and is exploratory, it is also in agreement 
with the case study method.  
 
Case studies (an interpretivist methodological approach for developing theory) can 
be defined in many ways (Benbasat et al, 1987; Bonoma, 1985; Eisenhardt, 1989; 
Yin, 1994), with Meredith (1998: 443) using the following definition: ‘A case study 
typically uses multiple methods and tools for data collection from a number of 
entities by a direct observer(s) in a single, natural setting that considers temporal 
and contextual aspects of the contemporary phenomenon under study, but without 
experimental controls of manipulations’.  
 
An important consideration for case study research is that any understanding 
developed by the research can only be considered knowledge, within the researcher’s 
perceptual framework. This distinguishes case study research from rationalist 
research, as understanding developed through case study research is not objectively 
‘out there’, rather it is meaningful only within the constructs of assumptions, beliefs, 
perspectives, histories and language utilised by the researcher. Bonoma (1985: 203) 
argued that the goal of case studies was to understand as fully as possible the 
phenomenon being examined, through ‘perceptual triangulation’, where ‘the 
accumulation of multiple entities as supporting sources of evidence [can be used] to 
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assure that the [institutional] facts being collected are indeed correct’ (Meredith, 
1998: 442).  
 
Within case study research is the potential to use single or multiple cases to explore 
the phenomenon of interest (Yin, 1994). A single case may be relevant where one 
very large organisation can provide a high level of detail about the phenomenon 
being examined, with many possible sampling and an array of possible behaviours, 
such as the National Health Service. The antiviral disinfectant sector is not like the 
NHS, being made up of very few companies which are small, entrepreneurial and 
where few managers (‘experts’) have the ‘knowledge’ (Weiss (1994). A multiple 
case study approach was thus selected, with seven companies being examined in this 
study. Although seven companies may appear to be a low number, Payne and Cuff 
(1982) have argued that it is possible to generalise from a limited number of case 
studies, which was demonstrated by Fain, Kline and Duhovnik (2011) who used only 
two case studies as part of their study on the R&D/marketing interface. Importantly, 
the seven companies examined in this study, represent seventy percent of the 
industry in the UK.  
 
Looking at the advantages, of case study research, Benbasat et al (1987) argued that 
there are three ‘outstanding strengths’ of this approach. The first is that the case 
study allows the phenomenon to be studied in its natural environment if required, 
and that relevant theory can be generated from interacting with and observing actors 
of interest in such environments. Secondly, the case study allows the more 
meaningful question of ‘why’ to be asked, rather than just ‘what’ and ‘how’ and be 
contextualised against the backdrop of the phenomenon being examined. Thirdly and 
most inline with this study, is that the case study is ‘ideal’ for early, exploratory 
based investigations, where the variables are not as yet well understood. An example 
of prior research that has demonstrated all three of the previously mentioned research 
strengths of case studies is that of Gerwin (1981). Other academic studies by 
Eisenhardt (1989), McCutcheon and Meredith (1993) and Yin (1994) have argued 
the advantages of case study research for producing in-depth explanations and 
understanding.  
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Criticisms have been raised against case study research, with the first being that of 
resource i.e. cost, time and ability of the researcher to access the phenomenon of 
interest. This can be coupled with ‘the need for multiple methods, tools, and entities 
for triangulation; the lack of controls; and the complications of context and 
temporal dynamics’ (Meredith, 1998: 444). Academically, the case study method is 
less well known in comparison to rationalist based research, particularly in the areas 
of methodological procedures and how rigour is achieved. It has been argued that 
case study research may lack academic rigour (Larbi, 1998) due to difficulties in 
generalisation from small sample sizes. This criticism has been targeted not only 
against case study research, but often to numerous qualitative methods as well, 
which have been perceived as having tendencies for error, poor validation, and 
questionable validity. These issues can be linked to positivist researcher perceptions 
of qualitative and case study research. Numerous research papers and editorials have 
argued that there has been a relative lack of case study research in management 
studies (Wood and Britney, 1989; McCutcheon and Meredith, 1993; Meredith, 1998; 
Ebert, 1989). Meredith (1998: 441) argued that: ‘This form of empirical research 
continues to be poorly understood and infrequently published in top journals. In 
part, this may be due to unfamiliarity with nature of theory building using case and 
field methods.’ However, when assessing the case study method and aspects such as 
rigour and sample size, it is important not to judge the case study method against 
more rationalist orientated research, where one is more ‘rigorous’ than the other. 
Although criticism can be made that there is a small sample size being utilised in this 
study, 70 percent of the sample was captured and linguistically ‘triangulated’ 
throughout the groups (all executive managers compared, and all R&D managers 
compared), alongside between groups (executive managers versus R&D managers). 
More fundamentally, and through a phenomenological case study approach, ‘seeing’ 
the views of the respondents was a key aspect, which was embedded within 
subjectivism.  
 
Looking at more ‘traditional’ positivist approaches using optimisation, simulation 
and statistical modelling are still more favoured for building new management 
theories, and is potentially linked with a perception of the conclusions being drawn 
about phenomena are objectively ‘out there’ independent of the researcher (Klein 
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and Lyytinen, 1985; Guba, 1990). While these methods are valuable for developing 
management theories, they can be less beneficial for exploratory research, as is the 
case with this study. The next section makes a greater examination of research based 
theory development, with a particular focus on interpretive case studies.  
 
In some ways though, theory development based on research findings can be argued 
to transcend the philosophical divide of positivism and phenomenology. Whetten 
(1989: 491) argued that: ‘during the theory-development process, logic replaces data 
as the basis for evaluation...This requires explaining the whys underlying the 
reconstituted whats and hows’. In developing or extending theory, it is therefore 
important to gain an understanding of the ‘why’ of the phenomenon (Gerwin, 1981). 
Developing an understanding of ‘why’ is not without challenge, with Richardt and 
Cook (1979: 17) arguing that positivist methods are most appropriate for testing or 
verifying existing theory, whereas interpretive exploratory methods such as case 
studies are better used for generating or extending theory.  
 
Arguably one of the most critical elements of case study research is the challenge of 
deciding upon and defining the area, parameters and population that will make up the 
case(s) to examine the phenomenon of interest. It is imperative that the case(s) 
selected closely mirror the phenomenon, which in this study are R&D companies 
engaged in antiviral disinfectant process R&D. Whereas in positivist methodologies, 
variables can be controlled, this is not possible in interpretive case studies, 
necessitating the selection of a sample frame of case studies that will provide 
insights into the phenomenon of interest. The following section, therefore examines 
the sample frame for this study, as well as theoretical aspects that informed the 
researcher about his choices of management respondents to interview.  
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4.4. Sampling Frame 
 
The sampling frame is the collection of entities that are examined in a research study 
to draw out information, close to and representative of the phenomenon of interest. 
In this study, the sampling frame chosen can be considered, pragmatic, non-
probability based, and purposeful, where the researcher selected information rich 
cases (Patton 1990, cited in Wengraf (2004)) to closely represent the antiviral 
disinfectant R&D sector. It has been argued that this method of choosing the sample 
is biased but draws on Morse (1994: 220) who argued that qualitative research could 
be a biased activity, as well as rationalist studies. The choice of sample frame to 
discern  ‘different “types” of behaviour and distinguish the “typical” from the 
“atypical.”’ (Mays and Pope, 1995: 110) is now explored. Where sampling is used 
to provide this information in qualitative and case study research, a choice must be 
made for whether to use probability or non-probability samples for interviewing 
respondents. A probability sample is selected at random to try to capture the 
population of interest, with a general perception that such samples can be more 
representative of populations where this technique is employed. A non-probability 
sample is not selected at random, and is utilised where some parts of a population are 
more desired than others for examination (Bryman and Bell, 2011).  
 
The choice of sampling type can be based on numerous factors such as funds, time, 
and availability of interviewees, but with a critical consideration being the data that 
can be drawn out from any type of sampling. Due to the low number of R&D 
managers (‘experts’) in the antiviral disinfectant sector, it was not deemed wise to 
use probability-based sampling. Mays and Pope (1995) argued that using 
probability-based sampling (particularly with the use of statistical methods) is not 
the most appropriate methodology where the study is trying to elucidate and 
understand social processes. The use of non-probabilistic sampling does not intend 
to capture a population, but only the individuals who are of perceived interest to the 
researcher (Mays and Pope, 1995). Case study based sampling is also not necessarily 
aimed at trying to represent samples from a population, and can go ‘hand-in-hand’ 
with non-probabilistic sampling to examine specific phenomena (Meredith, 1988).  
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The sample should be representative of the phenomenon of interest, which in this 
study is the UK-based antiviral disinfectant R&D sector. This necessitated 
respondents to be selected from managerial positions from companies within this 
sector. Specifically, executive and R&D managers were chosen for interview, as they 
are both directly involved in antiviral disinfectant management. Only the UK was 
examined due to the researcher’s sensitised perception from working within this 
sector that legal governance specific to individual countries, such as the UK, can 
influence R&D. An extension of this study outside of the UK may provide 
difficulties in comparing like for like for results produced, or may expand the model 
view constructed.   
 
In language and explicitation studies, the nature of the sample being examined is just 
as important as in other methodologies including those based on rationalist thinking. 
Potter and Wetherell (1987) argued, that for discourse-based studies, it is the 
language being used that is of interest, as opposed to focussing too heavily on the 
language users. This is not to negate the importance away from the language users 
(as they can be considered the vehicle for attaining the language of interest) but 
rather to say that it is important to identify language users who can provide the 
language relevant to the phenomenon of interest. Wood and Kroger (2000: 79) 
suggested: ‘Selection is thus provisional, but it is not haphazard, as long as it 
permits the inclusion of discourses that are relevant to the phenomenon of interest. 
The important point is to avoid unwarranted assumptions about the persons who 
generate the discourse’. In case study and explicitation-based studies, it is always 
possible to increase or modify the sample size, if perceived necessary. The next 
section, examines the choice of sample size and philosophical aspects behind the 
choice made for this study.  
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4.4.1. Sample Size 
 
It is often questioned for case study research, what size sample should be used? 
Addressing this issue, Hycner (1999), suggested that sample size could be used to 
aid in determining methodological factors. In this study, a multiple case approach 
with interviews was used, which in turn was used to select the sample size. As Kvale 
(1996: 101) argued: ‘to the common question, “How many interview subjects do I 
need?” the answer is simply, “Interview as many subjects as necessary to find out 
what you need to know.’ While conceptually helpful, this does not answer the 
question about what size sample should be used. There are of course numerous 
suggestions on how many interviews to carry out, with the on-going debate being 
captured by Baker and Edwards (2012), where a number of between six and twelve 
interviews with elites (‘experts’) was considered ‘enough’. Looking at 
phenomenology-based studies, Creswell (1998) suggested between five to twenty 
interviews, Morse (1994) at least six, and Boyd (2001) between two and ten. In this 
study, one interview per company was carried out with an executive and R&D 
manager, with a total of seven companies participating, meaning a total of fourteen 
managers were interviewed. The companies examined in this study are generally 
small, with the executive management and R&D manager often being perceived as 
having the ‘knowledge’, with the rest of the organisational members being perceived 
as being less suitable as experts.   
 
As well as the references cited above, the justification for the seemingly ‘small’ 
number lies in the argument of ‘quality not quantity’ i.e. to achieve ‘saturation’ 
enabling a thorough examination of the phenomenon. Practically, Glaser and Strauss 
(1967) argued that sampling could be carried out in qualitative research until the 
collection of new data revealed no new insights. In addition, Mason (2010) examined 
five hundred and sixty PhD’s over the last few decades, and found that there were 
nineteen studies that used phenomenological case studies, which is the same as this 
study, and they all used seven participants. Looking more specifically, at examples 
of product development processes, the prior studies of Adler, Mandelbaum, Nguyen 
and Schwerer (1996) interviewed twelve manager’s to develop their article on 
getting the most out of the product development process, which is not far from the 
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number used in this study. It was accepted by the researcher that should the study 
warrant it and information become available about other potential respondents, 
snowballing could be carried out to increase the sample size.  
 
With this study using interviews with explicitation, it has to be recognised that these 
methods are relatively time-consuming activities, which limits the sample size for 
practical reasons. However as explicitation studies focus on language as well as 
language users, the main concern is the nature of sample producing material to go 
through the process of explicitation, rather than focussing heavily on sample 
numbers. This is not to negate the importance of sample size, as there have been 
criticisms that small sample sizes in comparison to other types of studies, can limit 
generalisability of findings produced (Wood and Kroger, 2000). It must be noted 
though that in this study, the unit of analysis is not the respondent as in survey work, 
but the individual and distinct utterances being explicated in terms of distinct 
meanings. This issue is explored more thoroughly in the section ‘4.7.4. 
Generalisability’. Moving beyond the sample size is the ‘Interview Stage’ in the 
following section, which directly examines the ‘Pilot Study’, the ‘Main Study’ and 
‘Verifying/Warranting the Model’.  
 
 
4.5. Interview Stage 
 
To understand the R&D process stage, necessitated interviewing respondents, who 
are actively involved in managing the business and scientific aspects of this process 
R&D. The individuals interviewed were regarded as ‘experts’, who are ‘persons who 
have a high degree of skill and knowledge in a certain domain, field or industry due 
to long–time experience and have status, power-­‐to-­‐act and decision-­‐making 
opportunities based on these skills and knowledge.’ (Belting 2008). According to 
Weiss (1994) and Belting (2008) the ‘expert’ interview is a specific form of semi-­‐
structured interview which focuses on expertise in a certain field of activity with the 
intent of reconstructing the knowledge of experts interviewed (Robson, 2002). 
Interviews are well known for being able to provide a deep and rich understanding of 
complex phenomena, and can be useful for providing multiple subject views 
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(Gubrium and Holsetin, 2002). They are also useful where the study is exploratory 
(King, 1994). 
 
Before the interviews were carried out, a series of questions was developed for the 
(1) the pilot study and (2) the main study, (based on the sensitisation of the 
researcher to the literature and practical experience within the sector), which were 
taken into the interviews. These questions addressed numerous aspects of the process 
R&D stage and are detailed in section ‘4.5.1 Pilot Study’ and ‘4.5.2. Main Study’. 
Using semi-structured interviews enabled a clear focus for discussions but also 
allowed respondent flexibility. The interview sheet formed the basis of all interviews 
in the main study, which enabled a comparison between interviews. Although each 
question was explored in each interview, flexibility was allowed during the 
interviews to allow questions to be asked in different orders if perceived as pertinent. 
As Bryman and Bell (2007) argued, this method allows fuller explanations to be 
sought by the researcher, when required. In the next section, the ‘Pilot Study’ is 
discussed with the methods of this activity being explained.  
 
 
4.5.1. Pilot Study 
 
Before the main study was carried out, exploratory interviews were used to define 
the questions to ask in the main study and to potentially add new areas of 
investigation i.e. a ‘pilot study’. As stated by Sehdev (1996) and Sehdev, Parker and 
Reddish (1997), exploratory interviews can be used as pilot studies to further define 
an area of interest, which is particularly helpful in areas that are potentially perceived 
as under researched. The areas and questions explored throughout the pilot study are 
detailed in Section 5.2 (page 104) in Table 5.1. 
 
A pilot study using semi-structured interviews was carried out with three executive 
and three R&D managers (‘experts’) from three R&D companies (one R&D and one 
executive manager from each company). An ‘expert’ is an individual with a 
perceived high-level of knowledge about the phenomenon of interest. Three 
companies were examined as they represent 30 percent of SMEs involved in the 
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antiviral sector in the UK. The pilot study was used to inform the topic areas and 
questions asked in the semi-structured interviews carried out on the main study. 
Although ‘snowballing’ was a potential method to increase the sample size and 
‘further’ inform the researcher (Bryman and Bell, 2011), this was not carried out, as 
(1) no further respondents were suggested, and (2) the researcher felt that the 
responses had been saturated, within the aims of the pilot study.  
 
The pilot study was also used to understand aspects of the ‘experts’ being 
interviewed, such as whether they would perceive themselves informed ‘enough’ to 
discuss and describe their company’s R&D processes. This decision to interview 
individual interviewees was based on the belief that ‘individuality is reduced when 
the individual participates in a group’ (Lipnan, 1959: 126) and more ‘open’ 
responses could be attained by interviewing individuals as opposed to groups. In part 
the difficulty of interviewing an individual to understand organisational processes is 
based on it being that individual’s view of the organisation. However, according to 
Lipnan (1959: 126): ‘...interpretations of individuality vacillate between the notion 
that an individual is an elementary unit of some larger complex and the notion that 
an individual is a single composite organization of parts’. The extent of decision-
making for process R&D was more fully explored, with other aspects within the 
‘Main Study’, which is considered in the following section.  
 
 
4.5.2. Main Study 
 
The main study consisted of interviewing fourteen managers (seven executive and 
seven R&D managers) ‘experts’ from antiviral disinfectant R&D companies, to 
allow the collection of primary cross sectional data. The interviews directly posed 
the research question amongst others, with the questions being defined by the 
sensitisation of the researcher to the literature and the ‘pilot study’. In-depth semi-
structured interviews were carried out with all interviewees in a private room at the 
R&D companies. Open and expansive questions were used to allow the interviewees 
to explore the topic being discussed (Smith et al, 2009).  As Benney and Hughes 
(1970: 176) stated, interviewing is the ‘favoured digging tool’ of social scientists.  
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From examination of academic and business literature, which was used as the basis 
of this proposal, the following a series of topics being pulled together to investigate 
with interviewees through semi-structured interviews. These topics were used to 
guide the conversation between interviewer and interviewee, with the areas and 
questions explored throughout the main study being detailed in Section 6.1 (page 
113-114) in Table 6.1.  
 
Through the use of semi-structured in depth interviews: ‘the interviewer leads the 
subject to certain themes, but not to certain opinions about these themes’ (Kvale, 
1996: 34). The questions asked were used to act as a flexible interview guide 
(Warren, 2002). Following the work and suggestion of Rapley (2004), the researcher 
of this study attempted to genuinely engage with the interviewees rather than asking 
a large number of tightly bound questions. No more than three, two-hour interviews 
were carried out per day, as recommended by King (2004). Once the data was 
collected, ‘The Process of Explicitation’ was used to examine the recorded 
information, as detailed in the following section. The author perceived that enough 
material was gathered in the interviews to permit saturation and proceed to the 
explicitation stage (and this was reconfirmed during the process of explicitation).  
 
 
4.6. The Process of Explicitation 
 
Meaning was made clear by carrying out the following processes of: (1) collecting 
and recording respondent interviews (pilot and main study), (2) transcribing the 
interviews, and (3) subjecting the transcribed interviews to a form of content 
analysis, which in this case was explicitation (Hycner, 1999). Through the use of 
explicitation it is possible to explore the difference between linguistic meanings, for 
instance (1) conventional and semantic meanings, and (2) for an individual, the 
pragmatic meaning. Pragmatic meanings are invaluable for understanding the 
subjective world of an individual, but drawing out their meanings from an individual 
is not without challenge. While the speaker making the communication may 
understand their meaning, the researcher may interpret other non-intended meanings. 
Subjectively, and for a researcher aspiring to make discourse clearer, it could be 
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argued that explicitness leading to research meaning is not without ‘wiggle room’ for 
any meaning produced. Schiffrin (1994: 199) stated that explicitness is concerned 
with: ‘presentation of information that actually enables [the researcher] to correctly 
identify a referent, i.e. the lexical clues that allow [the researcher] to single out 
whom (or what) [the researcher] intends to differentiate from other potential 
referents’. Schiffrin (1994), stated further that explicitation can be argued as being 
relative to the researcher and their background. In other words, whatever conclusion 
one researcher arrives at, there is no guarantee that another would reach the same 
conclusion. Perhaps a different way of looking at this is that the explicated meaning 
will be influenced by the researcher’s cognitive store of information regarding the 
phenomena.  This aspect was reinforced by Vinay and Darbelnet (1995: 185) who 
stated that explicitation requires a: ‘solid background of knowledge which ultimately 
depends on the [researcher’s] general education, breadth of knowledge, 
philosophical outlook, etc’. The researcher of this study believes that his background 
of working in antiviral disinfectant R&D had the potential of inducing a dyadic 
closeness during the interview stage via language, and allowing a fuller examination 
of the phenomenon to aid in the process of explicitation of the phenomenon. While 
an emic approach may be beneficial for cultural awareness that may allow rich data 
to be discovered, an etic approach was also utilised to ground research findings 
within prior literature and minimise bias. It could be argued that a phenomenological 
explicitation study should consider researcher bias, and while this is necessary, the 
foundations of bias within this type of study must be considered. This study is 
embedded within a subjectivist approach towards ‘seeing’ the R&D reality from 
respondent views and as such may well be considered biased. The phenomenological 
paradigm directly challenges positivist claims of researchers as non-biased objective 
participants and through the use of phenomenological bracketing and reflexivity 
engages with bias and attempts to show where it exists. Thus, it can be argued that 
phenomenological research is ‘more honest’ as it attempts to show bias, and drive 
exploratory research towards greater rigour.  
 
Moving on, the method of explicitation is defined by Hycner (1999) as having five-
stages, which include:  
 
	   90	  
1) Bracketing and phenomenological reduction.  
2) Delineating units of meaning.  
3) Clustering of units to form themes.  
4) Summarising each interview, validating it and where necessary modifying it.  
5) Extracting general and unique themes from all the interviews and making a 
composite summary.  
 
These aspects are examined in the following sections: 
 
 
4.6.1. Bracketing and Phenomenological Reduction 
 
In the natural sciences, the term reduction can often be equated with splitting the 
phenomenon into constituent parts to establish cause and effect, whereas in 
phenomenological research this is not the case. Hycner (1999) has regarded the 
original term reduction in the phenomenological context as unfortunate as it suggests 
the use of a paradigm from the natural sciences. In the phenomenological context 
reduction can be taken to mean a finding ‘in its own right with its own meaning’ 
(Fouche, 1993; Hycner, 1999). It is important for the researcher to undertake 
bracketing of their own preconceptions of meanings and interpretations, to reduce 
induced potential bias between researcher and respondent. An example of bracketing 
is the researcher limiting their perception that R&D has to be carried out in a certain 
way. Through the use of bracketing, any such judgement is suspended, which might 
bias their interpretation and use of the explicitation process.  
 
Once the interviews were completed, Holloway (1997) and Hycner (1999) stated that 
the researcher should listen to the recorded interviews multiple times to more fully 
imbibe the interviews was followed. It is through this process that aspects such as the 
‘how’ and ‘why’ may be drawn out and discerned. Unlike quantitative research, 
where the unit of analysis could be a person’s behaviour, object or measure e.g. sales 
per contact, in phenomenological research used here, the researcher is looking for 
units of meaning. This meaning is found from R&D manager responses and could be 
many ‘units’ rather than a single one. This is expected from the research. As Pope, 
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Ziebland and Mays (2000: 115) point out: ‘Indexing the data creates a large number 
of “fuzzy categories” or units. Informed by the analytical and theoretical ideas 
developed during the research, these categories are further refined and reduced in 
number by grouping them together. It is then possible to select key themes or 
categories for further investigation— typically by “cutting and pasting”—that is, 
selecting sections of data on like or related themes and putting them together.’ It is 
therefore important to be able to carry out the process of ‘Delineating Units of 
Meaning’ as examined in the following section.  
 
 
4.6.2. Delineating Units of Meaning 
 
Delineating units of meaning is the first step towards drawing out information from 
the interview stage that is pertinent to the researcher further understanding the 
phenomenon of interest. Carrying out this process is not without challenge but as 
Groenewald (2004: 18) stated, it: ‘is a critical phase of explicating the data, in that 
those statements that are seen to illuminate the researched phenomenon are 
extracted or isolated.’ Moustakas (1994) suggested that this is the stage where 
meaningful units of interest are extracted, with the process of removing data of 
limited importance being started. An example of delineating units of meaning could 
be a respondent justifying an R&D process based on there being ‘a clear financial 
driver for this process’. In this example, the delineated units of meaning could be the 
financial driver for an R&D process. Utilising this unit of meaning would require the 
use of methodology described throughout this section to draw out further meaning 
and contextualise the meaning. Carrying out this procedure is inherently subjective 
with the potential for construing greater or lesser importance to a unit than should be 
afforded. Factors such as the literal content of the interview, frequency for 
statements and terms and non-verbal communication are important for making 
decisions about which are the units of relevance and importance. As Hycner (1999) 
emphasised that the context and environment of verbal statements to be taken into 
account throughout this stage.  
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4.6.3. Clustering Units to Form Themes 
 
The process of clustering units to form themes involves grouping similar units 
together, which can be used to form significant topics (King, 1994; Moustakas, 
1994; Creswell, 1998). It has been suggested that rigorously assessing interview 
material (including aspects potentially perceived as having limited value) can be of 
great benefit for the formation of themes from units of meaning (Holloway, 1997; 
Hycner, 1999). It is intended that examining the data in this way may result in 
central themes being exposed, which for this study may lead to ‘why’ R&D 
processes are carried out in the way that they are, and how management perceives 
these processes. An example of clustering units to form themes could be that 
management believes that ‘there is a market demand for antiviral disinfectants, 
based on low product toxicity.’ Like delineating units, the process of clustering units 
to form themes is also subjective and personal, without a numerical benchmark to 
assess decisions by. Care must be taken throughout this stage, to cluster not only 
within the same interview but also between interviews, to enable cross themes to be 
identified, which aids in determining the significant elements to draw out of the 
respondent interviews.   
 
 
4.6.4. Summarising each Interview and Warranting 
 
In phenomenological studies, the researcher often aims to reconstruct and potentially 
mirror the inner and subjective worlds of the respondents as closely as possible. 
Groenewald (2004) has argued that summarising each interview moves towards goal 
in a holistic way.  As Hycner (1999: 153-154) argued: ‘Whatever the method used 
for a phenomenological analysis the aim of the investigator is the reconstruction of 
the inner world of experience of the subject. Each individual has his own way of 
experiencing temporality, spaciality, materiality, but each of these coordinates must 
be understood in relation to the others and the total inner ‘world’’.  
 
At this stage in the research process, a ‘validity check’ or ‘warranting’ of findings is 
carried out, by returning to the interviewees so that the researcher could determine if 
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they perceive that the essence of the interviews had been captured. Modifications 
carried out at this stage are part of the validity/warranting process.  
 
 
4.6.5. Extracting Themes and Summarising 
 
Once the previous explicitation processes had been carried out for all interviews 
(section 4.6.1. to 4.6.4.), the researcher examined ‘themes common to most or all of 
the interviews’ (Hycner, 1999: 154). One of the challenges of clustering common 
themes is based on how to deal with ‘significant’ differences between themes. 
Although challenging for how to deal with differences between themes, this is one of 
the strengths of phenomenological research, as it enables ‘minority voices [which] 
are very important counterpoints to bring out the phenomenon [being] researched’ 
(Groenewald, 2004: 21) and should not be ignored.  
 
As Hycner (1999) and Moustakas (1994) argued, at this stage, the researcher must 
conclude the explicitation by writing a composite summary, which reflects the 
context from which the themes emerged. According to Sadala and Adorno (2001: 
289), the researcher: ‘transforms participants’ everyday expressions into expressions 
appropriate to the scientific discourse supporting the research’. However, Coffey 
and Atkinson (1996: 139) emphasise that ‘good research is not generated by 
rigorous data alone... [but] ‘going beyond’ the data to develop ideas’. Importantly, 
and linked to this is the thought that initial theorising is often linked to qualitative 
data such as derived by this method and in this study. Linked with these aspects 
(although not directly labelled as being part of the explicitation process) are the 
aspects of the reliability and validity of data collected, which are explored in the 
following section.  
 
 
 
 
 
 
	   94	  
4.7. Reliability and Validity of Data Collected 
 
The ‘quality’ of data collected and examined, is a vital part of many research studies, 
with reliability and validity often being regarded as pivotal to the study. Achieving 
reliability and producing data, with a high-level of validity is not necessarily easy, 
and it is important that these processes are included in the research design. The 
following sub-sections therefore consider the following aspects of ‘Rigour’, 
‘Validity’, ‘Warrantability and Trustworthiness’, ‘Generalisability’ and the 
‘Researcher Background’.  
 
 
4.7.1. Rigour 
 
Achieving ‘rigour’ through research design, data collection and methods such as 
explicitation is often perceived as being pivotal for case study research. Producing 
enough rigour is not simple, and there is often much criticism across the research 
method spectrum that some methods, particularly those based within qualitative 
research are not rigorous enough. Lee (1989: 39-41) has argued that there are four 
factors for research rigour as shown in Table 4.2.  
 
Table 4.2. Factors for Research Rigour 
 
 Controlled 
observation 
Controlled 
deduction 
Replicability Generalisability 
Rationalism Laboratory or 
statistics 
Mathematics Results Assumptive 
Case study Natural Logic Theory Theoretic 
 
Source: Lee (1989: 39-41).  
 
Although this study has not carried out rationalist research, rationalist factors have 
been left alongside the case study aspects, as it was perceived as informative for 
understanding case study rigour in comparison to the more commonly used methods 
found in rationalism. Examining Table 4.2, rationalist research typically utilises 
laboratory testing or statistics, whereas case study research utilises natural methods, 
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with arguably the same ‘controls’ that astronomers and geologists use (Meredith, 
1998). It is not possible to control interpretive case study research in the same way 
that rationalist studies do, in that the ‘control’ is more through selection of cases for 
interview for cases studies. Although there is also the potential for interpretive case 
study researchers to control the questions asked, general discourse and the interview 
environment.   
 
There have been criticisms against qualitative research (including interpretive case 
studies), based on the lack of mathematical (often statistical) analysis on behalf of 
the researcher carrying out the research. This is an interesting point and looking at 
Table 4.2 the column labelled as ‘controlled deduction’ listed rationalism as using 
‘mathematics’ and case studies as using ‘logic’. Considering that formal logic 
encompasses mathematics, the requirement in Table 4.2 for controlled deductions 
can be applied by applying the rules of formal logic to verbal propositions arising 
from case study interviews. Beyond arguments of mathematics being useful for 
‘precision’, which is a term more suited to rationalism, it is not necessary to 
mathematically quantify all variables in a study. It is worth pointing out that not all 
rationalist based theories were developed using mathematics, with some such as 
evolution being deduced by logic using words. Looking at business examples of 
theory deduction using words and not numbers, the studies of Pressman and 
Wildavsky (1973), Hayes and Wheelright (1979), Meredith (1981) and Gerwin 
(1988) can be cited.  
 
Linked to mathematic and verbal examination is replicability, which is regarded 
differently in rationalist and case study research. In rationalist studies, replicability 
has the aim of achieving the ‘same’ quantitative results, when a study is ‘precisely’ 
duplicated, and is often measured mathematically. In other words, if the study is 
duplicated, and is replicable, the same results should be obtained. However, in case 
studies, the same conditions can never be exactly duplicated (arguments can also be 
made in the direction of rationality for this aspect), which means that replicability is 
attained by examining resulting theory from the first case studies, under a different 
set of conditions in the replicability test. This has the potential of producing 
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differentpredictions and means that although the prediction is different, the same 
theory is still being tested.  
 
In this study, various researcher processes were carried out to increase study rigour. 
For instance, interviewee deception in interviews was reduced by the use of 
informed consent, which also aided in ensuring ethical research (Kvale, 1996; 
Holloway, 1997), as Bailey (1996) believes that it may be counter-productive. Bailey 
(op. cit.) suggested that deception on the part of the interviewer might act as a barrier 
to information, whereas the combination of honesty and confidentiality has the 
potential to reduce suspicion and promote more sincere responses.  
 
In the next section, the validity of this study and research methods utilised are 
examined.  
 
 
4.7.2. Validity 
 
In conventional and rationalist research, validity is based on an assumption that 
research findings can closely and objectively mirror the ‘real’ world, with the ‘real’ 
world having an independent existence, outside of the researcher’s notions about it. 
Discourse researchers including those using explicitation do not necessarily share 
this view, as via the discursive perspective, they perceive the world to be constructed 
discursively, as not only is their discourse about the world, it is also part of the 
world. With discourse being socially constructed it can have multiple meanings, with 
it being possible to construct an argument that discourse researchers findings are 
only one meaning, within a sea of many, and are neither true nor false.  
 
Wood and Kroger (2000: 166) suggested that: ‘Truth and realism are themselves 
social, that is, discursive constructions. There is no basis for selecting one account 
over another on the grounds that one is a truer or more valid version of the world’. 
This argument does not suggest that reality is not real, or deny the existence of 
physical objects, but rather that the evaluation of discursive research should not be 
based purely on correspondence to objective reality. It is noteworthy that this stance 
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does not itself mean that there are no criteria for selecting among versions of 
discourse, or that some discourse may be considered ‘good’ or ‘bad’. Although 
Bashir, Afzal and Azeem (2008) have suggested that reliability and validity are 
pivotal in qualitative research, for reasons explained in the following section: 
‘Warrantability’ is preferred in this study.  
 
 
4.7.3. Warrantability  
 
‘Warranting consists of providing justification and grounds for one’s claims’ (Wood 
and Kroger, 2000: 163), and is a process often used in discourse and 
phenomenological studies. This approach is quite different to subjects embedded 
within positivism, where warranting can be taken to mean ‘reliability’ and ‘validity’ 
(Rosenthal and Rosnow, 1991), and is often linked to a need for claims to be backed 
up by statistics. The way that the researcher views subjective and objective reality is 
pivotal for whether warrantability or reliability and validity are used as a measure of 
research ‘quality’. The belief in a single ‘true’ objective reality can be difficult to 
incorporate within phenomenological and discourse studies, as the way that 
individuals describe the phenomenon often varies, making a singular-view unlikely.  
 
In language and phenomenological studies such as this, there can be multiple 
representations of reality, all of which are discursively presented and all of which 
may be valid. The variation described is not argued as being linked to error, but more 
the discursive process, which produces multiple accounts of examined phenomena. 
This necessitates the use of warranting rather than validity as a check upon the 
research carried out.  
 
Conventionally, reliability can be considered by itself and in relation to validity, 
where simplistically, reliability is taken as repetition. In such research, the 
phenomenon is examined multiple times as a variable within a sample and 
throughout samples, which can be problematic in discourse-based studies, as simply 
repeating an examination in discourse studies does not necessarily create a higher 
level of repeatability. In studies based in positivism, there is the belief that although 
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the values of the variables might change, their nature will not, and that they are thus 
the same variable. This is not to say that discourse-based studies do not engage in 
repetition, particularly of repeated readings of text, but that the use of respondent 
warranting of transcribed and explicated data, as well as models produced can be 
used to increase the validity of researcher constructions and findings. In the 
following section, the issue of generalisability is also considered as a measure of 
validity.  
 
 
4.7.4. Generalisability 
 
Generalisability (also known as ‘external validity’) is often perceived as a critical 
part of research rigour (Wood and Kroger, 2000). Hedrick et al (1993: 40) defined 
external validity as the ‘extent to which it is possible to generalize from the data and 
context of the research study to broader populations and settings’. There is a 
difference in the way that researchers using different methods perceive 
generalisability and draw conclusions from their research based on this aspect. Many 
case study researchers believe that the developed from case studies can be applied to 
similar situations and even dissimilar situations at times (Meredith, 1998).  
 
Discourse and case study research ‘claims are as generalizable as those generated in 
other forms of research, particularly in experimental social psychology’ (Wood and 
Kroger, 2000: 76). There are differences between the ways that claims of 
generalisability are made and justified, which in turn influence the way that the 
sample size is viewed. Looking at more ‘conventional’ and non-explicitation 
research, claims can be made about statistical relationships between variables. In 
explicitation, ‘claims are not about variables...they are framed discursively’ (Wood 
and Kroger, 2000: 76). Another way of looking at this is that more ‘conventional’ 
work is based more on externality i.e. quantifiable variables whereas explicitation is 
focussed on the meaning of the inner subjective world of the respondent. As Douglas 
(1970: 11) stated, discourse researchers try to avoid the: “fallacy of abstractionism, 
that is, the fallacy of believing that you can know in a more abstract form what you 
do not know in the particular form”.  
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Sample size in case studies has been criticised for low generalisability in 
explicitation work, as well as sample randomness (Wood and Kroger, 2000). The 
question of whether a sample should be random, was partially addressed by 
Rosenthal and Rosnow (1991: 205) who argued that a lack of random sampling was 
often not an issue in many studies, because unlike surveys, experiments are not 
supposed to provide estimates of population values, which is the same in 
explicitation. As Rosenthl and Rosnow (1991) further argued, problems can occur 
with random sampling that over uses an unrepresentative sample, where authors 
conclude research findings on incorrectly sampled populations. It is important 
however to understand that with different explicitation studies, there is variability 
within and across the approaches, with regard to the generality of claims, which must 
be acknowledged within this method.  
 
In the following section, a consideration is made of the ‘Researcher Sensitisation’ to 
the aspects explored throughout this study.  
 
 
4.7.5. Researcher Sensitisation 
 
The researcher’s sensitisation and prior engagement with the phenomenon of interest 
in this study is a complex issue and potentially influences data explicitation, as well 
as the construction of the study as a whole, and is thus explored in this section.  
 
Academically, the researcher has carried out post-doctoral research, examining and 
carrying out antiviral disinfectant R&D. This has been as well as working as both an 
R&D and executive manager in an antiviral disinfectant R&D SME located within 
the UK. This meant that all of the respondents interviewed in this study were aware 
of the researcher, although they had not met him prior to this study. Importantly, the 
researcher felt that his background allowed him a high level of access to respondents 
that might not have been possible if the researcher was viewed as an outsider.  
 
Using theory suggested by Layton (1998), the researcher suggests that he has been 
sensitised to the sector of interest to this study before and throughout the study, and 
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the bias from this sensitisation has to be taken into account. Although, there was a 
prior sensitisation to the sector and reality of R&D from the researcher’s experience 
of working as an R&D manager and executive manager, it is noteworthy that 
arguably all interactions are at some level biased, with varying preconceptions. 
Examining the thoughts of Schutz (1932), who through the use of ethnography 
claimed that interpretive methods (as used in this study) meant that a researcher’s 
awareness and meaning are obtained by ‘reflecting’ back, or casting a retrospective 
glance upon lived experience. Thus on this basis, any researcher would have an 
inherent and constructed set of preconceptions about antiviral disinfectant R&D.  
 
The high-level of researcher sensitisation to the phenomenon of interest, may have 
aided in closeness through similarity of language, symbolism and meaning (Owusu, 
1978) between researcher and respondents, which may in aid in drawing out 
information relevant to this study.  
 
Although an argument has been put forward by this researcher about his own 
background and reasons for his suitability for carrying out this research, there are 
counter arguments, such as researcher sensitivity to the phenomenon being 
examined. Briefly, these differences are based on individuality and experiential 
closeness to the phenomenon being researched, with the issue of sensitisation being 
one that can occur through the research process irrespective of researcher 
background, but must be considered throughout the research process.  
 
In the following section, a brief examination of ‘Ethical Considerations, Data 
Storage and Protection’ is made for this research.  
 
 
4.7.6 Ethical Considerations, Data Storage and Protection 
 
The researcher undertook all research in line with the rules, ethics and regulations of 
Heriot-Watt University and Edinburgh Business School. All research processes were 
carried out in a professional manner, and information collected from interviews was 
recorded via audio digital recording equipment, and was stored in accordance with 
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the Data Protection Act 1998. All interviews were transcribed for analysis, with 
transcribed data also being stored in accordance with the Data Protection Act 1998. 
Beyond data protection, information collected from interviews can be protected 
under intellectual property laws, including, patent, copyright and trade secret. 
Information protected by these laws was made accessible through non-disclosure 
agreements (NDAs) with the respondent companies. All information was 
anonymised to protect the companies and interviewees. To protect interviewees, all 
interviews were carried out after interviewees had signed informed consent forms. 
This followed the suggestion of Saunders et al (2009) who argued that organisations 
are less likely to cooperate with research that negatively impacts upon their business 
activities, ergo necessitating the protection of sensitive information. In line with the 
suggestion by Easterby-Smith et al (1991), the amount of time and resource required 
from interviewees was detailed in advance of interviews and was kept to a minimum. 
To aid in developing a relationship between researcher and interviewee, interviewees 
were allowed to schedule the date and time for their interviews. It was made clear to 
interviewees that data collected from interviews would be made available to each 
interviewee upon request.  
 
 
4.8. Summary 
 
In this chapter the research methodology was examined through the 
phenomenological research paradigm and with the use of multiple case studies, by 
semi-structured in-depth interviews with R&D and executive Managers. Practical 
and theoretical aspects were explored for carrying out the research via a pilot and 
main study, alongside explicitation. Finally research rigour was considered to 
increase the confidence in research findings. All of these aspects are depicted in 
Figure 4.1. 
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Research Question, Aim and Objectives 
Literature Review 
Literature Synthesis 
Pilot Study 
Main Study 
Explicitation 
Construction of the Alpha Model 
Construction and Verification of the Beta Model 
Figure 4.1. The Research Process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following chapter, details the pilot study, which is followed by the main study, 
data analysis and conclusions chapters.  
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Chapter 5. Pilot Study 
 
5.1. Introduction 
 
This chapter, the ‘Pilot Study’, focuses on the exploratory stage of the semi-
structured in-depth interviews, including the ‘Introduction’, ‘Findings from the Pilot 
Study’, and ‘Pilot Study Conclusions and Adjustments for the Main Study’. This 
aspect of the study was carried out to examine not only the appropriateness of the 
methodology, but also to gain further insight into the phenomenon of interest, which 
in this study is antiviral disinfectant process R&D. Beyond understanding the pilot 
study stage, the researcher also reflected on how these findings led to adjustments in 
the main study, to more fully reflect the pilot study findings.  
 
  
5.2. Findings from the Pilot Study 
 
Examination of academic and practitioner literature highlighted the lack of research 
into how UK based SMEs carry out process R&D for antiviral disinfectants. The 
pilot stage was therefore perceived as pivotal for drawing out the relevant issues to 
be explored in the main study. 
 
Initial contact with respondents was made by telephone, where the prospective 
interview was detailed, and which was followed up by a written request to 
participate. Dates and times were arranged to suit the respondents and took place in 
the respondent’s office.  
 
Individual interviews were carried out with one executive manager and one R&D 
manager from three R&D companies, which formed the basis of the pilot study. In 
each case, the interview was recorded using a Dictaphone, to increase reliability and 
warranting of data when examined and explicated. Each interview commenced by 
the interviewer outlined the study, scope of the research and what the perceived 
participation of the respondent might achieve. Before the interview was started, a 
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final assurance of confidentiality was made. The pre-prepared interview questions 
were segmented into the following areas as shown in Table 5.1.  
 
Table 5.1. The Areas and Questions Explored in the Pilot Study 
 
Area of Interest Questions Rationale 
Viruses and antiviral 
disinfectants, with regard to 
management 
understanding. 
‘Could you tell me about 
antiviral products and how 
they relate to viruses?’  
A foundationary step to 
determine what products are 
being developed in R&D, 
and whether the 
phenomenon of antiviral 
disinfectants is separate or a 
part of in vivo antivirals or 
vaccines.  
R&D management, 
including management 
segmentation of decision-
making. 
‘How do you perceive your 
role within your company? 
And what is your 
relationship to R&D?’  
To determine the decision-
makers within these 
companies and explore this 
in regard to the sector. This 
verified the respondents for 
the main study.  
Process R&D, including, 
how and why processes 
were carried out, as well as 
potential modelling.  
‘What processes occur 
during the R&D stage, and 
who carries them out?’  
A determination of the 
process stages and 
managers/staff involved. 
This enabled a preliminary 
examination of what would 
be used to model R&D.  
Other areas of interest for 
the respondents 
‘Are there any areas or 
aspects pertinent to this 
study of antiviral disinfectant 
R&D process management 
that you feel have not been 
discussed?’ 
Finally, respondents will be 
asked to detail any areas or 
aspects that they feel are 
important beyond what the 
researcher raised during 
interview.  
 
These areas for discussion were not raised before the interview, and were posed 
during the interview to allow the fullest consideration of these areas, with minimal 
constraint on the respondent. Using semi-structured interviews, allowed the 
interviewees to engage as much as they felt they wanted to, with flexibility and to 
allow information to be fed back to the researcher (Robson, 2002). Interviews were 
on average 23 minutes in duration.  
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5.2.1. Viruses and Antiviral Disinfectants 
 
The first discussion focussed on management perceptions of viruses and the business 
‘solution’ of antiviral disinfectant products. Executive and R&D managers were 
asked the following question which was used to guide this stage of the pilot study:  
 
‘Could you tell me about antiviral products and how they relate to viruses?’  
 
This question was intended to draw out the perceptions of both executive and R&D 
managers for the way they regarded antiviral products, but also their relationship to 
viruses (with potential answers being embedded within science, business or other 
frames). All respondents defined their products as being primarily antiviral in nature 
(as opposed to a generic cleaner/sanitiser), which was linked to marketing claims 
(based on the scientific testing) being made about the products. It appeared that 
executive management was keener to extend marketing claims about the products 
beyond the R&D testing that had been carried out, with R&D managers being 
cautious about extended claims for anything not tested. This theme was prevalent 
throughout this stage and showed a preference for R&D managers to base 
management decision-making upon scientific ‘facts’ that could be verified in a 
laboratory. In this way, R&D managers saw a more limited application for products 
coming out of R&D than executive managers.  
 
The way that both types of management discursively framed products and their 
applications appeared to be based on their individual backgrounds, as well as 
individual perceptions of the way that they ‘should’ use language to describe this 
phenomenon. Beyond this, there was uniformity in that all managers described their 
antiviral products as being liquid based and to be sold as market ready, although 
there were comments made that their products were potentially being incorporated 
into other products later in the supply chain, to enhance the functionality and 
marketing claims that could be made. Importantly R&D managers were much less 
aware of how products entered and were used in the market in comparison to 
executive managers.  
 
	   106	  
5.2.2. R&D Management 
 
The second discussion examined the management of R&D, with both executive and 
R&D management being interviewed in this area. The main focus driving this 
section was:  
 
‘How do you perceive your role within your company? And what is your relationship 
to R&D?’  
 
This question drew out that all three managers working directly with R&D defined 
themselves as R&D managers, who had biologically-related undergraduate degrees, 
but had had no formalised workplace or academic training in management. The other 
managers used variations of the term executive management to define themselves 
but all agreed that they were in executive management and in positions senior to the 
R&D managers (the R&D managers also perceived executive managers as senior). 
The executive managers all had undergraduate degrees in business-related subjects, 
with no formalised workplace or academic training in science. Both types of 
manager regarded the lack of knowledge transfer between managers as problematic 
for communication about R&D and its wider company contextualisation. It was thus 
argued that there were difficulties in constructing shared meaning for technical terms 
and management knowledge and processes from R&D.  
 
Upon probing further to understand how managers interacted with each other and 
R&D, it appeared that R&D managers had a far greater involvement with the 
technical aspects of management, which spanned all of the process stages. Perhaps 
not surprisingly, R&D managers perceived themselves as custodians and pivotal for 
the regulation and success of R&D. Executive managers saw their roles as being to 
oversee R&D in relation to wider company objectives, which they argued created a 
less focussed view of the minutia of R&D, but allowed a greater focus towards 
market opportunities, which had the potential to bring them into conflict with R&D 
managers. This appeared to be a crucial aspect of the process of R&D management, 
as R&D managers felt that they were not always aware of wider company aims, and 
changing drivers, which could be costly for products going through R&D. There was 
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a universal agreement from all managers (albeit expressed separately) that confusion 
of aims, successes and failures could only damage R&D in terms of product failure, 
and slowing down products successfully leaving the R&D stage.  
 
 
5.2.3. Process R&D  
 
The third main discussion focussed on the aspect of process R&D, and explored 
what R&D encompassed, its goals, and who carried it out. The question driving this 
exploration was: 
 
‘What processes occur during the R&D stage, and who carries them out?’  
 
While the aim of this section was to encourage both types of manager to segment 
and state the R&D process stages, it also enabled decision-making for the micro and 
macro elements of R&D to be considered. Importantly, this question showed a 
difference of views between executive and R&D management, based on the 
segmentation of the R&D stage. R&D managers were keen to segment the R&D 
stage into several smaller stages and predominantly scientifically orientated stages, 
and for which they made decisions. These stages were geared for whether a product 
should proceed to the next stage or re-enter a failed stage. The basis for R&D 
manager segmentation appeared to build upon differences of scientific testing, so 
that formulation and antiviral testing would have different scientific testing protocols 
and would thus be classed as different stages. Executive management, possibly due 
to their backgrounds and knowledge being more based in business, segmented the 
R&D stage differently to R&D managers. Executive managers were conceptually 
aware of the different stages, but with variations of R&D manager segmentations. 
Executive manager decision-making for R&D was on a macro-level for whether to 
enable R&D to start, or whether to stop it, and with their decision-making being 
reliant upon feedback from R&D managers, as well as other industrial actors and 
decision-makers such as potential clients. This is an important finding, and suggests 
that R&D and executive manages have potentially different views, with a blunt 
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differentiation being that executive managers are more macro-orientated and R&D 
managers micro-orientated.  
 
Finally, the aspect of manager comprehension of R&D processes and their 
contextualisation to wider company R&D goals were considered, alongside the 
potential use of a model. While R&D managers felt that they were well versed in 
R&D and what goes on, they did feel that others working within R&D were often 
less aware of how their stage fitted in with the whole of R&D, and that a model 
could aid in increasing understanding. Importantly none of the companies examined 
at this stage used an R&D process model. R&D managers also felt that it might be 
useful for executive managers to be able to visualise the R&D stage in the form of a 
model and not just see everything as a singular i.e. “it is just R&D”. Executive 
managers, were less aware of the minutiae of R&D and of some of the stages of 
R&D, and stated that due to their senior positions was not comfortable asking “less-
senior” managers what the stages were, or what their relevance was. Executive 
managers thus positively perceived the use of a model to be conducive towards 
creating shared meaning and understanding, as well as potentially being able to 
facilitate increased executive manager management of the R&D stage.  
 
Both types of manager seemed aware of using models to represent complex 
phenomena, but it was suggested that the differences in manager backgrounds might 
result in the different manager types approaching models from different perspectives. 
This area was therefore deemed worthy of further investigation, within the main 
study.  
 
 
5.2.4. Other Areas of Interest 
 
In this final section, respondents were given the opportunity to bring up other areas 
that they perceived relevant to this study through the following question: 
 
‘Are there any areas or aspects pertinent to this study of antiviral disinfectant R&D 
process management that you feel have not been discussed?’ 
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The first area that arose out of this questioning was based on perceived difficulties of 
communicating information between R&D and executive management. Both 
manager types perceived this as a knowledge-based issue where each type of 
manager was utilising knowledge-based frames of prior experience to communicate, 
which was not always helpful for creating shared meaning and understanding. At 
worst it was speculated that the use of ‘science’ and ‘business’ speak potentially 
confused R&D and was not conducive to the success of products leaving the R&D 
stage. All managers ventured that the use of a model, incorporating management 
specific views could address this shortfall and contextualise R&D towards company 
objectives. Beyond these aspects, nothing was suggested for the main study that was 
not already there. Practically, each of the participants interviewed in the pilot study, 
was also interviewed in the main study, which is not uncommon in qualitative 
research. 
 
 
5.3. Summary 
 
The pilot study showed that for the three companies examined, management was 
split into R&D and executive management, with day-to-day decision-making for 
R&D being taken by R&D managers, and with R&D managers potentially acting 
similarly to stage-gates in the Stage Gate Model. Executive managers functioned 
more as a ‘stop/go’ decision-making aspect, where they could enable a product to 
enter R&D, or stop the project altogether. Both R&D and executive management felt 
that this split was often intentional, and was due to commitments that managers had 
with their self-perceptions, and the roles they felt obligated to carry out. For instance 
R&D managers felt a strong compulsion to use scientific language to describe R&D 
phenomena, and executive management felt a need to use business language to 
describe the same phenomena.  
 
The issue of management backgrounds, knowledge and language used for decision-
making through R&D was raised numerous times during the pilot study, with all 
managers expressing concerns for a lack of shared meaning and understanding. The 
main study has therefore explored this aspect more deeply. 
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The construction of a potential model was well received by all managers for aiding 
in shared meaning, setting objectives and creating closer understanding. The 
potential of a model simultaneously showing science and management processes 
were suggested as being useful. The researcher perceived that managers might have 
different mental constructions of what a model is based on their different 
backgrounds. This aspect was also drawn in to the main study, for further 
exploration. The most pertinent points for the summary have been depicted in Table 
5.2.  
 
Table 5.2. Summary 
 
Main Study 
Areas 
Findings 
Viruses and 
Antiviral 
Disinfectants 
All respondents regarded their products as predominantly antiviral, with 
discursive framing by executive and R&D managers being through 
business and scientific language respectively.  Both manager knowledge 
sets appeared to be embedded within their own expectations of how a 
business or R&D manager should perceive antiviral products and viruses.  
R&D 
Management 
A management divide was argued by all respondents as being executive 
managers, who had a senior overseeing duty for R&D, and R&D 
managers, who were responsible for the day-to-day running of R&D. Both 
managers described difficulties in communication and creation of shared 
meaning, based on different language used and a low-level of wider 
business drivers influencing R&D decision-making.  
Process 
R&D 
Both manager types segmented the process stages of R&D differently. 
Executive managers were conceptually aware of the stages of R&D, but 
often did not know what led to a stage being successful or not, and only 
being involved with stop/start decisions. R&D managers had a much more 
in depth view of the R&D stages, and made nearly all day-to-day 
decisions, but were often less aware of the business drivers for each stage. 
Both manager types expressed a positive perception of using R&D 
models, although none had used models in R&D.  
Other Areas 
of Interest 
Difficulties in communicating about business and scientific phenomena 
pertinent to the R&D stage was expressed by all managers, particularly as 
being difficult for creating sense between executive and R&D managers. 
It was argued by some managers that a model utilising facilitatory 
language could be used to aid in sense and decision-making.  
 
The following section explores the main study for respondent interviews carried out 
with executive and R&D managers, as well as the explicitation process.  
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Bracketing and Phenomenological Reduction 
Delineating Units of General Meaning 
Clustering Units to Form Themes 
Summarising Each Interview, Validating/Warranting/Modifying 
Extracting General and Unique Themes and Making a Summary 
Chapter 6. The Main Study and Construction of the Alpha and Beta 
Models 
 
6.1. Introduction 
 
In this chapter ‘The Main Study’ there is a focus on the explicitation of data 
collected from semi-structured in-depth interviews with executive and R&D 
managers. This stage built on the pilot study detailed in the previous chapter. Briefly, 
data from the respondent interviews was transcribed and underwent the process of 
explicitation using the methodology described by Hycner (1999). Using Hycner’s 
method, the following processes were carried out, as is shown in Figure 6.1.  
 
Figure 6.1. Explicitation Process 
 
 
 
 
 
 
 
 
 
 
 
 
The following section considers the ‘Data Collection and Handling’, which leads 
onto other sections for the results from the explicitation process.  
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6.2. Data Collection and Handling 
 
Data was collected in one phase for the ‘main study’, with ethical considerations and 
the collection and explicitation of data being a priority to maintain the integrity of 
this research and findings.  
 
 
6.2.1. Data Collection: Semi-Structured Interviews 
 
Data was collected from interview respondents via in-depth semi-structured 
interviews, where questions were prepared before the interviews took place, and 
followed a pilot study detailed in the previous chapter. Pilot study respondents were 
interviewed in this the ‘Main Study’ and were facilitated to answer a wider variety of 
questions than engaged with in the pilot stage. As mentioned previously, this is a 
common practice, where main themes drawn out in the pilot study are subsequently 
expanded on in much greater detail in the main study (Yin, 2009). Importantly, the 
discourse provided in both the pilot and main stages was compared from the same 
respondents and arguably created a further warranting stage for this study. 
Practically however, and with ‘low’ numbers of respondents being used for 
interviews, it was considered ‘necessary’ to interview the same respondents in both 
stages. Due to the ability to warrant discourse from both pilot and main study 
respondents engaged in both interviews, this was perceived as strengthening the 
methods used.  
 
Looking at the main study, and as with the pilot study, participants were not 
provided with the interview questions before or during the study, other than by the 
researcher verbally asking the questions. The research questions are detailed below 
in Table 6.1. 
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Table 6.1. The Questions Explored in the Main Study 
 
Questions Rationale 
1: ‘What is your job title? And 
how would you define your job? 
And position? 
To understand the respondent’s background in work, 
education and other areas that they perceive relevant 
to defined positions.  
2: ‘How is management 
segmented?* Does your academic 
or work experience play a role?’  
A background contextualisation to the organisation, 
and individual managers responsible for R&D will be 
explored to set up the rest of this study. 
3: ‘What is your role with regard 
to R&D?’ 
Respondent self-identity and how this relates to their 
role in R&D, via language and sensemaking can be 
examined by and between managers (Weick, 1995).  
4: ‘What do you believe is the 
purpose of R&D within your 
company?’ 
The purpose of R&D as ‘it is’ and ‘could be’ 
provides an understanding of respondent macro-
structures that may influence R&D. In other words, is 
R&D following a marketing pull (Schmookler, 1966) 
or technology push strategy? (Schumpeter, 1947). 
5: ‘What do you believe the 
purpose of R&D should be within 
your company?’ 
6: ‘What products do you make in 
R&D?’ 
What products are made in R&D will be used to 
examine respondent companies and contextualise 
R&D strategies.   
7: ‘Could you tell me about your 
understanding of viruses and 
antiviral disinfectants?’ 
Product understanding can be pivotal for the 
language used with complex high technology 
products (Mohr, 2001; Sperry and Jetter, 2009). 
8: ‘How do you carry out R&D?’ The main thrust of this study to elucidate how 
process R&D is carried out, with an explicit 
examination of each stage, and components. 
Following prior R&D models will enable the 
construction of an R&D model. Following this the 
order of the stages was sought to understand how 
different companies within this sector carried out 
R&D. The ability to determine what happens when a 
stage is passed or failed would allow a comparison to 
prior R&D models particularly technologically 
orientated models such as the Roche Model.  
9: ‘Could you tell me what the 
R&D processes are within the 
R&D stage? And detail what each 
stage is composed of?’ 
10: ‘What order do you carry out 
R&D processes?* How does a 
stage pass/fail? And what 
happens then? 
11: ‘Are R&D processes isolated 
from other departments? 
Isolation may impact on the language used between 
managers in relation to R&D (Davies, 2011).    
12: ‘Do you validate R&D?* And 
if so, how?’ 
Validation is important for the way that complex 
information is communicated for sense- 
 and decision-making.  
13: ‘Do you have specialists in 
each R&D stage?’ 
Specialists are likely to utilise specific terminology 
which may impact of sense- and decision-making.  
14: ‘Do you subcontract any 
R&D stages? And who makes 
these decisions?’ 
Decision-making is being explored in light of 
complex stages that are sub-contracted, and for 
example virology. This creates a potential need for 
managers to engage in inter- and extra-organisational 
discourse where complex information about the 
nature of products, company aims, customers and the 
process R&D stage is highlighted.  
15: ‘How are results interpreted 
in the context of R&D?* Who 
interprets and communicates 
this?’ 
Coupled with validation, the interpretation of 
complex results between R&D management and 
executive management may show linguistic vehicles 
for simplifying communication to aid in complex 
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areas (Davies, 2011).  
16: ‘Who makes R&D decisions?’ Linked to decision-making (Mudambi and Swift, 
2009) to determine the ‘who’ and ‘why’ for why 
decisions are made. Further to this, a link can be 
made between the language used by managers, their 
promoted self-identities and the sense they make of 
complex situations (Weick, 1995).  
17: ‘Do you or have you ever 
used an R&D model?’ 
R&D models are known for being able to create 
shared meaning and understanding for complex 
phenomena (Lyles and Mitroff, 1980; Morgan, 
1980). This aspect thus considered the use of models 
within respective companies and respondent 
perceptions towards their use to provide favourable 
or less complex views of reality. More than this it 
explored how R&D models can be used to aid in 
sensemaking and views that might not be ‘right’ but 
are ‘right enough’ to work.  
18: ‘Could you tell me how you 
regard R&D models?* And what 
you believe them to be? Do they 
have any importance?’ And how 
do you think your background 
influences your opinions? 
19: ‘Do you think the language 
and pictorial representation of an 
R&D model might be understood 
differently by different 
managers?* How might you 
address this?  
20: ‘How do you address different 
communication styles between 
management* i.e. different 
managers? 
Similar communication styles can lead to dyadic 
closeness, with the opposite being the case for 
dissimilar communication styles and can be linked to 
an individual’s background (Rogers, 2003).  
21: ‘Are there any areas or 
aspects that I have not covered 
that you feel are important to 
process R&D within your 
company?’ 
Finally, respondents will be asked to detail any areas 
or aspects that they feel are important beyond what 
the researcher raised during interview. This is a 
pivotal part to address perceived shortcomings. 
 
*If prompting of the respondent was required the following questions were asked. 
 
The duration of each interview was between 50 and 68 minutes, with each interview 
being recorded by a Dictaphone. All interviews were transcribed within one day, 
thus following the “24 h rule” set out by Eisenhardt (1989). To increase the 
validity/warrantability of this research, transcripts were returned to respondent to 
confirm whether they were perceived as a reflection of the interviews carried out. No 
significant amendments to the transcripts were required.  
 
Although the interviews were primarily focussed on understanding antiviral 
disinfectant R&D processes, and were thus project driven, they were left open 
enough for respondents to provide additional insights, which they felt appropriate 
(Verma and Sinha, 2002).  
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Throughout the interviews, discourse relating to sensemaking arose and was 
recorded. Deciding what might fall within a sensemaking paradigm was the first 
challenge and discourse driven repertoires given by the respondents were used as a 
method to hone in on potential sensemaking. Fitting within the suggestions by Weick 
(1995) that there are seven sensemaking properties, repertoires relating to these 
aspects, and using a hypothetical example ‘my identity helps me make sense of the 
world and make good enough decisions’ would be indicative of potential 
sensemaking. This however would not be ‘enough’ to demonstrate sensemaking, and 
through the use of further discourse given in interviews, could be contextualised with 
other discourse (where appropriate) to show instances of sensemaking.  
 
 
6.2.2. Findings: Semi-Structured Interviews 
 
After carrying out the semi-structured in depth interviews with executive and R&D 
managers from seven companies, the following explicated information was 
synthesised from all the responses to briefly highlight what the researcher perceived 
to be the most important and common findings from the answers given. The 
questions asked are shown below, with responses beneath each question for both 
executive managers (denoted as EM) and R&D managers (denoted as R&DM). 
Importantly, the respondents involved in the interviews carried out a warranting 
process for their individual discourse, to check it was a fair reflection of what had 
been transcribed, but also interpreted by the researcher. As a secondary warranting 
process, the synthesised answers were also shown to respondents to take feedback on 
their perceptions of conclusions drawn, which could be used to consider the 
researcher’s findings in relation to respondent perceptions of the antiviral 
disinfectant sector. This approach was considered to be more in line with a 
phenomenological paradigm than using coding or counting, which is arguably more 
suited to methods more based within rationalism.  
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Question 1: ‘What is your job title? And how would you define your job? And 
position? 
EM: The title of executive manager or terms synonymous with this such as 
senior manager were preferred, with positions all being ‘above’ R&D 
and R&D management, and perceived as more strategic. Respondent 
answers appeared to be more formalised than R&D managers i.e. “I 
am an executive manager of this company, and as such, I am at the 
highest level of management.”  
R&DM:  The title of R&D manager was used by all respondents, with their 
jobs being defined as custodians and managers of the R&D stage and 
staff engaged in R&D. These positions were all stated as being below 
the executive management being interviewed. Answers from 
R&D managers were typically less formalised than R&D managers, 
with more descriptive and humorous descriptors being used i.e. 
“Well…you know, I run R&D, and I guess this means, that I erm… 
manage it…or try not to. More seriously, I’m in charge of R&D, but 
am not captain of the ship, that’s what they do in senior 
management.”   
 
Question 2: ‘How is management segmented? Do factors such as your 
academic/work background/experience play a role in this?’  
EM: Segmentation occurred based on resource and need, in that all major 
business activities had managers. Areas such as accounts, R&D and 
marketing were not considered executive posts and had limited 
interaction with R&D. Knowledge of business from academic and 
practical knowledge was considered pivotal to hold a senior post 
(such as executive management). Importantly, EM respondents 
downplayed what were often higher-level qualifications of R&D 
managers (frequently R&D managers held PhD qualifications, with 
EM managers having lower qualifications i.e. “It’s all very well being 
a doctor and it sounds great for our business. We love saying to 
clients, that we, well, we have a very well qualified R&D manager, 
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with all of the technical know how, but we wouldn’t want them to run 
the company!” 
R&DM:  All major business activities were perceived as having managers. 
Importantly, although R&D managers regarded executive 
management as senior to R&D management, it was not universally 
respected, as R&D managers preferred in depth knowledge that could 
be demonstrated in areas such as R&D and accounts. Again, academic 
and practical knowledge was regarded as pivotal to being an R&D 
manager (i.e. there was a need for a scientific background). R&D 
managers often argued the relevance of a PhD to their ability to do 
their work and management i.e. “High level knowledge is imperative! 
You couldn’t do this job without it! I look at senior management, and 
erm…what do I see? Guys with business qualifications, 
who…who…couldn’t do any of what we do in R&D, and they are in 
charge of us…in a round-about way of course!” 
 
Question 3: ‘What is your role with regard to R&D?’    
EM: This role was described as being to oversee and manage from a 
distance rather than having in-depth knowledge about day-to-day 
activities. Interestingly, answers required from R&D staff and R&D 
managers were often based around simplicity such as “it works”, 
rather that in depth explanations i.e. “We just want to know it works, 
we don’t want product failures, or suing…just things that work…and 
feedback should reflect this!” 
R&DM:  R&D managers perceived their role as crucial to company 
performance and R&D and closely overseeing the R&D stage, which 
included managing different R&D staff, sub-contracting and 
orientating a pathway through to successful completion of the R&D 
stage. These managers also perceived their role to scope for new 
technological advances outside of product development (no mention 
of this was made by executive managers) and when R&D managers 
were asked about this aspect, they spoke about advancing science, and 
developing new technologies, which may or may not be relevant to 
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current company goals. An example of R&DM feedback is: “Its like 
steering a ship across a rough sea!...There is always far, far too much 
to do…And it’s my job, my job…to erm…make sure it is done. It never 
ends, and holding all this info, all of it in my head, well you know, it’s 
just not easy, and never ending.” 
 
Question 4: ‘What do you believe is the purpose of R&D within your company?’ 
EM: This question produced a variety of answers that were predominantly 
based around finance and market share; i.e. that successful R&D 
could result in more product sales, greater market share and customer 
satisfaction i.e. “Its money, pure and simple, we are here to make 
money…and lots of it. Keep those shareholders happy. The scientists 
want to do science, and we let them, but we are here…to…ah…make 
money!” Technological discovery outside of specific product 
development was not  mentioned.   
R&DM:  R&D managers produced a more uniform answer than executive 
managers and saw R&D as a vehicle to produce technological 
innovation through products that would be market ready by the time 
they left the R&D stage. Importantly, the R&D stage was framed as a 
way to solve technological problems experienced in the marketplace 
i.e. “We are technical wizards, fixing oh so many…problems. Senior 
management doesn’t get this, we are technically driven, have to be, 
where would we be without it? Bankrupt that’s where!”   
 
Question 5: ‘What do you believe the purpose of R&D should be within your 
company?’ 
EM: The answers from executive managers were almost identical to that 
produced in question 4, and there was a strong belief that R&D in its 
current format was how it should be. Some minor comments were 
made that it could be more optimised and better communicated 
however i.e. “The thing is, we all know…how to do R&D and make 
money. But ah..well..erm…sometimes the communication is useless, 
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and we…lose lots of money! Stupid really…we just don’t talk 
properly!” 
R&DM:  All R&D managers suggested that R&D should be more 
encompassing to explore technological innovation (similar to ‘blue 
sky’ research carried out in universities), which has the potential to 
bring forth serendipitous discovery for products currently not in 
R&D. Beyond this, there was a general consensus that R&D should 
be more focussed on understanding the scientific aspects of how the 
product works. It was argued that these two aspects received virtually 
no attention within the current R&D system i.e. “I’m continually 
hacked off [annoyed] by this! No long-term vision…no thought for the 
future and how to knock out the competition, we can do it with better 
science. But no! Not even on the agenda!” 
 
Question 6: ‘What products do you make in R&D?’ 
EM:  There was little deviation in this answer and discussion, as the 
response was  that R&D produces liquid based products to destroy 
viruses are made, and  for numerous sectors.  
R&DM:  Again, like executive managers, R&D managers described products 
as being liquid based and to destroy viruses in numerous sectors.   
 
Question 7: ‘Could you tell me more about your understanding of viruses and 
antiviral disinfectants?’ 
EM:  Viruses were predominantly perceived as similar to other 
microorganisms such as bacteria, but much smaller and harder to kill. 
Little was known about them as physical entities or as disease causing 
agents. Antiviral disinfectants were argued as being liquid products to 
sanitise areas where viruses were and kill them. Linguistic tools such 
as metaphor were used to describe antiviral products, with an example 
from one respondent being that using a product is like “carpet 
bombing the enemy”.  
R&DM:  Perhaps not surprisingly, R&D managers used scientific terminology 
to describe both viruses and antiviral products, and claiming that their 
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knowledge of science enabled them to get closer to the reality of these 
phenomenon, which it was further stated that executive managers 
were unable to do. Scientific language was predominantly used to 
describe antiviral disinfectants i.e. “antiviral disinfectant products 
inactivate viral particles.” 
 
Question 8: ‘How do you carry out R&D?’ 
EM: R&D was argued as being carried out by technical staff within the 
R&D department, with some aspects being sub-contracted to 
specialist companies and with day-to-day management being by R&D 
managers. The information forthcoming was somewhat limited i.e. 
“This is more of a question…for R&D…of course we know what they 
do, but specifically, you’d be better asking R&D.” 
R&DM:  It was stated that specific technical staff (qualified academically and 
through past experience) carry out each relevant stage. Sub-
contracting was argued as necessary for highly specialised work, 
where there was a lack of knowledge and physical capability in R&D 
i.e. “There are…erm…technical specialists for each stage here. Or as 
best they can be specialists, money…well there is never enough, and 
when…erm…we need to, we subcontract. Of course our bosses 
[executive managers] perceive this as a failure on our part. You know 
what I mean? That we aren’t skilled enough!”  
  
Question 9: ‘Could you tell me what the R&D processes are within the R&D 
stage?  And detail what each stage is composed of?’ 
EM:  The number of process stages ranged from between five to six, with 
six out of the seven executive managers arguing that they use a total 
of six stages. These stages and synthesised shared definitions are as 
follows: 
1. Decision-making meeting: This is to scope the potential for the 
product (whether it is client/market or technology driven) and the 
perceived likelihood for success and return-on-investment;  
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2. Formulation: This is where the product is made (little was 
forthcoming about this stage);  
3. Efficacy: Testing how well the product kills viruses (little was 
forthcoming about this stage);  
4. Safety: Testing how safe is the product for the environment it will 
be used in (little was forthcoming about this stage);  
5. Stability: Testing how stable the product is for its journey to the 
market, and in use (little was forthcoming about this stage);  
6. Decision-making meeting: The main perceived relevant points 
were described as being discussed at this meeting, such as how 
well the product performed at each stage, whether is was fit-for-
purpose, and economic considerations. If the product has passed 
all stages, this is where the decision is made for whether to send 
the product to market.  
R&DM:  The number of process stages ranged between four and five, with six 
out of the seven R&D managers arguing that they use a total of five 
stages. These stages and their synthesised shared definitions are as 
follows: 
1. Formulation: This is where the chemistry is carried out to make 
and analyse the product;  
2. Efficacy: This is where molecular biology techniques are carried 
out to analyse what percentage of viruses are deactivated by the 
product;  
3. Safety: This is where the safety of the product is scientifically 
tested, to understand is it safe for what it comes into contact with 
i.e. human skin, different manmade and natural surfaces and 
whether it is fit for purpose; 
4. Stability: This is where the stability of the product is tested, to 
ensure that it will not “fall apart” and remain stable throughout 
transportation, storage and use;  
5. Decision-making meeting: This is where R&D managers meet 
executive managers to discuss how the product performs at each 
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stage and the economics. R&D managers perceived the economics 
to be pivotal to whether a product would be commercialised.  
 
Question 10: ‘What order do you carry out R&D processes? And could you say 
more about how you decide whether a process stage is passed or 
failed? Do you even regard it as a pass or fail? And if there is a 
failure, what do you do?’ 
EM: The predominant order of R&D is as follows: (1) decision-making 
meeting, (2) formulation, (3) efficacy, (4) safety, (5) stability, and (6) 
decision-making meeting. R&D managers were argued as making 
decisions for whether a stage passes or fails, and scientific criteria is 
used to determine this (although the criteria was not always explicitly 
known by executive managers). If there is a failure, the stage is 
repeated.  
R&DM:  The predominant order of R&D is as follows: (1) formulation, (2) 
efficacy, (3) safety, (4) stability, and (5) decision- making meeting. 
R&D managers stated that they made decisions for whether a stage 
passed or failed, with  detailed scientific criteria (such as industry 
standards) often being used to determine this. If there is a failure, the 
stage is repeated. 	  
  
Question 11: ‘Are R&D processes isolated from other departments, such as 
marketing? And if they are, could you tell me more about this?’  
EM: The technical stages of R&D were argued as being separate from all 
other departments, but with a marketing influence before and after the 
R&D stage. To expand on this further, executive managers described 
a combination of technology push (for where they considered a 
market opportunity and would need to locate a buyer) as well as 
market pull (where a customer had a specific requirement for a 
product). It was felt by executive management that technical staff and 
R&D management preferred not to engage with other departments, as 
they felt that they were not relevant to R&D. This was not a view held 
by executive managers, who showed concern that R&D potentially 
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suffered from being decoupled from other departments and 
individuals who may bring insight to the R&D stage i.e. “Getting 
those guys in R&D to work with any other department…anybody else 
is a complete pain. Never seen anything like it. Refuse to engage. 
They obsess over science..and..ah..ah…want leaving alone to do their 
science.”   
R&DM:  R&D managers all used similar language to state their belief that 
R&D was separate from other departments, and should remain so. 
This appeared to be based on R&D being framed as a technical set of 
stages, and with individuals from other departments not 
understanding what was carried out in R&D, and thus could provide 
little benefit to it i.e. “The last thing we need in R&D is anybody else 
who doesn’t understand it! Everybody wants to be 
involved…marketers…accountants…we wouldn’t mind if they helped! 
But they really don’t understand what we do…and we are not science 
teachers.”  
 
Question 12: ‘Do you validate R&D? And if so, how?’ 
EM: There appeared to be some confusion over what it meant to 
validate R&D or any of the stages, with most of the managers 
believing that “everything” was validated. Statements were made that 
it was scientifically tested, so R&D, as a consequence must be 
validated. Numerous suggestions were made by executive managers 
that questions of validation should be posed to R&D managers as they 
would be best placed to answer them.  
R&DM:  Most R&D managers felt that R&D was not “properly” validated. 
R&D managers made  arguments that they were breaking the 
“principle rules of science”, in that standard practices to validate the 
R&D stages were not carried out. A simple example of this would be 
not carrying out replicates for samples tested and using language that 
suggested that statistical testing had been carried out, when it had not 
been. This practice raised concerns among all R&D managers, but 
they felt that executive management wanted to reduce the cost of 
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R&D, which due to a lack of validation created higher R&D failures 
than should have been the case.  
 
Question 13: ‘Do you have specialists in each R&D stage?’ 
EM:  From the view of executive management, each stage had a scientist 
carrying out the testing required for the stage, and was thus a 
specialist. Probing deeper, executive managers stated that they often 
found it difficult to determine what should constitute a specialist, but 
as far as internal and external communications about these individuals 
was concerned, there was a deliberate promotion of the use of 
specialists to increase confidence in R&D i.e. “It is very important for 
us to show the company and customers that our technical specialists, 
are what I said, specialists.” 
R&DM:  R&D managers did not necessarily believe that the scientists in each 
of the R&D stages were specialists. It was argued that scientists were 
used who understood what to do but often did not know the 
underlying theory, so could not interpret the data from their stage. 
The issue of a high cost for employing more knowledgeable 
individuals was cited as being a barrier to addressing this issue i.e. 
“There is always an argument going on in here…we always want the 
best people…specialists…but…I…well…they aren’t easy to come by. 
Within itself, this might not be a problem. The R&D scientists we 
have are good, but it is the way that senior management sells them to 
the company as experts in everything. Who can be that? And then 
senior management misunderstand what they say, then I get a 
problem!” 
 
Question 14: ‘Do you subcontract any R&D stages? And who makes these 
decisions?’ 
EM: It was stated by all executive managers that all R&D was carried out 
internally apart from the efficacy testing, which was subcontracted to 
external companies. This was argued as being related to high costs of 
purchasing equipment, insurance for handling pathogenic viruses and 
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a general lack of virologists. It was also speculated that a virologist 
would not find the idea of working for an antiviral disinfectant 
company an attractive proposition.  
R&DM:  Importantly, the views of executive management was mirrored by 
R&D managers, but with a heavier emphasis of virologists not 
wanting to work for antiviral disinfectant companies i.e. “So many 
virologists are in academia…an easier life than here I suppose. Why 
come here, when you get paid more there? So we make do as best we 
can! [Laughs] It’s all branding, we sell our microbiologists as 
virologists, everyone does!”  
 
Question 15: ‘How are results interpreted in the context of R&D? Who interprets 
and communicates these results?’ 
EM: The results were stated as being communicated and interpreted by 
R&D managers, which was regarded as potentially problematic. It 
was felt that R&D managers did not always seek to aid executive 
management (or non-scientist) understanding of results. Importantly 
however, where projects were customer driven, the customer would 
often interpret results through the use of hired specialists, and R&D 
managers would be obligated to communicate with these specialists 
i.e. “There are so many advantages of external clients interpreting 
results…we can’t be blamed for what R&D says, what they haven’t 
said to us. Client paid scientists…can fight it out with our R&D 
manager…it all sorts itself out in the end.” 
R&DM:  R&D managers generally collected data from R&D staff, with R&D 
managers thus communicating this information to executive 
management of customers. R&D managers argued it was easier to 
speak to hired specialists as they were scientifically trained, in 
comparison to executive management, who they felt it was difficult to 
communicate and create shared meaning with. Contextualising results 
was often perceived as difficult as R&D managers did not always feel 
well informed about the desired outcomes of R&D i.e. “Y’know…I’m 
blamed for everything that comes out of R&D. I spend my days telling 
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stories…trying to find ways to speak to management who don’t get it! 
At least if I speak to a client scientist, we are on the same page…same 
language. Its important!” 
 
Question 16: ‘Who makes R&D decisions?’ 
EM:  Executive managers argued that they made the decision for what 
products to send into R&D. Importantly, feedback from R&D 
managers and other staff was sought during the scoping stage, to 
more fully inform management decision-making. Executive managers 
also stated that they could stop R&D for numerous reasons such as 
poor economics, continued stage failures, but that they often sought 
the feedback from R&D management over this. It was felt that R&D 
managers were often too positive about failures in R&D and often did 
not factor in the need to take advantage of market opportunities. 
However, due to the nature of R&D being predominantly scientific 
and technical, most decisions were left to R&D managers. A telling 
comment about R&D decision making was: “Senior management 
makes the important R&D decisions, stop, start, but the everyday 
stuff, that’s what the R&D manager is for.”  
R&DM:  Day-to-day operational decisions were made by R&D managers, as 
well as whether a stage should be passed or failed. Critically, 
information from customers and the scoping stage prior to R&D was 
relied upon for decision-making (such as what percentage of viruses 
needed to be inactivated). It was acknowledged by R&D managers 
that executive managers made  decisions for what products to 
send into R&D and whether to terminate R&D. This was argued as a 
source of conflict, as the information being used  to make these 
decisions was not always shared with R&D managers i.e. “Go with 
me on this, we don’t get the information for what we are supposed to 
be doing…its all piecemeal…ad hoc…and then people wonder why 
mistakes are made, or erm…we go in the wrong direction! We need 
clear instruction! Then I can manage.”  
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Question 17: ‘Do you or have you ever used an R&D model?’ 
EM: None of the executive managers had used an R&D model, but all had 
academic and practical knowledge of using models for other business 
aspects.  
R&DM:  All but one of the R&D managers had experience of using an R&D 
model, which ranged from stage specific models to models for the 
entirety of R&D.   
 
Question 18: ‘Could you tell me how you regard R&D models? And what you 
believe them to be? Do they have any importance?’ And how do you 
think your background influences your opinions on modelling? 
EM: Perhaps not surprisingly, all executive managers felt that their 
academic and practical backgrounds in business management 
influenced their perceptions of R&D models, as they were based on 
business models used in different areas. The feeling towards models 
appeared positive; upon the condition that all parties could use them 
involved and were beneficial to R&D. Most  executive managers 
perceived R&D models to pictorially represent R&D in the form of a 
flowchart, which they felt could be helpful to their understanding, 
particularly when explaining R&D to potential customers.  
R&DM:  R&D models were almost universally regarded as useful vehicles to 
communicate complex information, particularly to non-scientists. 
This was coupled with the thought that it helped remind other 
managers the order of  stages carried out in R&D. R&D managers 
perceived R&D models to be a symbolic representation and often 
simpler than the reality that they communicate. As scientists, the 
respondents felt that they were more used to  scientifically orientated 
models, even if they did not use them in their current work.  
 
Question 19: ‘Do you think the language and pictorial representation of an R&D 
model might be understood differently by different managers? Might 
you suggest a way to address this? If any, what type of model would 
you like to use?’ 
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EM: It was agreed that the language and pictorial representation might well 
influence the way that the model was understood. It was suggested 
that both executive and R&D managers construct a model that jointly 
communicate different aspects, but with a focus on making the 
scientific aspects of R&D easier to engage with. A flowchart model 
with boxes was generally perceived as being the simplest to 
understand i.e. “There is…um…so much technical information 
coming out of R&D, we need simple information. Flowcharts 
work…we can make quick decisions on simple information.” 
R&DM:  R&D managers generally perceived executive managers as having 
difficulty in understanding the scientific and technical aspects of 
R&D, which led R&D managers to believe that an R&D model might 
be misunderstood, if not constructed to take this into account. It was 
argued that many practical aspects of R&D are modelled in testing 
protocols by flowcharts, so this method would facilitate 
understanding not only between manager types but staff undertaking 
R&D. Finally, the idea of using expanded model views was perceived 
as beneficial to individuals more versed in science, and the model 
could thus communicate different aspects to different individuals 
involved in R&D i.e. “I can see a model showing different info to 
R&D staff and senior manages. Yes…yes…this could be an 
improvement.” 
 
Question 20: ‘How do you address different communication styles between 
management i.e. one manager is a scientist and the other an 
accountant?’ 
EM: This was regarded as a particularly problematic area, as there were 
perceived cultural aspects that scientists were dismissive of executive 
management’s lack of scientific and technical knowledge. Likewise, 
executive management felt that there were difficulties in 
communicating various business aspects, such as being customer 
focussed to R&D managers. There were claims that language based 
tools such as metaphor and story telling were beneficial for 
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communicating complex ideas between individuals with different 
levels of knowledge i.e. “Unofficially we are…all looking, looking to 
communicate more…erm effectively. It’s a real problem, different 
worlds, different language, much confusion. Simple communication 
works.” More than this though, EM felt that miscommunication had a 
potential to increase risk and potential R&D failure. More effective 
communication was perceived as a way around this aspect.  
R&DM:  The majority of R&D managers were dismissive of communicating 
science to executive management, as they felt EM could not 
understand it. Interestingly, they R&D managers used language-based 
tools such as metaphor and science fiction based narrative to 
communicate complex ideas. R&D management felt that although 
they did not necessarily understand the business aspects of executive 
management, but that it was not as important as the science of R&D 
i.e. “Communication needs to be better! But communicating the 
complexity of science is hard! They have no background in it.” The 
inability to communicate effectively was however perceived as a 
potential risk to R&D success, in that directives from senior 
management were argued as often not clear i.e. “Senior management 
says, do this, do that, and they never think…what did we 
understand…but by the same token…we don’t have…have…a great 
attitude for making sure we…are…um…um understood either.” 
 
Question 21: ‘Are there any areas or aspects that I have not covered that you feel 
are important to process R&D within your company?’ 
EM:  There was little suggested that had not been discussed in previous 
questions. 
R&DM:  R&D managers mirrored executive manager comments, in that 
nothing new arose.   
 
The next section focuses directly on the processes of explicitation for all transcribed 
respondent interviews carried out in this ‘The Main Study’.  
 
	   130	  
6.3. Data Explicitation 
 
Once interviewees confirmed the transcripts as a reflection of their interview, they 
were used as the basis of explicitation, with Appendix B showing an excerpt of a 
transcribed interview. Alongside a literal transcription of the interviews, the 
researcher examined perceived significant verbal and para-linguistic 
communications recorded during the interview process (Hycner, 1985). The 
explicitation of data is shown in the following sections.  
 
 
6.3.1. Bracketing and Phenomenological Reduction 
 
In this the first stage of explicitation, the researcher approached the transcribed data 
from the recordings and transcriptions ‘with an openness to whatever meanings 
emerged’ (Hycner, 1985: 250). This is an important aspect of phenomenological 
reduction that would be used to elicit units of general meaning later in the process of 
explicitation. As Keen (1975) argued, this route helps the researcher become more 
open and see the phenomenon in its own right. In other words, an attempt was made 
by the researcher to suspend or ‘bracket’ his preconceived meanings and potential 
interpretations of the data being examined. Arguably though, bracketing 
encompasses more than an attempt to suspend preconceived research ‘realities’ about 
the phenomenon being researched, as it also covers the researcher endeavouring to 
enter the world of the respondent, and see the phenomenon through their eyes. As 
Hycner (1985: 281) stated: ‘it means using the matrices of that person’s world-view 
in order to understand the meaning of what that person is saying, rather than what 
the researcher expects that person to say’.  
 
Importantly, the bracketing process does not enable the researcher to exist in an 
absolute subjective space occupied by the respondent or in a place of complete 
objectivity. This is an important aspect of phenomenological studies, and is based 
upon the perceived difficulty for a researcher to exist in either of the previously 
mentioned states or to achieve a complete or absolute phenomenological reduction 
(Hycner, 1985). Merleau-Ponty (1962: xiv) expanded on this by stating: ‘The most 
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important lesson which the reduction teaches us is the impossibility of a complete 
reduction. ...that radical reflection amounts to: a consciousness of its own 
dependence on an unreflective life which is its initial situation, unchanging, given 
once and for all’.  
 
Determining, what if any prior presuppositions about the phenomenon this 
researcher had was examined by the researcher before the main study interviews. 
Using this method allowed the researcher to explore his presuppositions that he may 
not have been aware of. Once the researcher considered he had ‘bracketed’ his 
interpretations as much as possible, he sought to get a sense of each interview as a 
whole, and in other words as a gestalt (Giorgi, 1975). This process involved the 
researcher listening to the recorded interviews and reading the transcribed interviews 
several times. While the researcher listened to and read the recorded and transcribed 
interviews respectively, notes of specific issues considered important were also 
recorded. Recording such impressions, allowed further examination of issues that 
might influence the researcher’s bracketing. After these processes were carried out, 
the units of general meaning were delineated as described in the following section. 
 
 
6.3.2. Delineating Units of General Meaning 
 
After the prior explicitation stages of bracketing and phenomenological reduction, 
the researcher sought to draw out and explicate intended meanings expressed by 
managers during the interview process. This stage is ‘a crystallization and 
condensation of what the participant has said, still using as much as possible the 
literal words of the participant’ (Hycner, 1985: 282). Throughout this stage the 
researcher attempted to stay close to the literal data, and by doing so produced ‘units 
of general meaning’. Hycner (1985: 282) defined a unit of general meaning as ‘those 
words, phrases, non-verbal or paralinguistic communications which express a 
unique and coherent meaning’. The challenge for the researcher was to determine 
what might constitute a unit of general meaning, and where there was ambiguity, the 
researcher included it. An example of this process is shown in Table 6.2 where the 
processes of R&D were discussed with one R&D manager.  
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Table 6.2. Delineating units of General Meaning.  
 
Full Text Units of general meaning 
‘Hmmm, let me think...[pause]...we have 
several R&D stages1. They are relatively 
separate2 from each other, but, but they 
also feed into each other3, and er, are not 
entirely separate4. We start at the 
beginning5 with a customer telling us what 
they need, and so we put the idea into 
R&D6. So this is the first stage7, an idea 
stage8 and from this we start formulating a 
product, and this is the formulation 
stage9...[pause]...So, so, from here, we, erm, 
move the product into the antiviral testing 
stage10, y’know, does it work? All going 
well, and often it doesn’t...[laughs]...we 
have stages to test product safety11, 
stability12, and let me think, if this works, 
we do the numbers13 and, er, er, see if it is 
financially viable. So not too many process 
stages14, but all-important! 
1 Several R&D stages 
2 Relatively separate 
3 Feed into each other 
4 Not entirely separate 
5 Start at the beginning 
6 Put the idea into R&D 
7 The first stage 
8 An idea stage 
9 Formulation stage 
10  Antiviral testing stage 
11 Product safety [process stage]  
12 Stability [process stage] 
13 We do the numbers [process stage] 
14 So not too many process stages 
 
Prior to this, the respondent had discussed various other R&D aspects that led up to 
the response detailed in Table 6.2 of the process stages of R&D. As can be seen from 
this table, there is a continued emphasis by the respondent of the R&D stages, 
through repetition of the word ‘stage’ and explicit references to specific process 
stages throughout R&D. As Hycner (1985: 282) stated: ‘At this stage these meanings 
are those experienced and described by the participant irrespective of whether they 
later are determined to be essential, contextual, or tangential to the structure of the 
experience of wonder’. An example of one of the challenges was segmenting the 
units of general meaning, which are subjective decisions made by the researcher. 
Simplistically for instance, the researcher of this study may have segmented the 
discourse into one unit of general meaning, whereas another researcher may have 
segmented the same discourse into two units. ‘Given different perspectives among 
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phenomenological researchers there are bound to be minor differences even when 
utilizing the same general method’ (Hycner, 1985: 284). While there are challenges 
for determining the units of general meaning, the researcher can amend their choices 
later and throughout the explicitation stage.  
 
Beyond the brief demonstrative delineation of units of general meaning as shown in 
Table 6.2, this process was applied to the all manager-based interviews carried out in 
this study, to draw out units of general meaning for the research question, aim and 
objectives of this study, and as shown in the following sections.  
 
 
6.3.2.1. Units Relevant to the Research Question  
 
The prior stages to delineating units relevant to the research question, has created a 
platform to address the research question, which in this study is:  
 
‘How do UK based SMEs carry out process R&D for antiviral disinfectants?’  
 
This is a critical stage of the research, and in the process of explicitation towards 
addressing and understanding the phenomenon. Again, as this is a subjective 
process, the question of which units are relevant to the research question is not 
necessarily clear at this stage of the explicitation process. On this basis, and when in 
doubt, the researcher included units which appeared of value, with the potential of 
removing unnecessary units at a later point if required. Directly addressing the 
research question to the units of general meaning produced the following examples 
of units of general meaning shown in Table 6.3.  
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Table 6.3. Addressing Units of General Meaning to the Research Question 
 
Units of general meaning 
1 Several R&D stages 
2 Five R&D stages 
3 Six R&D stages in total 
4 We formulate, test product activity, safety, stability, and economics 
5 The R&D has five scientific component stages 
6 Six linked stages to get a product to market, that’s R&D! 
7 The market drives what we do in R&D 
8 The customer has an idea, and we use R&D to make it a reality 
9 We work with the client to get the product to market, R&D is the vehicle 
10 Our company is market and customer driven, we respond to both 
11 When a stage fails, we rethink, and cycle back through, we get there in the end  
12 R&D is somewhat linear, but with decision gates...to decide what stages pass and fail 
13 Sat with R&D is the economic analysis, this is important 
14 If the finances of the product are wrong, R&D has failed, we have no product 
 
With fourteen respondents having been interviewed, Table 6.3 is only a snapshot of 
the units of general meaning, but is intended to demonstrate this stage of 
explicitation. For the research question, units of meaning were considered relevant 
that either directly or indirectly interacted with the R&D process stage. On this basis, 
aspects such as the total number, order and naming of process stages was of interest 
for example. Only examining units related to the physical aspects of R&D as in the 
previous example, would have potentially biased any eventual constructed model of 
R&D. It was therefore necessary to examine units with a wider meaning, which 
could result in the researcher understanding the management aspects of R&D, 
market and customer drivers for R&D and what happens after the R&D stage. The 
units of general meaning drawn out of this stage were in practice much greater than 
shown in Table 6.3. With the wealth of data drawn out in this stage, it was important 
to be able to undertake the process of ‘Eliminating Redundant Units of Meaning’, 
which is explored in the following section.  
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6.3.2.2. Eliminating Redundant Units of Meaning 
 
In addressing the units of general meaning, with a view to eliminating redundant 
units, it was important to consider the relevance of each unit and their wider 
contextual aspects, to create a greater clarity to meaningfully engage with and 
understand the phenomenon of antiviral disinfectant R&D.  
 
Within these aspects are elements such as the frequency of units, are non-verbal and 
paralinguistic cues, which can alter the relevant meaning of the discourse given. An 
example of this is a respondent giving the same two units of meaning, but having 
different non-verbal or paralinguistic cues, which could be standing and shouting 
while giving one unit, and sitting laughing while delivering another. It was therefore 
important for the researcher not to place too much emphasis on literal frequency of 
units of meaning without examining a wider context.   
 
The process of eliminating redundant units of meaning was a long and repetitious 
task, where the researcher continually examined the transcribed discourse and units 
of meaning, in light of the research question, aims, objectives and chronology of 
discourse to try to draw out the ‘more’ relevant and important units. After 
eliminating redundant units, the researcher clustered the units to form themes 
relevant to this research, which is shown in the following section.  
 
 
6.3.3. Clustering Units to Form Themes 
 
After removal of the redundant units of meaning, the researcher again bracketed his 
preconceptions to cluster units into themes. The number of processes in the R&D 
stage, their segmentation and management perceptions were examined in the context 
of clustering units to form themes. In-depth clustering was carried out to rigorously 
interrogate the phenomenon of the R&D stage. This stage of the work involved the 
researcher’s subjective interpretations of the importance of themes and it is worth 
drawing on the thoughts of Colaizzi (1978: 59): ‘Particularly in this step is the 
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phenomenological researcher engaged in something which cannot be precisely 
delineated, for here he is involved in that ineffable thing known as creative insight’.  
 
As there were a number of units relevant to the phenomena of interest, it was 
possible to cluster units of relevant meaning, for example, into the ‘number of R&D 
stages’, ‘R&D stage segmentation’ and ‘whether there was stage decision-making’ 
and ‘the use of feedback loops’, which is shown in Table 6.4, with numbers 1-7 
being linked to the respondent number in this table.  
 
Table 6.4. Clustered Units to Form Themes  
 
Theme Executive Management R&D Management 
R&D 
Stage 
Number 
1 Six, 2 Six, 3 Six, 4 Six, 5 Six, 6 Five, 7 Six 1 Five, 2 Five, 3 Five, 4 Five, 5 Five, 6 
Five, 7 Five 
Stage 
Order 
1 Decision-making, Formulation, Efficacy, 
Stability, Safety, Decision-making. 
2 Product meeting, Formulation, Efficacy, 
Health, Stability, End meeting. 
3 Product meeting, Formulation, Efficacy, 
Safety, Stability, Decision-making. 
4 Meeting, Formulation, Efficacy, Safety, 
Stability, Meeting. 
5 Formulation, Efficacy, Stability, Safety, 
Stability, Meeting. 
6 Meeting, Formulation, Efficacy, Safety, 
Meeting. 
7 Product meeting, Formulation, Efficacy, 
Safety, Stability, Product meeting. 
1 Formulation, Efficacy, Stability, 
Safety, Decision-making. 
2 Meeting, Formulation, Efficacy, 
Health, Meeting. 
3 Product meeting, Formulation, 
Efficacy, Safety, Decision-making. 
4 Meeting, Formulation, Efficacy, 
Safety, Stability, Meeting. 
5 Formulation, Efficacy, Safety, 
Stability, Health & Safety. 
6 Formulation, Efficacy, Stability, 
Safety, Meeting. 
7 Product meeting, Formulation, 
Efficacy, Safety, Product meeting. 
Stage 
Decision-
Making 
1 Yes, 2 Yes, 3 Yes, 4 Yes, 5 Yes, 6 Yes, 7 
Yes 
1 Yes, 2 Yes, 3 Yes, 4 Yes, 5 Yes, 6 Yes, 
7 Yes 
Feedback 
Loops? 
1 Five, 2 Five, 3 Five, 4 Five, 5 Five, 6 Four, 
7 Five 
1 Four, 2 Four, 3 Four, 4 Four, 5 Four, 6 
Four, 7 Four 
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In Table 6.3 all the units of relevant meaning have been clustered by the researcher, 
which involved examining Table 6.1 And Table 6.2, as well as revisiting the 
interviews several times. For brevity, discrete units of measure were used for aspects 
such as the total number of R&D stages, which in conjunction with interviews, was 
used to produce a stage order of R&D processes. Whether the stages were gated for 
decision-making and whether feedback loops were employed were also considered. 
Throughout the process of clustering units to form themes, the research question was 
continually posed to the data, and the data posed to the research question, in a 
resonant fashion, to draw out important themes for this study. In doing this, the 
central theme was the production of an R&D process model (for antiviral 
disinfectants).  
 
Table 6.3 showed that R&D managers tended to more thoroughly segment process 
stages into individual aspects and more easily describe each stage, which was linked 
to be closer to the phenomenon and their management practices. Executive managers 
were used slightly different segmentations, but which were similar to those used by 
R&D managers. Under a thick description, both management types used similar 
descriptions for R&D, in that both manager types perceived that feedback loops were 
used throughout R&D, when a stage failed, to potentially rectify the failure. 
However, when digging deeper into management knowledge of R&D, differences 
between managers were observed, but at this stage, were recorded but not more fully 
examined until the next stage in the explicitation process. 
 
Finally, after the process of clustering units to form themes, the explicitation stage of 
‘Summarising each Interview and Warranting’, was carried out and is examined in 
the following section.  
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6.3.4. Summarising each Interview and Warranting 
 
After completing the previous stages, the researcher went back to the interview 
transcripts and wrote a summary of the interviews incorporating the themes drawn 
out from the explicitation process, to give a greater sense of a whole context for the 
emerging themes (Hycner, 1985). A second interview with all interviewees was 
conducted to verify and warrant research findings produced so far. These findings 
were discussed with the respondents, and additional information perceived relevant 
by the researcher and respondent were discussed as perceived appropriate to more 
fully capturing the phenomena of interest. This further information provided further 
knowledge for the final stage of the explicitation process of ‘Extracting Themes and 
Summarising’, as shown in the following section.   
 
 
6.3.5. Extracting Themes and Summarising 
 
After carrying out confirmatory interviews with respondents, the procedures utilised 
in the explicitation process prior to this stage were repeated, which produced minor 
changes to the research data. Although there were minor modifications, the themes 
were not changed, only the contextualisation, which is discussed in Chapter 7.  
 
Summarising the extraction of themes, there were two groups of managers assessed 
in this study, including executive and R&D managers, with variations between and 
in groups being produced from the interview stage about the R&D process stage. 
Using a thick examination and description, there was a similarity of the surface-
based phenomena being examined, but as a greater depth of understanding was 
sought, this varied between executive and R&D management. Chapter 7 shows the 
differences more explicitly through expanded model views, for the construction of 
models built on different manager perceptions, understanding and construction of the 
reality of the R&D process stage.  
 
The following composite summary was composed to ‘capture the essence of the 
phenomenon being investigated’ (Hycner, 1985: 294). The main themes drawn from 
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this stage was that there are differences in the number of perceived R&D stages from 
executive and R&D managers, but that there are many similarities between 
management perceptions. R&D managers showed a much deeper knowledge of 
R&D processes, particularly from a scientific viewpoint, but were often less aware of 
the wider organisational and business aspects that R&D interacted with. The 
converse of this was shown for executive managers who were less aware of the 
scientific processes but much more knowledgeable about the interaction of R&D 
with other organisational aspects. Executive managers stated that they were less 
involved with the day-to-day running of R&D and particularly decision-making, 
which was confirmed by R&D managers who appeared to act like stage-gates for all 
R&D management decisions. Importantly however, executive managers had an 
overriding decision-making capability of stopping and starting the R&D stage. It was 
noted that this led to conflict between executive and R&D managers, due to different 
perceived drivers for R&D (executive managers being more profit driven than R&D 
managers who often focussed on ‘advancing’ science). Coupled with this was the 
difficulty that both types of managers described for communicating complex 
business and scientific aspects, to each other, and which were both considered 
pivotal for successful R&D. Importantly, no company used a model for R&D, 
although some of the managers had experience of models for R&D from previous 
employment. Upon questioning the managers, there was a general feeling that a 
model may aid in developing understanding throughout the company, but concerns 
were raised about how it could be constructed to enable sense to be made of complex 
phenomena. The researcher detailed the potential of using expanded model views to 
encompass both scientific and business phenomena, which appeared to be well 
received as a vehicle of addressing this issue.  
 
Table 6.5 highlights the themes extracted and summarised between executive and 
R&D managers. 
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Table 6.5. Extracting Themes and Summarising  
 
Summarised Themes Response by Executive 
Managers 
Response by R&D Managers 
Perception of R&D Predominantly a scientific 
activity leading to product 
commercialisation to satisfy 
market requirements.  
Predominantly a scientific 
activity leading to new 
knowledge and subsequent 
product commercialisation 
Organisational 
Interaction 
Carry out organisational 
management including 
overseeing R&D.  
Limited to R&D, with 
interactions mainly coming 
from executive management.  
Knowledge of R&D Limited to process stage 
names with basic 
understanding of what goes on 
in each stage.  
In depth knowledge of the 
scientific process stages of 
R&D but with less 
understanding of business 
drivers for R&D.  
Decision-Making Focused towards stopping and 
starting the R&D stage. 
Executive management does 
not deal with decision-making 
for scientific aspects.  
Focused towards the day-to-
day decision-making for R&D, 
and where business aspects are 
relevant, executive 
management is involved.  
Management 
Communication 
Discursive framing is 
predominantly through 
business language.  
Discursive framing is 
predominantly through 
scientific language. 
Perceptions of R&D 
Models 
Viewed through the lens of 
management drivers, but 
perceived as a way of 
increasing sense between 
executive and R&D managers. 
Viewed through the lens of 
R&D/scientific drivers but 
perceived as a way of 
increasing sense between 
executive and R&D managers. 
 
In the next section, the ‘Construction of the Alpha Model’ is considered.  
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Formulation Efficacy Safety Stability Meeting 
Repeat Failed Stages 
Efficacy Safety Stability Meeting Formulation 
Repeat Failed Stages 
Meeting 
6.4. Construction of the Alpha Model 
 
The explicated information was used to construct the alpha model shown below for 
both R&D and executive managers. Both executive and R&D managers expressed 
that the alpha model should be constructed pictorially and represented using a 
flowchart, which encompassed the different process stages. Alpha models for both 
R&D and executive managers were constructed using the explicated R&D stages, 
and are shown in Figures 6.2 and 6.3 respectively.  
 
Figure 6.2. R&D Manager Initial Process Alpha Model 
 
 
 
Figure 6.3. Executive Manager Initial Process Alpha Model 
 
 
 
Importantly, both Figure 6.2 and 6.3 showed a progression of the R&D process 
stages in the same order, with the only difference between the models being the 
additional ‘meeting’ stage in the executive R&D model. The decision of the order of 
the stages was made based on the majority of R&D and executive managers arguing 
that R&D occurs in this order. A main path has been shown in both models, with a 
Main Path 
Main Path 
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potential to cycle back through the stages if a stage fails. There is also the potential 
to terminate R&D, if required. Between each stage is a decision-making gate where 
R&D managers decide to go forward to the next stage, repeat a stage or an executive 
manager might terminate R&D.  
 
After the construction of both models, these models were firstly shown to respective 
managers to seek their opinion on the representation of R&D (i.e. the R&D model to 
R&D management, and the executive model to executive management). After 
feedback was taken, both models were discussed with R&D and executive managers 
to synthesise these models into a single model, with an expanded view, which is 
shown in the following section ‘Construction of the Beta Model’.  
 
 
6.5. Construction of the Beta Model 
 
Upon showing R&D and executive managers both alpha models constructed from 
the previous section to verify them as a reflection of their perceptions of R&D, a 
synthesis was undertaken to construct one model (the beta model). Simplistically, 
this involved adding the first stage of the ‘meeting’ from the executive model into 
the R&D stage. Although, not a scientific stage, upon further discussion, there was a 
general consensus that this additional stage should be added to the R&D model. 
Upon this addition, the models became identical, while under a non-expanded view. 
This warranting stage, also considered an expanded model view, which enabled the 
additional shared meaning for each of the stages that would make sense for executive 
and R&D managers. The reconstructed model with expanded views is therefore 
shown in Figure 6.4.  
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Repeat Failed Stages 
Meeting Stability 
Scoping 
with R&D 
& Executive 
Managers 
Chemists 
put product 
together 
Sub-
contracted 
to test 
percentage 
viruses 
killed 
Testing 
product 
toxicity 
Testing 
product 
stability 
End 
meeting to 
determine 
product 
economics 
etc. 
Figure 6.4. Beta Model of Process R&D 
 
 
 
 
 
 
 
The wording and pictorial representation was drawn on from the explicitation stage 
but also directly from manager feedback to enable the production of a model to 
facilitate shared meaning, and aid in the R&D stage. Shared meaning between 
managers was examined by the language used by managers as a proxy to their 
sensemaking on an implicit level, and in other words similarities between repertoires 
used (Weick, 1995). A more explicit approach was also used in the warranting stage 
to directly ask respondents about shared meaning, which enabled an examination 
within the R&D manager and executive manager groups, as well as a totality of all 
managers. Directly posing the question about shared meaning and the model, as well 
as the consideration of repertoires used, enabled the researcher to feel confident from 
discourse given that shared meaning was being achieved through the model. The 
notion of enabling the managers to act as practical authors for the R&D model was 
argued as being pivotal by the managers for creating shared meaning. Thus although 
the model was constructed by the researcher, it was heavily guided by the 
respondents in the pilot and main study as well as warranting stages.  
 
Importantly and to increase shared meaning technical terminology and descriptions 
beyond what executive management used, were predominantly left out of this model, 
as they were not perceived as being constructive. R&D managers expressed an 
Main Path 
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interest in being able to create a second layer of the expanded view to define what 
was carried out in their respective stages. It was however felt that this was a task that 
should be undertaken by R&D managers in respective companies, due to the 
sensitivity of the minutia that might be detailed. A perceived advantage of this 
potential addition is based on this additional view not being necessary for executive 
managers to understand or engage with, but is more of a practical guide for those 
engaged directly with R&D.  
 
Warranting of the beta models with individuals beyond executive and R&D 
managers was not undertaken, as attempts at snowballing into other organisational 
members was rejected by the respondents, as it was argued that they had the 
knowledge. This mirrored earlier discourse in the study from initial engagements 
with the respondents, where executive and R&D managers presented themselves as 
the ‘experts’. Importantly, no mention was made of other individuals that should be 
engaged with throughout the interview stages, and on this basis, no further attempt to 
warrant the model was made with any other individual.   
 
After respondent warranting of the beta model, the model was utilised by three 
different respondent companies and trialled for its suitability, which at the end of this 
study was still on going. Preliminary feedback from executive and R&D managers 
was positive and although a greater length of testing was argued as being required to 
demonstrate the longer-term suitability of the model, short-term findings supported 
the use of the antiviral disinfectant beta model. As one R&D manager stated, it is ‘an 
easier way through R&D that makes more sense’ that ‘means we speak to each other 
better’. A longer-term study of the implementation of this model, particularly if 
utilised by other companies may well be of academic interest. However, as was 
described by one executive manager of a company not yet trialling the model ‘R&D 
is not set in stone, but it takes time, it takes time to move to a different system. We 
need to wait until an R&D cycle is finished, then we start, start with a product and 
see how the model works’. This respondent highlighted the practicality of trialling 
this model and need to wait until a new product R&D cycle can be started to 
minimise the disruption to current operations.  
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Looking beyond the previously discussed aspects, Table 6.6 highlights the 
similarities, differences and contribution between the antiviral disinfectant process 
R&D model produced in this section and prior examples of R&D models. 
 
Table 6.6. An Examination of this R&D Model against Others 
 
Prior Models Similarities Differences Contribution of the 
Antiviral Disinfectant 
Model 
Stage Gate 
(Figure 2.3.) 
Both are stage gated 
and split into process 
stages.  
The antiviral disinfectant 
model has a predominant 
focus on scientific testing 
stages, with an expanded 
model view. 
Elucidation of technical 
stages specifically for 
executive and R&D 
managers with an 
expanded model view. 
Facilitating technical 
stage sensemaking for 
antiviral disinfectants.  
Design 
Thinking 
(Figure 2.5.) 
Both show a linear 
route through R&D.  
The Design Thinking 
model has a greater focus 
on the mental aspects of 
R&D, in comparison to 
the antiviral disinfectant 
model, which is 
physically orientated.  
The showcasing of 
physical stages enables 
managers to target mental 
processes such as found in 
the Design Thinking 
Model towards ‘practical’ 
goals as in the Antiviral 
Disinfectant Model.  
Technological 
R&D 
Framework 
Model (Figure 
2.6.) 
Both scientifically 
focused towards 
physical stages to 
develop a product and 
take it through R&D 
to commercialisation.  
The Technological R&D 
Framework Model is more 
focused towards achieving 
legal compliance in 
comparison to the 
Antiviral Disinfectant 
Model. This is a 
consequence of the 
different legislative 
requirements, which echo 
into the different process 
stages ‘legally’ required.  
A sector specific R&D 
model for the antiviral 
disinfectant sector, 
highlighting a simpler 
legislative system in 
comparison to the ‘harder’ 
legal requirements from 
drug R&D in the 
Technological R&D 
Framework Model.   
Technological 
R&D with 
Increased View 
(Figure 2.7.) 
Both models have a 
linear path through 
technical R&D, with 
physical stages being 
shown, which are 
gated.  
The Antiviral Disinfectant 
Model shows greater 
flexibility, in that a failed 
stage does not mean failed 
R&D as in the 
Technological R&D with 
Increased View Model. 
The Technological R&D 
Model with Increased 
View is more focused 
towards achieving legal 
compliance in comparison 
to the Antiviral 
Disinfectant Model. This 
is a consequence of the 
different legislative 
requirements for the 
products being developed. 
An expanded model view 
for all stages, with failed 
stages being repeated. The 
technological model 
frames outcomes as 
‘success’ or ‘failure’ 
which is linked to the cost 
of the R&D stage, and 
where failure occurs R&D 
stops. A sector specific 
R&D model for the 
antiviral disinfectant 
sector, highlighting a 
simpler legislative system 
in comparison to the 
‘harder’ legal 
requirements from the 
Technological Model. 
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In the next section, the ‘Summary of the Results’ is discussed to draw together and 
build on the findings in this chapter.  
 
 
6.6. Summary of the Results 
 
This study investigated the research question: How do UK based SMEs carry out 
process R&D for antiviral disinfectants? From the seven R&D companies examined, 
R&D was shown to have an executive management structure, which oversaw R&D 
but often with limited decision-making beyond stopping and started R&D. The day-
to-day management of R&D was undertaken in these companies by a single R&D 
manager, who had been scientifically trained, and who made nearly all R&D 
management decisions, and oversaw technical staff in this stage. Both sets of 
executive and R&D managers used different language to communicate about R&D 
based on their knowledge and experience, which was a perceived source of 
confusion and conflict. This extended into which stages were considered part of 
R&D. For example, R&D managers argued that only technical and scientific stages 
were part of R&D, whereas executive managers considered pre-R&D scoping, 
decision-making and meetings as part of R&D. Importantly, all managers considered 
the R&D stage to be linear from start to finish (albeit with different stages involved), 
with each stage being gated by decision-making for whether to proceed, repeat the 
stage, or stop. This enabled the production of an alpha and beta model (with the beta 
model having been warranted) and with expanded views to show more detailed 
information. The model produced (with six stages), has elements of other models 
(such as the Stage Gate), but is unique in that it incorporates two management 
constructions (executive and R&D) and created shared meaning for management. 
These and other aspects are discussed more thoroughly in the next section for the 
‘Discussion of the Results’.  
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6.7. Discussion of the Results 
 
The purpose of this study and thesis was to examine and understand antiviral 
disinfectant R&D, at a sufficient depth that would enable the construction of alpha 
and beta R&D models. The objectives were thus: 
 
a) Through a literature review and current practice, to determine the current
  scientific and business processes for UK SMEs engaged in antiviral 
 disinfectant process R&D; 
 b) Informed by a) above to produce an initial alpha model for UK SMEs 
 engaged in antiviral disinfectant process R&D; 
 c) Informed by a) and b) above, to verify/warrant the initial alpha model and 
 so produce a beta R&D model. 
 
This research produced the following outcomes to address the objectives: 
 
1. An understanding of how antiviral disinfectant process R&D is managed and 
carried out in UK SMEs, with the different types of management interactions 
within R&D being drawn out;  
2. An understanding of the perceptions of executive and R&D managers for 
how R&D is carried out in their companies, as well as the difficulties in 
communicating between different managers; 
3. The Construction of an alpha and beta model of R&D that was warranted by 
both R&D and executive managers; 
4. The Production of an expanded model view for the process stages to aid in 
the construction of shared meaning between managers.  
 
This study examined seven R&D and seven executive managers employed in UK 
SMEs engaged in antiviral disinfectant R&D. The themes used to draw out the 
questions during the interview stage were based on the literature review in Chapter 2 
and the sensitisation of the researcher to the sector.  
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Both executive and R&D managers perceived the R&D stage to consist of almost 
identical stages (using similar language to label and describe each stage), and 
ordering the stages similarly and in a linear fashion. The main difference between 
manager views was based on executive management regarding the initial scoping as 
being part of the R&D stage and R&D managers, not regarding this stage as part of 
R&D. Interestingly however, both manager types regarded the end meeting as part of 
R&D. Importantly, upon warranting being carried out and the two alpha models 
being shown to the different managers, the R&D managers opted to include the 
initial scoping meeting as part of R&D. By doing this, a synthesised singular R&D 
model was produced as the foundation of all other model aspects that would be 
added. Arguably, it was an important finding that both types of manager across 
several companies constructed R&D in such a similar way, indicating that the model 
produced from this study has a potential to be used by other antiviral disinfectant 
R&D companies.  
 
It was important to study this model and contextualise it in light of prior R&D 
models. As a starting point, the antiviral disinfectant process model constructed in 
this study, herein referred to as the ADP model is focussed towards a different sector 
than models previously examined, which echoed into the process stages constructed 
by respondents and model view expansions. Thus, the ADP model reflects the 
phenomenological paradigm used in this study, where the phenomenon of interest, 
i.e. antiviral disinfectants was ‘true to itself’ and was modelled accordingly. More 
explicitly, this approach differed from the philosophical basis of other models, which 
have been grounded in methodologies geared more towards the physicality of R&D, 
but have not given as much attention to the constructing lens of R&D respondents as 
within a phenomenological approach. This is an important aspect and arguably 
extends the theory of R&D process models, as the model produced may more closely 
mirror the management reality of process R&D than other models.  
 
Looking at the ADP model, it appears to be embedded within both the technological 
model (Canongia, 2007) and market/consumer model (Cooper and Edgett, 2013). 
This claim is made, as there are elements of the ADP model, which are encompassed 
within both technological, and market/consumer models, which will now be more 
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fully explained. Looking at the Stage Gate Model first as an example of a 
market/consumer model, the ADP model is gated, with decision making being made 
on a day-to-day basis and between stages by R&D managers, with the potential for 
executive managers to terminate any failed stage. Importantly, within the ADP 
model, there is no discovery stage at the beginning, as the R&D companies either 
utilise customers to drive demand, through specific requests for product development 
(market pull) or, alternatively, develop technology without a specific customers 
(technology push). The first stage in the ADP model is the meeting (scoping) stage 
and which is the second stage in the Stage Gate Model. The third stage in the Stage 
Gate Model (Build Business Case) is rolled into the meeting (scoping) stage of the 
ADP model. The next stages of ‘development’ and ‘testing and validation’ are 
expanded in the ADP model into ‘formulation’, ‘efficacy’, ‘safety’ and ‘stability’, 
which are all the technical stages. Importantly, the expansion of the ADP model 
differs from the Stage Gate Model in that although both have expansions, the ADP 
model is more orientated towards isolated use by a limited number of managers. 
Finally in the Stage Gate Model, there is a ‘launch’ stage, which is not present in the 
ADP model, as the ADP model is focussed on the pre-commercialisation aspects of 
R&D. Arguably however, and although there is a final stage in the ADP model of a 
meeting to discuss economics and potential customers etc. it is conceivable that if the 
ADP model went beyond the pre-commercialisation aspects of R&D, the final Stage 
Gate Model stage of ‘launch’ could be used.  
 
Although there is a similarity to the Stage Gate Model, upon examining the 
technological model used by Roche (2013), there is also a similarity between the 
ADP model and the Roche model, as both models have a focus on displaying the 
technical stages and aspects of R&D, including expanded views. Looking also at the 
technological model by Cassimon et al (2013), this is also a gated model, with 
options of success, failure and discontinuation for each stage. Examining the 
fundamentals of all of the models discussed so far are commonalities, in that they are 
all linear progressions through R&D, with a potential for success, failure and 
discontinuation at each stage. The technological models are perhaps not surprisingly 
more orientated to displaying the process stages of R&D, which is the case for the 
ADP model. There is also less focus with the technological models for displaying 
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business or market aspects, but which the ADP model takes into some account at the 
beginning and end of R&D. Importantly, however the recycling elements back into 
failed stages for ADP model enabled a ‘new’ view of a ‘failed’ stage, as due to what 
is often a chemical simplicity of the product, it could be used to start a new product 
R&D cycle. In other words, a failed stage may well be repeated to complete an R&D 
cycle, but it may also generate new potential products suitable for other products.   
 
The ADP model uses expanded views to communicate shared meaning between 
different managers for all of the stages within the model. This is similar to the Roche 
(2013) model, which also appears to communicate shared meaning between different 
industrial actors. Creating shared meaning between R&D and executive management 
was raised as being crucial to the R&D stage by many of the respondents, during the 
interview stage. This is an important finding, as it arguably enabled a foundation for 
the giving and making of sense between executive and R&D managers, where the 
focus can be made towards creating a simpler or preferred view of R&D in 
comparison to one that is more complex. In other words, although different managers 
have their own constructed views of R&D, a model can be used to aid management 
working together towards the goal of a product successfully leaving the R&D stage 
into commercialisation. This has the potential to decrease the time and cost of a 
product going through R&D as well as removing some of the communicated 
‘fuzziness’ of the R&D stage. Warranting the ADP model through respondent 
discourse, while making the respondents practical authors of this model, could be 
argued as an attempt to more deeply embed this model within the shared subjective 
realities of respondents in comparison to prior models. It is important to recognise 
that while no objective claim can be made about which R&D model is ‘closest’ to 
the phenomenon of R&D, the approaches taken in this study were all focussed 
towards closely mirroring the ADP model with constructed respondent realities of 
R&D. This is argued as increasing the strength of a claim made by one respondent 
that this model is ‘something that works’.  
 
Nobelius (2004) has argued that the technological model has advanced into the sixth 
generation, whereas the consumer model is a mixture of the second and fourth 
generations, with a particular focus on cost, quality and particularly time to market 
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(Chaudri, 2013). Examining the consumer model in greater detail however (Liedtka, 
2011; BRIDGE Collaboration, 2013) indicated that due to a desire to collapse the 
process time, the first stage at least, requires that all actors in the R&D process are 
identified and utilised. This is certainly the case with the ADP model in both of the 
meeting stages (at the beginning and end of R&D), which has some resonance with 
the sixth generation of R&D, with an emphasis and networking and collaboration. 
Also the efficacy stage (antiviral testing) was in all cases sub-contracted to perceived 
specialists, who would work closely with the R&D company, which also draws in 
elements of the sixth generation of R&D. Considering that the APD model appears 
to have aspects of both the consumer and technological models, it is perhaps not 
surprising that different generations of R&D appear at different stages of R&D. 
Looking at the ADP model, where the model mirrors the technological or consumer 
models, the respective generation of R&D is also mirrored. Many of the respondents 
felt it important to capture the phenomenon of R&D, but to able to modify it as they 
saw fit through further expanded views. Thus while the stages of R&D and expanded 
views reflect the R&D experience of the respondents, it is also reflexive enough to 
be able to evolve as required by respondents. Again and drawing on the 
phenomenological paradigm, this is a perceived strength of this model, and 
showcases a difference between the ADP and prior R&D models. This is not to 
suggest that other models cannot be adjusted but that using phenomenology enabled 
a core foundation of the R&D experience to be captured, allowing adjustments while 
maintaining the core reflection of antiviral disinfectant R&D.  
 
There is of course no one size fits all for R&D, and the question of how to model 
R&D is subjective, and with no one model having gained industrial acceptance of 
how to carry out R&D. While technological models enable a greater view of process 
stages, they potentially complicate and confuse, and in this study, it was perceived as 
critical to make the model useable. Thus it was discursively framed and warranted to 
enable shared meaning between managers, with a potential for further expanded 
views if required to convey greater in depth knowledge about specific process stages.  
 
In the final chapter of this study, ‘Conclusions and Recommendations’ are made for 
this and future work, and is examined in the following section.  
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Chapter 7. Conclusions and Recommendations 
 
7.1. Introduction 
 
The preceding chapters have established the research framework, detailed the 
collection and explicitation of data, and presented the research findings. Based on a 
review of the literature and the researcher’s sensitisation to the phenomenon, a 
research gap regarding antiviral disinfectant process R&D was identified. The 
research question, aims and objectives were constructed to address the research gap. 
Through the use of a phenomenological approach, this study was designed and 
implemented to provide an answer to the research question that also enabled the 
construction of an R&D process model. The model has extended academic literature 
and has already been utilised by companies within the antiviral disinfectant sector, 
who have described it as of ‘practical benefit’.  
 
This chapter has focussed on drawing conclusions and recommendations from this 
study. Study limitations are also recognised and discussed in light of this study, and 
recommendations for future work are made. In the following section, a summary of 
the results is made.  
 
 
7.2. Conclusion of the Study and Recommendations 
  
From the results drawn out from this study, the following conclusions and 
recommendations, are highlighted in this section for UK based antiviral disinfectant 
SMEs. This is alongside demonstrating the key contributions for the advancement of 
knowledge, theory and managerial practice for each conclusion.  
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Conclusion and Recommendation 1 
Key theme:  R&D.  
Conclusions: R&D was cited by many of the respondents as being a 
confusing environment to work within, where there was often 
conflicting departmental, and wider organisational drivers and 
discourses. Although the purpose of R&D varied between 
respondents, there were two separate discourses, which were 
prevalent within each management group (executive and R&D 
managers).  Executive managers were keen for R&D to be a 
vehicle of taking a specific product to market, often to satisfy 
a perceived customer need and arguably fitting more within a 
market pull view of R&D. R&D managers felt that R&D was 
a vehicle to discover new insights for the technology being 
developed, which may have longer-term benefits beyond the 
product being developed, with unknown products waiting to 
be discovered, and thus sits more within a technology push 
view of R&D. Importantly R&D managers did not always feel 
that they understood executive manager requirements for 
products being in R&D, and coupled with this, they perceived 
executive managers as ignoring technological discovery. 
Conversely, executive managers argued that R&D managers 
did not appreciate customer requirements. This point raised an 
important issue about the communication between 
management, as all managers argued that they did not always 
do well to communicate effectively about R&D, which was a 
perceived limitation by the managers to R&D being more 
effective.  
Key contributions: Respondent discourse about R&D explicitly drew attention to 
the different views espoused by different managers, and 
highlighted a technology push/marketing pull divide. These 
opposing views resulted in confused action about what stage 
to do when, when to repeat a stage and what it meant to pass 
or fail a stage. A synthesis of these views was achieved by the 
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use of a model, which facilitated a more fit-for-purpose view 
of R&D for both managers that could include elements of 
technology push and market pull. This was coupled with the 
managers deciding to be more proactive in problem solving 
through discourse. This was argued by the managers as having 
been facilitated by the approach used in this study, which was 
perceived as a ‘more forgiving’ view of organisational life. 
This can be linked to sensemaking being learning based, 
where a right answer is not necessarily sought, but more 
something that is good enough.   
Recommendation:  The use of a sensemaking and reflexivity based system within 
an often chaotic and uncertain technologically based R&D 
environment has potentially much to offer these respondent 
companies. This is particularly the case where a move can be 
made in many instances for a view that is not right but good 
enough. This deviates from the Technological Models 
examined in this study where a heavier legislative requirement 
is arguably much less forgiving of this stance. However, with 
a softer approach to antiviral disinfectant regulation that is 
often determined ‘in house’ this approach may be beneficial. It 
may also find synergy with the move to consider technology 
push and market pull aspects of R&D, which has received 
little discourse prior to this study. Engaging with this aspect 
further may well enable more open discourse where product 
failure can result in new product R&D cycles, without the fear 
from R&D managers as having to report a failure. Due to the 
R&D cycle being relatively quick and adjustable, this 
approach has the potential to deliver products to customers 
and in line with a market pull strategy, but also be more ‘blue 
sky’ for the R&D managers who are interested in technology 
push.  
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Conclusion and Recommendation 2  
Key theme:  Creating shared meaning within R&D. 
Conclusions:  R&D management is split into executive and R&D managers, 
where executive managers predominantly take a macroscale 
view of R&D and are responsible for stopping and starting 
R&D. R&D managers engage with R&D at a much deeper 
level and are responsible for the day-to-day running of R&D, 
decision-making and communication of technical aspects of 
the R&D stage in comparison to executive managers. 
Executive managers had backgrounds in business and self-
identified as such, whereas R&D managers were keen to self-
identify as scientists managing R&D i.e. R&D managers. 
Importantly, a divide was recorded for the education and 
workplace backgrounds that both respondents constructed. 
Simply, executive managers had a cultural background from 
‘business’ and R&D managers from ‘science’ with much 
discourse being provided by all respondents about how little 
cross over there was between these areas in their respective 
workplaces. In practical terms, this meant that both manager 
types used language-based repertoires to promote their 
organisational identities, and all aspects of R&D. This created 
a conflict between ‘business’ and ‘science’ speak where 
repertoires were used to increase the power of the person 
using them to legitimise their view of R&D as ‘correct’. R&D 
suffered from this style of discourse, resulting in limited 
shared meaning, which in turn impacted on sense- and 
decision-making. It was recognised by all managers that this 
was problematic for R&D as well as the wider organisation, 
and also impacted upon managers’ ability to effectively 
manage.  
Key contributions: Identification was made that repertoires were resulting in 
cultural confusion based on the language used i.e. science 
repertoires versus business repertoires. Through the 
	   156	  
phenomenological paradigm, this area was honed in on to 
highlight how conflicting repertoires could cause confusion 
within R&D and result in R&D cycle failure. Thus 
respondents were facilitated to actively engage with trying to 
draw closer to the phenomenon of R&D, rather than 
perceiving the construction of an R&D model as a ‘box 
ticking exercise’. Importantly the researcher promoted a view 
that there were no ‘right’ or ‘wrong’ answers and that if 
reflexivity was engaged with alongside phenomenology, this 
may enable a more fit-for-purpose view of R&D that was 
close to the respondents ‘real’ views. Thus, respondents 
actively engaged with the research process producing much 
rich discourse about the phenomenon, and in conjunction with 
warranting processes led to a model being constructed to 
promote shared meaning.  
Recommendation:  Creating shared meaning and understanding of the R&D stage 
between executive and R&D managers has the potential to 
facilitate sense- and decision-making (Billig, 1996). Most 
importantly a distinction was made by managers from this 
study that greater understanding and shared meaning could be 
achieved by ‘talking more’ using ‘good discourse’. Although a 
model has been constructed in this study, more academic and 
managerial data still remains to be explicated, including 
repertoires that inhibit or increase sense- and decision-making 
between managers. This area has received little attention in a 
technology context for R&D. It is interesting to draw on the 
work of Davies (2011) from a B2C consumer sales study, 
which considered the linguistic tools where metaphor, 
narrative and science fiction etc. have all been found to aid in 
the communication of complex phenomena particularly 
through repertoires (Davies, 2011), and can be linked to 
improved decision-making. While no claim is being made 
about how this might work for an R&D cycle, it is 
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conceivable that an exploration of the linguistic tools linked to 
repertoires may well facilitate increased shared meaning, due 
to the increased cultural similarity of discourse being used. 
Practically and considering wider organisational aims, it is 
suggested that executive managers work to disseminate 
company objectives to R&D managers, and likewise R&D 
managers disseminate the more in depth R&D aims and 
realities to executive management using lower levels of 
‘business’ and ‘science’ speak than might normally be used in 
R&D orientated organisational life.  
 
 
Conclusion and Recommendation 3 
Key theme:  Modelling R&D.  
Conclusions: Due to differences in cultural backgrounds including 
education and work experience, all respondents viewed 
models differently. A divide existed between executive and 
R&D managers in the way that both groups viewed R&D, and 
was linked to prior experience with executive managers 
having experience with business models, and R&D managers 
with science models. Importantly, none of the companies were 
using R&D models at the time of the study or had any direct 
experience of using them. More than this though, no company 
had put together a system from start to finish of what was 
encompassed in R&D prior to this study. Although no 
company was using an R&D model, all expressed a 
willingness to undertake a study examining this aspect, with 
three company’s trialling the developed R&D model. This was 
argued, as needed on the basis that ‘we will do anything to 
resolve the communication problems in this company’. 
Expanding on this aspect, all managers considered themselves 
experts, but unable to rectify the issue of a lack of fit-for-
purpose communication, which was, perceived as damaging 
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R&D. Through the construction of a warranted R&D model, a 
synthesised view of R&D was constructed by the researcher in 
conjunction with the respondents. The high level of interaction 
from the respondents was argued by the respondents as 
increasing their positive perceptions towards being creators of 
a model they might use. The phenomenological approach with 
the method of explicitation aided in this aspect, by helping 
make the meaning clear for respondents engaged in this study. 
In other words, it helped the respondents become practical 
authors, and take ownership of the model. It is accepted that 
the model developed in this study has a similarity to other 
models such as the Stage Gate Model and Technological 
Models, but there are aspects of the antiviral disinfectant 
model that are different from prior models. The philosophical 
basis is arguably closer to the perception of R&D from 
respondent views in comparison to other models, although this 
claim cannot be verified, but is made on the nature of the 
phenomenological method in comparison to other methods 
used for model building. The high level of interaction with 
respondents was argued by respondents as essential to making 
them take ownership of the model and as one executive 
manager stated ‘we don’t want someone else’s model, we want 
something we made’. Practically this appeared to make a 
difference for this respondent as the respondent’s company 
has trialled this model.  
Key contributions: The model produced in this study was argued by respondent’s 
as being authored by them, and as such useable. This suggests 
that there is a potential that high technology companies 
engaged in complex and opaque research may prefer to be 
involved in the model building stage. The method of 
phenomenology found favour with the respondents as it 
placed respondent perceptions as key, thus validating their 
identities as experts in their respective areas. More than this 
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though, the approach taken in this study was argued as being 
pivotal for achieving a high level of interaction and a desire on 
the part of the researcher and respondents to closely mirror the 
reality of R&D in a model. This led to an antiviral disinfectant 
model being produced that was claimed by all respondents as 
being fit-for-purpose for this sector and has been trialled, with 
positive feedback at this time from three companies. The 
strength of this model is the closeness to the phenomenon of 
interest and high-level of respondent participation and 
warranting. It is therefore suggested that a phenomenological 
approach with warranting may have much to offer to gain 
access to respondents as well as securing their active 
participation to facilitate model building.  
Recommendation:  A further investigation into the reasoning behind high levels 
of respondent interaction may well be worthwhile. This is 
particularly the case for phenomenological research using 
respondents who perceive themselves as experts. As one R&D 
manager stated ‘you can’t do some silly stats on what I know, 
its what I know that’s important’. While not attempting to 
undervalue the potential value of rationally based research, 
allowing respondents to reinforce their own self-identities 
might be important for drawing out phenomenon related data. 
Coupled with this is the status of the researcher who has a 
background as an executive and R&D manager, who was 
given a high level of access to respondents, argued by 
respondents as based on his background. Managers in this 
sector appear to expect someone with a similar background to 
speak to them using promoted repertoires to show a 
comparable background and legitimacy. Thus for further 
studies in such sectors, utilising specific researchers with 
favoured backgrounds might be advantageous.  
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Conclusion and Recommendation 4 
Key theme:  The R&D Model.  
Conclusions: All managers had what appeared to be a varied set of criteria 
for how to construct a model, but preferring simplicity, a 
linear flowchart was preferred, with boxes to enable expanded 
model views as this preferred to aid in sense- and decision-
making. In comparison to other models, this model is more 
reflexive which can be linked to the phenomenological 
paradigm, and as such has a higher level of respondent 
interaction for their perceptions. The antiviral disinfectant 
model was warranted to produce the synthesised model 
between executive and R&D managers, and found acceptance 
by all respondents. Explicitly the issue of sense- and decision-
making was addressed within the warranting stages, via 
further discourse between the researcher and respondents. 
Evidence of sensemaking was drawn out by the researcher 
collating repertoires suggestive of the stages of sensemaking 
(Weick, 1995) and by direct questioning of sensemaking. 
From the model constructed, there was much predictive 
discourse from respondents that the model should be able to 
enable a higher level of sensemaking albeit often not couched 
in the term sensemaking. Coupled with the potential for 
sensemaking was the argued potential for more fit-for-purpose 
decision-making based on increased sensemaking. While 
important for the models grounding within phenomenology 
and the respondent perceptions of the models reflecting of 
R&D, and potential for sense- and decision-making, an 
objection could be raised that although warranted (a discursive 
process) it had not been physically verified. Thus three 
companies undertook to examine the model in their R&D 
product cycles from start to finish, which had the potential to 
include R&D failure, or recycling through failed stages. This 
aspect occurred at the end of this study and feedback has so 
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far highlighted initial success for enhancing clear 
communication leading to more desirable sense- and decision-
making. It is expected that this stage, although now outside of 
the DBA study will be followed up as more information 
becomes available from the R&D companies.  
Key contributions: The antiviral disinfectant model is based within prior literature 
from executive manager, R&D manager and joint 
perspectives. Importantly, the environment within which R&D 
is undertaken has echoed into the model construction and for 
example, with lower regulatory requirements, the path through 
R&D can be more reflexive and is arguably more open to 
manager introspection regarding each process stage. This was 
shown from the ability to recycle through failed stages, where 
other models had to stop the R&D cycle as the product had 
failed. A failure within the antiviral disinfectant model does 
not mean a classical failure as with the allied antiviral 
technologies of vaccines or in vivo drugs, but creates an 
opportunity to learn more about the R&D stage and product. 
More than this though it may result in new R&D product life 
cycles being undertaken to generate new products from a 
failed stage. In other words, a failed stage may lead to new 
product opportunities, which are more likely to be exploited 
due to the quick R&D cycle time, and low resource costs from 
failures. The issue of verifying the model as a physical aspect 
beyond discursive warranting is in the process of being 
examined. It will be carried out in more depth outside of this 
study as more data is relayed from respondent companies and 
will act as a greater verification of the suitability of this 
model.  
Recommendation:  The construction of the beta model was through the consensus 
of all managers, with all managers stating their satisfaction 
with the model itself and method of constructing it. The most 
pertinent recommendation for the R&D model is the external 
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verification that can come from data relayed from respondent 
companies carrying out testing on the model by using it in 
their R&D cycles. Beyond the three companies using this 
model and comparing it to past R&D cycles (which will give 
quantitative data) is the potential for other companies in this 
sample to use the model. At present a further two companies 
(which will give 50 percent of the total UK sector if added to 
the other three companies already using the model) have 
stated they will test this model, upon completion of their 
current R&D cycles. In a practical sense, the researcher will 
continue his engagement with these respondent companies to 
collect further data from the implementation of this model and 
its suitability. It will be interesting to see how respondent 
companies use this model based on their perceptions of how it 
should be implemented, whether changes are made, and how it 
holds up against prior practices, and what merit a 
phenomenological approach to modelling R&D has in 
comparison to other methods and respondent company 
verification.  
 
In the next section, ‘The Contribution to the Knowledge Base’ have been considered 
and addressed. 
 
 
7.3. The Contribution to the Knowledge Base 
 
This study has contributed to the literature on process R&D, with a particular focus 
on the research gap identified in antiviral disinfectant R&D, in the following ways: 
 
1. An R&D process model was developed and warranted from 
interviews with R&D and executive managers. Although there was a 
heavy emphasis on the technological aspects of R&D, the model was 
based not just within the concept of technological models but also 
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within the consumer/market model. Through the warranting of the 
model, it was possible to produce an increased view of technological 
aspects discursively framed to facilitate executive manager 
understanding of R&D.   
2. The issue of management communication, to give shared meaning for 
R&D, was continually cited as being problematic. It was felt by both 
manager types that the challenge for communication was based on 
R&D managers and executive managers having been trained in 
science, and business respectively, with little cross over of knowledge 
and language. This study extended that of Davies (2011), which 
explored the use of linguistic tools such as storytelling, metaphor, 
narrative etc to communicate complex technological ideas to non-
scientists. In this study, it was found that R&D managers utilised such 
tools to communicate complex knowledge from R&D to executive 
managers.  
3. The process stages of R&D had a high similarity between all 
companies, and the managers interviewed to ascertain this data. This 
suggests that within the sector, there is conformity for how to carry 
out R&D, even though the companies do not carry out R&D together.  
4. The model produced in this study highlighted elements of the sixth 
generation of R&D models, in that there was a high-level of 
inclusionary input, and decision-making in the meeting stages at the 
beginning and end of R&D. Importantly there were also elements of 
earlier generations (second and fourth), with a focus on aspects such 
as cost and time. As the model developed in this study has aspects of 
both the technological and consumer models, this is perhaps not 
surprising.  
5. The attitudes of many of the respondents based on their background 
and use of corresponding language was explored. It was found that 
both manager types appeared to have a negative bias to the others 
knowledge, based on the challenging of effective communication and 
creating shared meaning. R&D managers also promoted their right to 
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speak about R&D, based on their scientific knowledge, which also 
extended into executive management not having a right to speak.  
6. At a macro level the beta R&D model has provided an explicated 
pathway through the R&D processes, which has been argued by 
respondents as creating shared knowledge between managers for the 
stages included in R&D as well as their order. In this simple way, the 
R&D model is functioning in a comparable way to a flowchart, 
guiding the way through R&D. Practically this may reduce confusion 
about which stage is being carried out when, and may echo into wider 
discourse from both types of manager throughout the R&D company 
and out to customers. The creation of this macroscale view has the 
potential to facilitate executive management sensemaking of the 
processes of R&D, where discursive repertoires can be linked to 
action. More than this, it as a potential to provide a good enough view 
for executive managers who are seeking a lower level of the practical 
elements of R&D than R&D managers. However, through the 
expanded model ‘micro’ view, a greater insight and knowledge of the 
R&D cycle can be achieved, which as a reflexive element can be 
further expanded on for individual companies using the model. 
Through a sensemaking perspective, the aim of the model is to enable 
enough sense to be made by respondent managers, whereby 
organisationally suitable decisions can be made about R&D, that 
support a knowledgeable culture within R&D and its management.  
7. The construction of the Beta R&D model was developed to facilitate 
sensemaking, but also decision-making based on respondent manager 
sense made. Primarily, by using a phenomenological approach, it was 
perceived that the constructed model would closely model the 
experience of management experiences of R&D, and thus enable 
more fit-for-purpose decisions made. When approaching the R&D 
model, it is expected that it will function to facilitate sense made 
through the different stages shown, whereby decisions can be made. 
Importantly any claim about the model improving the practicality of 
R&D would have to be externally verified by the respondent 
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companies, where their experiences could be monitored and 
potentially measured. At the end of this study, three respondent 
companies, with another two companies having agreed to test this 
model, are carrying out this process. Preliminary feedback from the 
three companies testing the model has been favourable, but a more 
detailed examination and expansion of this work is required to 
ascertain the validity of the claims being made.  
8. The R&D model developed in this study has similarities to models 
such as the Stage Gate and Technological models but with a different 
philosophical foundation. The foundation of the antiviral disinfectant 
model varies from prior models, as rather uniquely for an R&D model 
it was constructed through the use of a phenomenological paradigm. 
The basis of the model echoes into the constructed reality the model 
mirrors from R&D, with a phenomenological approach arguably 
mirroring the respondent reality of R&D more closely than other 
philosophical approaches. Importantly the antiviral model was 
constructed using the explicated phenomenologically based views of 
respondents, by the respondents and for the respondents. The 
respondents argued that this created a sense of ownership and will 
result in 50 percent of the companies in this sector testing this model. 
Within the approach used to construct the antiviral disinfectant model 
is a high level of reflexivity, and coupled with a sense of respondent 
ownership has the potential to allow the model to evolve particularly 
through expanded model views, which may become bespoke within 
testing companies. In comparison to other Technological models, 
increased reflexivity within the model, which can potentially be 
coupled with greater regulatory freedom, has the potential to enable 
this model to be further honed to more closely mirror R&D in an 
evolving process.  
 
After drawing together ‘The Contribution to the Knowledge Base’ in this section, the 
following section explores ‘The Limitations of the Study’.  
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7.4. The Limitations of the Study  
 
This study was not without limitations, and it is worth pointing out that limitations 
arguably exist within all research studies. Specifically though, the following 
potential limitations were identified in this study: 
 
Researchers from positivist and rationalist backgrounds may raise the claim that this 
study is non-scientific, and uses qualitative and subjective methods (Yin, 2003; 
Saunders et al, 2009). This aspect was addressed throughout this study, but it is 
worth recognising that this was an exploratory study that was language based, and 
was interrogating the mental and subjective realities of the respondents, to further 
understand antiviral disinfectant R&D. Coupled with this was the use of low 
numbers of respondents (seven executive and seven R&D managers) but who made 
up 70 percent of the UK-based industry in this sector.  
 
There is the issue of the ability to generalise research findings from these companies 
to other R&D companies carrying out antiviral disinfectant R&D, and companies 
carrying out other types of R&D. This is an important aspect that needs digging into 
to more fully understand what it is to be able to generalise data between different 
groups and companies. Firstly, in this study, both executive and R&D management 
were interviewed, which make up 70 percent of this type of management in the UK, 
and it is logical to assume that this study is generalisable to the other 30 percent of 
the same sector group as used in this study. Looking beyond antiviral disinfectant 
R&D, the issue arises for how reality is potentially being symbolically represented 
by a model. For instance, in the model developed in this study, there are scientific 
and technical stages directly taken from the phenomenon of antiviral disinfectant 
R&D that may not exist in other types of R&D. It is of course possible to step back 
from such a close representation of reality and use more generic R&D models such 
as the Stage Gate.  
 
This study utilised a multiple case study method (different antiviral disinfectant 
R&D companies), and there are arguments that could be made that it is difficult to 
replicate data. As this study was language based, warranting was used instead of 
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validation and is in agreement with the suggestion by Wood and Kroger (2000). The 
warranting process was carried out in conjunction with respondents to check on the 
data collected from interview, and the construction of the model. Thus, multiple 
checks were made by respondents to check on their perceived ‘validity’ of the data.  
 
In depth semi-structured interviews were used as the source of data collection, which 
can be criticised for producing bias in the responses given. To mitigate and limit this 
potential difficulty, the researcher spoke to the respondents on more than one 
occasion for the warranting of the data produced, which is believed to have aided in 
producing more ‘robust’ data.  
 
Importantly, the researcher was sensitised to the antiviral disinfectant sector prior to 
this study. Due to the method of explicitation used in this study, the researcher did 
not need to be knowledgeable about the phenomenon being examined (Urquhart et al 
(2001). It was however necessary for the researcher to continually bracket his 
perceptions about the phenomenon and make mental checks of feelings and thoughts 
that may have resulted in bias. This was a subjective process, and it was not possible 
for the researcher to make any substantive claim of how successful his bracketing 
was.  
 
In the next section, ‘The Implications of the Study’ is addressed:  
 
 
7.5. The Implications of the Study 
 
This study has produced contributions to academic knowledge as well as insights for 
business practitioners, particularly for those involved in R&D management. 
Specifically, the R&D landscape was described as being potentially opaque, 
uncertain and complex, with it being difficult to communicate shared meaning 
between key managers for high-level business or technological R&D aspects. These 
following areas are therefore addressed within this section: 
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1. The environment of R&D: Throughout this study, the difficulty of carrying 
of complex technological R&D was described as challenging due to the 
varied number of factors interacting with the R&D stage. These factors can 
range from the physical location of the R&D company, to its customers, 
suppliers and staff within the company. The language used to communicate 
sense and understanding of the phenomenon of R&D was often cited as being 
particularly troublesome, as many managers felt that there was a wide 
difference between the perception of what was communicated and the 
perception of what information was up taken. The use of an R&D model 
specific to antiviral disinfectant R&D was well received by R&D and 
executive managers as a vehicle of communicating some of the complex 
ideas behind R&D, particularly through the use of expanded model views.  
2. Increasing clarity and shared meaning: Importantly, when the alpha 
models were constructed for R&D and executive managers, R&D managers 
did not regard the initial meeting (scoping) stage as being part of R&D and 
attributed a low importance to it. Upon the researcher detailing the theory 
expressed from executive managers about this stage to R&D managers, the 
stage was included in the beta model. Interestingly, this addressed a concern 
from R&D managers of not necessarily understanding the goal of R&D 
beyond scientific aspects. Arguably, this enabled R&D managers to step 
outside of prior constructions of R&D and examine customer requirements, 
rather than being too technologically focused.  
3. Business versus science driven R&D: Both manager types expressed a 
concern that the other manager type was too focused on their own perception 
of R&D and how it should be carried out. For example, executive managers 
believed that R&D managers were too focused on producing non-profitable 
scientific discoveries, and likewise R&D managers thought that executive 
managers were too shortsighted, with no interest in longer-term discoveries 
that could be profitable. Through the construction of the model and 
particularly the model view (with a potential for further views to be attached) 
enabled, the managers to openly consider their own, and other manager 
perceptions of R&D  
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The examination of these factors within antiviral disinfectant R&D has the potential 
to improve R&D output, customer satisfaction, management, and communication.  
 
The following section draws on information drawn out so far in this chapter to 
consider ‘The Recommendations for Future Research’. 
 
 
7.6. The Recommendations for Future Research 
 
This study addressed the identified research gap in how UK SMEs carry out pre-
commercialisation based antiviral disinfectant process R&D. Further research in this 
area should explore the processes of the closely allied R&D areas of antibacterial, 
antiyeast and antifungal disinfectants. As these are all highly technically specialised 
areas, with arguably similar processes to antiviral disinfectants, it will be important 
to draw out similarities and differences in the processes and to understand the how 
and why. This could be carried out as a comparative study, and has the potential to 
lend itself to quantitative as well as qualitative methods and analysis. Beyond these 
areas is the aspect of a more in depth examination of how language is used between 
management using different knowledge to communicate business and scientific 
sense, enabling decision-making. This could also draw on elements of linguistic 
tools to communicate and how sense is made of potentially complex areas between 
different industrial actors. This would have the potential to expand on work carried 
out by Davies (2011) who examined the use of metaphor, storytelling and science 
fiction to convey shared meaning for high technology. These linguistic ‘tools’ have 
been shown to be important for creating dyadic closeness in communicating complex 
information, particularly where science and technological flows from an individual 
with a high-level of knowledge to an individual of low-knowledge. An expansion of 
this study would be able to directly examine this flow and linguistic tools used for 
scientists communicating complex information to non-scientists, but also for 
executive management to communicate complex business phenomena to scientists, 
which has not previously been examined. Thus, it would be possible to compare 
language-based tools in these different settings. Finally, as three respondent 
companies were testing the Beta model at the end of this study, and with a further 
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two companies waiting to test the model, findings should be compared to prior R&D 
practises to validate this model. Importantly data coming out of this final aspect may 
well shed further light on the applicability of this model, and the use of a 
phenomenological paradigm for R&D model construction.  
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Appendix A – Letter Sent To Prospective Interviewees 
 
Page 1         19/08/2012 
 
Dear Sir/Madam, 
You are regarded as an industrial expert in the research, development and 
commercialisation of non-in vivo antiviral disinfectant products. I would like to ask 
for your support in research I am carrying out for a Doctorate in Business 
Administration (DBA) in Edinburgh Business School at Heriot-Watt University. The 
title of this research is: ‘An Antiviral Disinfectant Research and Development 
Process Model for Small to Medium Enterprises Based within the United Kingdom’. 
This research is focused towards the pre-commercialisation aspects of antiviral 
development, and I would like to carry out in depth interviews with you, at your 
convenience. All interviews will be confidential and anonymised, with no link to you 
or your organisation. If you are in agreement with either yourself or members of 
your organisation taking part in this study, please sign this document on your 
letterhead and e-mail it to me at andrewdean@spartannano.co.uk. 
 
Organisation: 
Address:  
 
I/We hereby agree to support this research in the form of an in depth interview to 
support the production of a DBA on the following subject: ‘An Antiviral Disinfectant 
Research and Development Process Model for Small to Medium Enterprises Based 
within the United Kingdom’. 
 
Name:  
Signature:  
Position in organisation: 
Date:  
Once this document is signed, please e-mail it to: andrewdean@spartannano.co.uk 
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Appendix B – Excerpt from Transcript with an R&D Manager 
 
In this appendix, part of Question 2 from the main study is examined with one of the 
R&D managers as an example of an excerpt from the interviews.  
 
Question 2: ‘How is management segmented?’ If the answer was perceived as 
limited, the following question gave guidance: ‘Do factors such as your 
academic/work background/experience play a role in this?’  
 
Respondent:  “Hmmm, well management is segmented by need in many ways, with 
several err, company drivers meaning there is a need, so we have a manager.  
Interviewer: “Could you tell me more?” 
Respondent:  “Ok, so for what we do in R&D, I’m the guy in charge on, if...as the 
R&D manager. I’m in charge of R&D, as the R&D manager. But...I have a boss, 
someone senior, you know, a business guy, someone who knows little about science, 
profit obsessed. Ok, I’m being cliché...but you get what I mean?” 
Interviewer:  “I think I understand...So you are in charge of R&D? And you have a 
senior manager overseeing R&D? Could you say more about this?” 
Respondent:  “Sure, I make all of the nitty gritty R&D decisions, what to pass, what 
to fail, and...I...also know, when, you know...when to call the senior 
management...usually when there’s a big problem...the kind that screws things up...I 
don’t want that responsibility. So he steps in, sorts it out, you know...makes erm, a 
decision, continue or stop R&D. Suits me fine. But in every other way I run the daily 
stuff, I have to, I know the science, business managers don’t!” 
Interviewer:   “You feel that business managers don’t know the science?” 
Respondent:  “Not at all, they get very confused, and this, this…well it just hampers 
communication and R&D in general. Its not easy trying to communicate complex 
sci…science ideas to a manager who doesn’t understand.” 
Interviewer:  “This leads me back to part of my original question about how you 
feel that academic and work experience relates to how management is segmented. 
Do you think you would be able to say a bit more about this?” 
Respondent:  “It is pretty simple...I’m a scientist and I run R&D. Senior 
management are business guys...and they run the company” 
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Interviewer:  “Could you go a bit more in depth with how this works?” 
Respondent:  “Ok...So I have a background in science, did a degree...and MSc in 
Science...erm...its what you do to be a scientist...and...hmmm...then I worked in 
various science companies, doing different stuff! Lots of R&D! Lots of different 
positions in R&D...I feel qualified to manage R&D. But you know, senior 
management they study business! They don’t understand science...but feel they 
do...and get confused about what we do. Can’t understand what we say, erm, half the 
time. It complicates everything! We live in different worlds”. 
Interviewer:  “Is there any cross over of knowledge between science…and business 
orientated managers?” 
Respondent:  “At the moment…if there is, it is unintended and coincidental, and no 
we don’t have any mechanisms to transfer what we say, what we mean. For 
instance…in R&D…we…we often don’t, I mean, we often have little idea what the 
product is needed to do. It is an over simplification to say it just kills viruses. No 
communication to us about this. We need to know! 
Interviewer:  “Ah yes, I can see how this could be challenging, and thank you, we 
will definitely pick up on some more of these aspects, and go more in depth, later in 
the interview”.  
	  
 
 
 
 
 
 
	  
	  
	  
	  
	  
	  
	  
